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Abstract
The marmoset monkey {Callithrix jacchus) has been used as a non-rodent species in 
non-clinical development studies for a number of years. However, there is only 
limited information available on the drug-metabolising enzymes in this species. This 
study determined the marmoset liver microsomal kinetic parameters (Km and Vmax) for 
the following activities: 7-ethoxyresorufin 0-deethylase, S-mephenytoin N-
demethylase, tolbutamide methylhydroxylase, debrisoquine hydroxylase, lauric acid 
11-hydroxylase, testosterone 6(3-hydroxylase and lauric acid 12-hydroxylase. These 
activities, which are indicative of the presence of specific cytochrome P450s 
expressed in the human liver, were evaluated in marmoset liver microsomes to 
investigate possible similarities between the two species.
The metabolism of the human CYP2D6 probe substrate debrisoquine was 
investigated further, using marmoset liver microsomes and a combination of 
techniques including HPLC-RAM, LC-MS/MS and NMR. Debrisoquine was 
metabolised by marmoset liver microsomes to a number of hydroxylated products, 
including a previously unidentified 6,7-dihydroxydebrisoquine. Interestingly, the major 
marmoset hepatic metabolite appeared to be 7-hydroxydebrisoquine rather than 4- 
hydroxydebrisoquine, as is the case in human.
The expression of CYP enzymes in marmoset liver was investigated by Western blot 
analysis of microsomal protein and compared by parallel analysis to liver microsomal 
protein of male human donors and male Sprague-Dawley rats, using anti-CYP 
antibodies primarily raised against the human enzyme. The analyses revealed 
extensive expression of: CYP2C19, CYP2E1, CYP3A4 and CYP3A5 in marmoset.
CYP2C9 and CYP2E1 in human, and CYP2A6 and CYP2E1 in rat. There was little or 
no expression of proteins detected by antibodies raised against CYP2A6 and 
CYP2D6 in marmoset, CYP2B6 in human and CYP2B6, CYP2D6 and CYP3A5 in 
rat.
Finally, Inter-species comparison of CYP expression between human and marmoset 
was examined at the genetic level. Primers and probes were selected to specifically 
match human CYP mRNA, and then used to determine sequence identity between 
the human hepatic CYPs and their marmoset counterparts. These analyses 
established a species comparison for CYP2B6, with the primer and probe targeted 
binding region within the marmoset enzyme being identical (or very similar) to that of 
the human protein.
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Chapter. 1; Introduction
Chapter 1
Introduction
Chapter 1: Introduction
1.1 : The need for animal models
In 1975 Krebs stated that “for many problems there is an animal on which it can be 
most conveniently studied”; this philosophy holds as true today as it did three 
decades ago. However, it has become obvious that the choice of species for 
toxicological testing should be based upon consideration of a large range of variables 
(Gad, 2007). Ideally these species should be chosen based on their similarity to the 
target species, e.g. human, in the way that it handles the test article 
pharmacologically and, provide information on the safety of the test article in or by 
human. Substantial differences in ADME between test species and human will 
undoubtedly reduce the predictive ability of any animal model. This issue of species 
selection has been a topic of concern for a number of years. Parke (1979) discussed 
some of the differences in animal models, including the rates of hydroxylation, 
highlighting the need for comparative metabolism studies to investigate the 
consequences of these differences in the pathways and rates of metabolism prior to 
the selection of the most appropriate animal species. These concerns have been 
addressed more recently by Wood and Hart (2007), who believe the literature 
surrounding the identification of the most appropriate animal model as ‘murky’ at 
best. An alternative to searching the literature is the web-based resources now 
available, such as the Animal Models and Stains database provided by The Institute 
of Laboratory Animals Research. However, the resource appears to be in its infancy, 
does not provide comparative metabolic data, concentrates on mouse models and 
seems to be hampered by unavailable web page links. It is now generally accepted 
that detailed studies on hepatic enzyme expression and activities are needed to 
understand metabolic aspects of inter-species differences and variations.
Chapter 1: Introduction
1.2: Choice of animal model
It has been suggested by Zuber et al. (2002) that metabolic pathways mediated by 
highly conserved cytochrome P450s, such as CYP1A, can be appropriately 
investigated in all of the commonly used experimental models, except dog. However, 
according to their work dog seems to be suitable for modelling processes linked to 
CYP2D. CYP2C, possibly the largest and most complex sub-family appears to be 
well represented by the rhesus monkey, whilst the pig or mini-pig may be good 
models to represent CYP3A metabolism. The profile of CYP activities best 
resembling man was recently compared in an in vitro study by Turpeinen et al. 
(2007), who employed the enzyme model substrates; ethoxy resorufin 0-deethylation 
(CYP1A1/2); coumarin 7-hydroxylation (CYP2A6); tolbutamide hydroxylation 
(CYP2C9); dextromethorphan 0-demethylation (CYP2D6); chlorzoxazone 6- 
hydroxylation (CYP2E1); midazolam a-hydroxylation and omeprazole sulphoxidation 
(CYP3A4/5): bupropion hydroxylation (CYP2B6) and omeprazole 5-hydroxylation 
(CYP2C19). The best similarity was seen in mouse followed by monkey, mini-pig, 
and dog liver microsomes, with rats displaying the most divergent activities. 
However, selectivity of the most appropriate animal model will always differ 
depending upon the test chemical.
Frequently the pharmacokinetics of a new chemical entity will be unknown in human 
or test species at the time of species selection; as a result, in general, two or more 
species will be used, one of which is normally a rodent. The selection of one species 
as rodent is somewhat historical, although large amounts of background data are 
available for rat and mouse, with rat CYPs being among the first to be characterised 
with many families and sub-families isolated. In addition, these rodents have the 
advantages of being small, economical to obtain, house and care for; and have a
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short gestation and natural life-span. The main disadvantage of these smaller 
rodents relates primarily to their size, with the associated hindrance to sample 
collection and higher metabolic rate that results in rapid ADME. It is, however, for this 
very reason that the mouse with its rapid metabolism and short natural life is often 
the model of choice for cancer studies. It can of course be argued that the use of 
these small rodents as animal models for surrogate human investigations is 
scientifically flawed due to fundamental differences in the metabolising enzymes in 
the mammalian species. The answer may lie in having detailed enzymic 
characterisation available or as many species as possible, thereby allowing informed 
choices, based upon GYP characteristics, rather than convenience or historic 
preference.
1.2.1: Suitability of animal models
To this day, the results of preclinical animal model studies are sometimes 
disappointing, even when multiple species have been used. A recent example of a 
spectacular failure of animal models in human efficacy prediction was the human trial 
of TGN1412, an anti-inflammatory drug that brought about multiple organ failure in 
six human volunteers (Suntharalingam at a!., 2006) TGN1412 had been tested 
extensively in rabbits and cynomolgus monkeys with no serious side effects reported. 
Other examples, although less dramatic than that of TGN1412, for species 
differences in the toxicity of foreign compounds have been cited: voliconazole is 
rapidly cleared in mice and rats, with a terminal half life of 1 -  2 hours compared to a 
10-hour terminal half life in human (Perfect at a!., 1985); omeprazole is metabolised 
primarily by CYP2C19, with CYP3A4 playing a minor role in most mammalian 
species; however, due to the large CYP3A4 component in human liver, an increased 
clearance of omeprazole via the CYP3A4 route of metabolism is present in man
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(Andersson et al., 1993); multiple metabolic pathways of tamoxifen metabolism have 
been demonstrated (Lewis et al., 1998). These phase I pathways are mediated by 
various CYPs in rodents, whilst being metabolised by CYP2C9 and CYP3A4 in 
human.
Although animal testing does not always display the desired predictive value, given 
the limited usefulness of computer models, in vitro models, and phylogenetically 
lower organism models, animal models remain the best alternative. The findings of 
the ENCODE project. Encyclopaedia Of DMA Elements (Birney et ai., 2007), suggest 
differences in gene regulation between species should also be taken into account 
when selecting a surrogate for human drug metabolism. Unfortunately, it is unlikely 
that the gene regulation of the parameters of interest will be known for either human 
or potential animal models for many years to come (Wall and Shani, 2008).
1.3: Drug metabolism
When a drug is administered to a patient, the human body breaks down converts the 
xenobiotic molecule and tries to dispose of it. This drug disposition is often 
accomplished by biotransformation of the drug into a more hydrophilic molecule(s), 
and thereby facilitating its excretion. Biotransformation of xenobiotics is mainly a 
metabolic process performed by a number of enzymes. The liver is the principal 
organ where drug metabolism occurs.
Most phase I metabolism reactions are catalysed by the microsomal membrane- 
bound mixed-function oxidase (MFC) reactions, which are composed of cytochromes
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P450 (GYP), NADPH-P450 reductase and lipid. MFO reactions involve the initial 
insertion of a single oxygen atom into the molecule that is being metabolised, this 
reaction catalyses the hydroxylation of hundreds of structurally diverse drugs and 
chemicals that have a reasonably high degree of lipophilicity (Parkinson, 1996; 
Gibson and Skett, 2001). An important feature of the CYP system is its broad and 
overlapping substrate specificity, primarily as a consequence of the multiplicity of the 
terminal oxygenase, resulting in a large array of chemicals becoming potential 
substrates for this system. Because of the frequently overlapping substrate 
specificity, the CYP enzymes are classified based upon their amino acid sequences. 
In general CYPs with less that 40% amino acid sequence identity are assigned to 
different gene families, or superfamilies. CYPs that are 40-50% identical are 
assigned to different subfamilies and those that are more that 55% identical are 
classified as members of the same subfamily. Currently, there are 17 different P450 
gene families encoded by approximately 60 genes in any given mammalian species 
(Nelson, 1999; Guengerich et al., 2005; Johnson and Stout, 2005). CYPs involved in 
drug metabolism control drug clearance and toxicity, a subject of great concern to the 
pharmaceutical industry. The elimination of unchanged drugs via urine, bile, expired 
air, or faeces represents on average approximately 25% of the total elimination of 
compounds, metabolism by the multiple CYP forms represents approximately 55%, 
with all other metabolic processes making up the remaining 20% (Clarke and Jones, 
2002).
Generally, the cytochrome P450 system appears to functionalise the xenobiotic by 
exposing or adding a chemically reactive group, via which phase II reactions can 
occur. Therefore, in most cases a phase II reaction cannot occur until the molecule in 
question has undergone phase I metabolism. The main site of phase I metabolism of 
xenobiotics is the liver. The liver has up to twenty times the amount of microsomal
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protein compared to that of other tissues, and for this reason hepatic metabolism of 
drugs is considered far more important than non-hepatic metabolism (Pacifici et al.,
1988). To further the advance of preclinical drug metabolism, cloning and expression 
of human liver CYP enzymes have lead to direct identification and enzyme based 
prediction of the in vivo actions of drug. These predictions of in vivo pharmacokinetic 
and pharmacodynamic characteristics from in vitro data may well also predict the 
potential for drug interactions, and genotypic/phenotypic enzyme variabilities in the 
population (Korzekwa, 2002).
1.3: Cytochrome P450
In the past three decades, much has been learned about the multiple forms of 
cytochrome P450 enzymes of liver microsomes including the characterisation of 
these CYP forms with respect to their properties and catalytic activities. Until 1982 
the characterisation or isolation of various human enzymes had not been undertaken; 
this task was carried out using SDS PAGE, which revealed nine different protein 
bands (49-58 kDa) in the region of P450 enzymes (Ekstrom et ai., 1982). In the 
following year, six P450s were purified by electrophoresis. Biochemical markers were 
used in the identification of distinct enzymes, which differed in catalytic activity (Wang 
et al., 1983). The cytochrome P450 system comprises a large superfamily of proteins 
(Nelson et ai., 1996) that are of central importance in the detoxification and activation 
of a huge number of therapeutic drugs, chemical carcinogens and environmental 
pollutants. Consequently, cytochrome P450 is one of the most extensively studied 
groups of proteins. CYP reactions are generally characterised through in vitro 
experiments and generated data can then be used to predict in vivo metabolism, 
interactions, etc.
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1.3.1: CYP1A
The CYP1A subfamily consists of two members, CYP1A1 and CYP1A2. CYP1A 
shows quite strong conservation amongst species (Mugford and Kedderis, 1998) with 
an amino acid sequence identity between human, rat, mouse and dog higher than 
80% and approximately 95% between human and cynomolgus monkey. CYP1A1 
and 1A2 have been extensively studied as they were the first to be identified; they 
catalyse the metabolism of two important classes of environmental carcinogens, 
polycyclic aromatic hydrocarbons (Dipple, 1983) and arylamines (Sugimura and 
Sato, 1983). CYP1A1 is expressed at very low levels in the human and cynomolgus 
monkey liver (Bullock et al., 1995) and is mostly an extrahepatic enzyme that is 
present predominantly in the intestine (Guengerich, 1997), lung (Shimada et a!., 
1996), placenta (Hakkola et a!., 1996) and kidney (Choudhary et a!., 2003). CYP1A2 
is expressed in human liver and may account for 13% of the total CYP content 
(Shimada et a!., 1996; Guengerich and Turvey, 1991) and is involved in the 
metabolism of approximately 4% of the drugs on the market (Zuber et a!., 2002). In 
cynomolgus monkey CYP1A2 is expressed at low levels in the liver, restricting the 
use of this species in CYP1A2-linked metabolism and toxicology studies. However, 
higher concentrations, corresponding to levels documented in human, have been 
previously published for the marmoset (Edwards et a!., 1994).
1.3.2: CYP2A
CYP2A6 is the major CYP2A enzyme in human, and is expressed in both liver and 
extrahepatic tissues. CYP2A6 has been documented as representing approximately 
1-10% of the total cytochrome P450 expression in human liver (Yum et a!., 1991; 
Maurice ef al., 1991). CYP2A6 exhibits different substrate specificity when compared 
to CYP2A enzymes from other species (Honkakoski and Negishi, 1997); this is also
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evident within the monkey species, with a lack of coumarin 7-hydoxylase activity in 
marmoset liver microsomes (Lake et al., 1989), although, like human, cynomolgus 
monkey liver microsomes have been reported to catalyse coumarin 7-hydroxylation 
(Bogaards et al., 2000).
1.3.3: CYP2B
The only CYP2B protein expressed in the human liver is CYP2B6 (Yamano et a i,
1989). CYP2B6, possibly due to the very low level of expression detected originally, 
was historically thought to only play a minor role in drug metabolism. However, 
recent studies have demonstrated that human CYP2B6 is involved in the metabolism 
of almost 25% of the drugs on the market today (Xie and Evans, 2001), is highly 
inducible by barbiturates (Kwon, 2001) and may comprise up to 10% of the total 
human hepatic CYP content (Stresser and Kupfer, 1999). This enzyme expression 
has also been found to be sexually dimorphic in human (Lamba et a i, 2003). 
Cynomolgus monkeys express a single liver CYP2B (CYP2B17) that resembles the 
amino acid sequence of human CYP2B6, and is said to contribute about 5% of the 
overall hepatic P450 complement of this non-human primate (Ohmori et al., 1998).
1.3.4: CYP2C
The CYP2C liver enzymes are major contributors to drug metabolism, with CYP2C9 
being the most abundant CYP2C enzyme in human, representing 60% of the total 
CYP2C complement, whereas the CYP2C subfamily accounts for approximately 20% 
of the total hepatic P450 (Shimada et al., 1994), the other members being CYP2C8 
and CYP2C19, and are involved in the metabolism of about 16% of the currently 
available drugs (Doherty and Charman, 2002). Although CYP2C19 only represents
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approximately 1% of total human CYP2C in the liver, it is highly polymorphic with 3- 
5% of Caucasians and 12-100 % of Asian groups being classed as poor metabolisers 
(Goldstein, 2001). Polymorphisms such as these can result in toxic effects where the 
drugs involved have fairly narrow therapeutic index and, in the case of CYP2C19, 
involves drugs such as tricyclic antidepressants and barbiturates (Adedoyin et al., 
1994). The human CYP2C enzymes are all inducible but to date relatively little is 
known about the mechanism of CYP2C regulation. Three CYP2C cDNAs have been 
identified in the Japanese macaque, cynomolgus and rhesus monkeys (Matsunaga 
et al., 2002). The last has two CYP2C liver enzymes, of which the closest to human 
is CYP2C43 that showed a 92% amino acid sequence identity to CYP2C9, and is 
capable of metabolising the human CYP2C19 probe substrate, S-mephenytoin, but 
not the human CYP2C9 probe substrate, tolbutamide. Therefore, although the rhesus 
CYP2C43 is similar in structure to CYP2C9, its function resembles that of CYP2C19 
(Matsunaga et al., 2002).
1.3.5: CYP2D
CYP2D6 was the first CYP shown to be polymorphic, when debrisoquine (Mahgoub 
et a i, I977j and sparteine (Eichelbaum et a i, 1979) were found to be metabolised at 
different rates in separate individuals. Significant interethnic differences in CYP2D6 
allele frequencies have been demonstrated, which have clinical implications (Bernard 
et a i, 2006). Generally, up to 10% of Caucasians inherit mutant CYP2D6 alleles as 
an autosomal recessive trait (Evens et a i, I980j. More recently, drug therapies can 
be tailored to an individual’s genotype, obtained using polymerase chain reaction 
(PCR) methods that have become available; these individuals can be genotyped 
using a small blood sample and, the resulting CYP2D6 allele profile can be used to 
modify the drug regime, thus avoiding potential toxic consequences. In human
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CYP2D6 is expressed only in the liver and is thought not to be inducible, whilst the 
expression of CYP2D in the monkey appears to be strain related; the cynomolgus 
monkey expresses CYP2D17, a protein that has a 93% amino acid identity to human 
CYP2D6 (Mankowski et al., 1999); the rhesus monkey, expresses CYP2D42, which 
is probably an orthologue of human CYP2D6; the marmoset, expresses two CYP2D 
enzymes, CYP2D30 and CYP2D19, both showing strong homologies in their amino 
acid sequences but exhibit relatively different debrisoquine catalytic activities, with 
marmoset CYP2D30 representing a better model for human metabolism (Hichiya et 
al., 2004); the Japanese macaque, expresses CYP2D29, a protein having 96% 
amino acid homology to human CYP2D6 (Hichiya et al., 2002). All of the above non­
human primate CYP2D enzymes catalyse the metabolism of the human CYP2D6 
probe substrate, debrisoquine, albeit at different rates.
1.3.6: CYP2E
CYP2E1 is the only CYP2E enzyme expressed in human. This enzyme is strongly 
conserved among animal species with the cynomolgus monkey having an amino acid 
sequence identity to human CYP2E1 of 96% (Komori et al., 1992), although, when 
identified in the marmoset by Schulz et al. (1998) it was found that the C-terminus of 
the CYP2E1 was extended by two animo acids. CYP2E1 induction has been strongly 
linked to alcohol intake and abuse, as this enzyme plays a significant detoxification 
role in ethanol consumption and is induced in human in response to intake in order to 
prevent ethanol from reaching excessive levels (Salaspuro and Lieber, 1978), This 
has also been documented in experimental animals (Lieber and DeCarli, 1972) 
including cynomolgus monkey (Ivester et al., 2006). CYP2E1 is also upregulated 
during periods of low carbohydrate consumption, type I diabetes or starvation as
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CYP2E1 contributes to the metabolism of fatty acids as well as converting ketones to 
glucose (Lieber, 1997).
1.3.7: CYP3A
CYP3A4 is the major human liver cytochrome P450 enzyme, exhibiting considerable 
inter-individual variation, and is responsible for the oxidation of the majority of drugs 
in the clinic today. CYP3A enzymes are said to represent the largest fraction of 
phase I enzymes in the human liver, accounting for approximately 30% of the total 
hepatic P450 complement. CYP3A5, normally the minor CYP3A form in human, is 
polymorphic and only expressed in about 50% of humans (Gibson and Skett, 2001). 
However, when expressed, it is possible that CYP3A5 can represent more than 50% 
of the total CYP3A in some individuals (Kuehl et al., 2001). CYP3A enzymes are 
highly inducible by a range of xenobiotics including synthetic glucocorticoids, 
macrolide antibiotics and barbiturates (Jones et al., 2000). CYP3A is present in all 
species, representing one of the most important drug metabolising enzymes, and as 
such has been the subject of a large number of studies. The cynomolgus monkey 
expresses CYP3A8, representing approximately 20% of the total hepatic CYP 
component in monkey liver (Ohmori et al., 1993) and exhibits 93% similar amino acid 
identity to human CYP3A4 (Komori et al., 1992). Marmoset expresses CYP3A21 at 
levels similar to human CYP3A4 (Koehler et al., 2006). However, differing substrate 
specificity of the various CYP3A enzymes expressed across species has made 
extrapolation of this most important contributor to drug metabolism from animal to 
man, somewhat hazardous (Martignoni et al., 2006).
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1.3.8: CYP4A
Human hepatic CYP4A11 is a highly polymorphic enzyme (Oho et al., 2005) 
responsible for the catalysis of long-chain fatty acids such as arachidonic acid (Hsu 
et al., 2007). CYP4A is not known for its ability to metabolise drugs or other 
xenobiotics but is mentioned herein because its expression is strongly influenced by 
hypolipidemic drugs such as fibrates known to cause species-specific peroxisome 
proliferation (Bell et al., 1993), or non-steroidal anti-inflammatory drugs (Rekka et al., 
1994). CYP4A11 is also involved in the regulation of blood pressure in the kidney 
(Lasker et al., 2000).
1.4: Regulation of xenobiotic metabolism
In addition to species differences in the level of expression of CYP enzymes, they are 
also subject to different regulation by nuclear receptors that bind to DNA as 
monomers, homodimers, or hetrodimers and, in conjunction with a variety of 
cofactors, affect gene transcription (Figure 1.1). Currently, there have been 
approximately fifty nuclear receptors identified in human (Mangelsdorf et al., 1995; 
Chawla et al., 2001; Makishima, 2005). The biological effects of these nuclear 
receptors are far reaching, since their signal is greatly amplified downstream, even in 
the presence of a small amount of ligand. Therefore, interaction with nuclear 
receptors by endogenous or exogenous ligands can have an array of consequences 
on the metabolism of drugs. (Miller and Wilson, 2001).
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Nuclear receptor dimer
Cognate DNA 
elements
Adapted from Honkakoski and Negishi (2000)
Figure 1.1: A schematic representation of the Interactions resulting In gene 
transcription. Two distinct domains bring about the nuclear receptor dimer formation seen 
above, one in the DBD and the other involving helix 10 in the LBD (Honkakoski and Negishi, 
2000).
There is a common general pathway involving specific members of the nuclear 
receptor superfamily, which regulates the mechanism of induction of the major drug 
metabolising CYPs. All nuclear receptors share a similar modular structure 
composed of four domains which are involved in the function of these receptors. 
These domains are the N-terminus activation function 1 (AF-1) whose action is 
independent of the presence of a ligand, the DMA-binding domain (DBD) that 
consists of two highly conserved zinc finger motifs, the ligand-binding domain (LBD), 
and the C-terminus ligand-dependent activation function 2 (AF-2) transactivation 
domain (Figure 1.2). Exposure to drugs (ligands) activates specific nuclear receptors 
by interacting with the ligand-binding domain (LBD). Once bound, the ligand induces 
structural changes in the ligand-binding domain resulting in the repositioning of the 
AF-2 in the C-terminal extension, which in turn is often required for correct binding to 
their cognate DNA elements by the DNA-binding domain (DBD). This then stimulates 
CYP target gene transcription (Honkakoski and Negishi, 2000).
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NH; AF-1 DBD LBD AF-2 COOH
Adapted from Honkakoski and Negishi (2000)
Figure 1.2: Nuclear receptor modular structure. Identification of the DNA and ligand 
binding domains (DBD and LBD), and activation function 2 (AF-2) whose action is dependent 
on the presence of bound ligand.
Nuclear receptors that code for the transcription factors, which transform chemical 
inducer signals into cellular responses by triggering the transcription of nuclear 
receptor target genes, have been the focus of much investigation in recent years. 
This has provided new and interesting depths to the known cellular mechanisms 
involved in the biotransfomation of xenobiotics. The nuclear receptor superfamily is 
divided into seven groups and seven subfamilies, which are then further divided. 
Nuclear receptors in the same group share at least 80-90% identity in their DNA- 
binding domains and have at least 40-60% identity within their ligand-binding 
domains (Nuclear Receptor Nomenclature Committee 1999). The more commonly 
investigated xenobiotic sensing nuclear receptors are: constitutive androstane 
receptor (CAR) and pregnane X receptor (PXR, alternatively named SXR, steroid 
xenobiotic receptor or PAR, pregnane activated receptor); these belong to a 
superfamily of nuclear receptors which also include the vitamin D receptor (VDR), 
thyroid receptor (NR2C1-2), peroxisome proliferator-activated receptor (PPAR) and 
glucocorticoid receptor (GR). One of the most extensively studied receptors is the 
aryl hydrocarbon receptor (Ah receptor or AHR), this ligand-activated transcription 
factor is involved in the regulation of several genes, including those for xenobiotic- 
metabolizing enzymes including CYP1A (Harrigan et al., 2004). Ligands for the AHR 
include a variety of aromatic hydrocarbons, including the chlorinated dioxins and
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related halogenated aromatic hydrocarbons whose toxicity occurs through activation 
of the AHR (Denison et al., 2002).
It has been suggested that some overlap in nuclear receptor targets may exist 
(Honkakoski and Negishi, 2000). For example some CAR activators such as 
phénobarbital, clotrimazole and some polychlorinated biphenyls seem to be ligands 
for PXR as well, while heterodimers of CAR and RXR have also been associated 
with phénobarbital induction (Mashahiko and Honkakoski, 2000), and a PXR/RXR 
heterodimer appears to be essential for the activation of CYP3A4 (Gibson et al., 
2002). The role of the nuclear receptors is indeed a complex one, with some nuclear 
receptors having direct or indirect roles in the transcription of target genes, while 
some may exhibit both direct and indirect roles, as may be the case with the 
glucocorticoid receptor in human CYP3A4 gene activation (Gibson et al., 2002).
1.5: Induction
Repeated doses of a drug may enhance the metabolism of that drug (autoinduction) 
as in the case of carbamazepine (Magnusson et al., 2008). The enzyme activity may 
also become induced by another drug, or an environmental constituent such as 
dietary components or tobacco smoke. If the metabolism of a drug is induced, it may 
lead to the loss of pharmaceutical effect due to sub-therapeutic concentrations. 
However, if the drug is a prodrug (i.e. becoming active upon metabolism) or 
generates a toxic metabolite, induction could result in unwanted side-effects or 
unexpected drug-drug interactions (Rodrigues et al., 2008).
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Many of the drug metabolising CYPs are known to be inducible, an obvious 
exception being CYP2D6, which appears to be refractive to inducers (Davis and 
Homsi, 2001). CYP3A4, the most important CYP enzyme in drug metabolism 
because of its large substrate-binding pockets, multiple active sites and high degrees 
of expression in human, also seems to be an enzyme with a high potential for 
induction (Backman et al., 1996; Wang et al., 2001; Gerber et al., 2005). CYP1A on 
the other hand is expressed at low levels in human but is, however, highly inducible 
(Ma and Lu, 2007). Enzyme induction generally occurs at the transcriptional level and 
is the result of ligand binding and activation of one of the nuclear receptors 
controlling the CYP gene transcription (Fisher et al., 2008). Induction of CYP1A and 
CYP3A are subject to significant species differences. For example, omeprazole is a 
CYP1A inducer in human, but has little or no effect in mice and rabbits (Diaz et al., 
1990; McDonnell et al., 1992). Rifampicin is a potent inducer of CYP3A enzymes in 
human and rabbit, but has little effect on CYP3A in rat (Kocarek et al., 1995). These 
differences have been shown to exist due to structural differences in the nuclear 
receptors within these species (Jones et al., 2000; Xie et al., 2000).
1.6: Inhibition
The mechanism of inhibition can be divided into different categories; reversible 
inhibition (including quasi-irreversible inhibition) and irreversible inhibition (Lin and Lu 
1998). Reversible binding occurs when there is competition at the substrate-binding 
site of the enzyme, the binding of one drug may then inhibit other drugs from binding. 
Some drugs are capable of binding to, and acting as competitive inhibitors of different 
CYP enzymes from the ones that are responsible for the metabolism of that particular 
drug (Meyer and Rodvold 1996). Irreversible binding (mechanism-based inhibition)
occurs when biotransformation of certain compounds results in an active metabolite
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that is capable of binding to the CYP enzyme causing irreversible loss of function. 
More complex mechanisms of inhibition can also occur, with some drugs undergoing 
metabolic activation that can then generate relatively stable CYP/inhibitor complexes 
so that the enzyme is held in an inactive state. It should be noted that it is considered 
highly desirable to develop new drug candidates that are not potential CYP inhibitors 
and are not susceptible to the effects of known CYP inhibitors (Lin and Pearson, 
2002).
Interactions can also occur between drugs and dietary components. A recent case 
study presented in The Lancet, by Grande et al. f2009), described a slightly over­
weight 42-year old woman walking with difficulty, shortness of breath and feeling 
light-headed, who was examined in a hospital emergency department. She did not 
smoke and rarely drank alcohol, but had begun an aggressive weight-loss diet 
including 225g grapefruit juice every morning. After prolonged investigations it was 
concluded that her condition had been brought about by her new diet. Grapefruit 
juice inhibits CYP3A4 by a mechanism based inactivation described by Chan et al. 
(1998), and as a result of the high grapefruit juice intake, inhibition of CYP3A4 
occurred, leading to an increase in the bioavailability of ethinylestradiol (orally bio­
active oestrogen, a component of oral contraceptive pills), that had resulted in 
enhanced hypercoagulability (blood clots), highlighting the potential serious nature of 
CYP inhibition.
1.7: Polymorphism
Significant genetic variation has been described for several of the drug metabolising 
CYPs, such as CYP2C19 and CYP2D6, both having allelic variants and as such are
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termed polymorphic. Polymorphism is generally defined as a CYP with more than 1% 
frequency of an allelic variant in the population (Flockhart and Bertilsson, 2007). The 
majority of the allelic variants are single nucleotide polymorphisms (SNPs); however, 
gene duplication also occurs. The presence of a polymorphism can lead to enhanced 
or depleted enzyme activity, resulting in lower or higher plasma concentrations of 
circulating drug than expected. Individuals with decreased enzyme activity are called 
intermediate or poor metabolisers, and normally carry one or two defective alleles, 
respectively. Individuals with normal enzyme activity are called extensive 
metabolisers and individuals with gene duplication and increased activity are known 
as ultrarapid metabolisers.
An example of the serious consequence that can be brought about by these 
poloymorphisms has been highlighted by Koren et al. (2006), who described a case 
of a previously healthy full-term male infant who, at 13 days of age, was found dead. 
Postmortem analysis discovered s blood concentration of morphine (the active 
metabolite of codeine) of 70 ng/ml (typically 0-2 ng/ml in breast fed infants). The 
mother had been taking paracetamol/codeine tablets for after birth episiotomy pain. 
Genotype analysis revealed that the mother was heterozygous for CYP2D6*2A allele 
with CYP2D6*2x2 gene duplication, classified as an ultra-rapid metaboliser. This 
genotype had resulted in the increased formation of morphine from codeine in the 
mother and had subsequently passed to the infant during breast feeding. The infant 
was only an extensive metaboliser with two functional CYP2D6 alleles, resulting in 
opiod toxicity.
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1.8: Non-human primates
The monkey, the evolutionarily closest species to humans, shows not only 
phenotypic but also physiological similarities to humans in such biological 
circumstances as aging (Roth et a/., 2004), reproduction (Bellino and Wise, 2003), 
and neurological disease, including Parkinson’s disease (Takagi et al., 2005). Some 
of these similarities can be equated to the high protein sequence conformity of 
approximately 97% between the two species (Magness et al., 2005).
Drug metabolism investigations during preclinical trials and drug discovery often 
utilise monkeys as a non-rodent species to evaluate drug effects, because they 
generally show pharmacokinetic behaviour more similar to humans than other non­
primate models. At present, the most common non-human primates used in drug 
metabolism are cynomolgus or crab-eating macaque {Macaca fascicularis), 
Japanese macaque {Macaca fuscata) and rhesus macaque (Macaca mulatta) 
monkeys. They have been extensively used in predicting pathways of drug 
metabolism, cytochrome P450 induction and toxicity in humans (Jacqz et al., 1988; 
Ojiha and Kohli, 1994; Bullock et al., 1995), and are considered to be suitable 
surrogates for human, because of their high amino acid sequence identity (93-96%) 
to human CYPs (Uno et al., 2007). However, it has become apparent that these 
monkeys do not always generate drug metabolism data predictive of human 
metabolism (Stevens et al., 1993; Sharer et al., 1995; Guengerich, 1997; Weaver et 
al., 1999; Bogaards et al., 2000; Narimatsu et al., 2000). Such species differences 
may be due to small genetic variations in the cytochrome P450 profile compared to 
human. Moreover, these primates are quite large, sometimes fierce, difficult to 
handle and generally have poor fertility (Jacqz et al., 1988). New world monkeys, on 
the other hand, especially the common marmoset {Callithrlx jacchus), an arboreal
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primate of the family Callitrichiae, have many advantages over the use of these old 
world monkeys: they are much smaller, easier to handle, can be hand-tamed and 
have good fertility, making captive breeding a more successful option. As the 
marmoset is of a similar size to that of a rat, techniques and methodologies for rats 
may easily be adapted (McAnulty, 1996).
1.8.1: The common marmoset (Callithrix jacchus)
The marmoset has been used in research for over 40 years and since the early 
1980’s its usage has increased substantially. The University of Berlin first attempted 
the isolation and purification of marmoset hepatic cytochrome P450 using fast protein 
liquid chromatography (FPLC) (Kastner at al., 1989). A single marmoset cytochrome 
P450 was isolated from the liver of male marmosets treated with phénobarbital. The 
characteristics of this P450 included high aldrin epoxidation activity and low 
ethoxycoumarin deethyation, while ethoxyresorufin and pentoxyresorufin dealkylation 
activities were not detectable. The estimated molecular weight for this protein was 51 
KDa. This early work was advanced within the University of Berlin over the next few 
years (Kastner and Neubert, 1991 and 1994), resulting in the purification of a total of 
seven cytochrome P450s However, only three of these were present in untreated 
marmoset liver, with molecular weights originally estimated to be 48, 51, and 52 KDa. 
The remaining CYPs were isolated from the livers of marmosets that were treated 
with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TODD), the estimated molecular weights of 
these induced proteins ranging from 49 to 56 KDa. Two of the constitutive forms 
were investigated further using immunoblotting techniques with polyclonal anti-rat 
CYP1A1 and CYP1A2 antibodies. These experiments revealed positive response to 
the anti-rat CYP1A2 antibody only, implying that the main or sole CYP1A in the 
marmoset liver is CYP1A2.
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Two years later, the Berlin University group collaborated with the Royal Postgraduate 
Medical School, London (later to become the Imperial Collage School of Medicine) to 
investigate the inducibility of marmoset hepatic and extrahepatic P450s by dioxins. 
After a series of Western blot studies using anti-human antibodies targeted towards 
CYP1A1, CYP1A2, CYP2B6 and CYP3A4, it was demonstrated that CYP1A1 and 
CYP1A2 were inducible by dioxin treatment. However, only CYP1A2 was shown to 
be constitutively expressed in the marmoset liver (Schulz et al., 1996). Two years 
later the same workers investigated the induction of CYP2E1 in marmoset (Schulz et 
al., 1998). Increased catalysis of the known CYP2E1 substrate, chlorzoxazone, after 
treatment with isoniazid, demonstrated the possibility of CYP2E1 induction. However, 
Western blot analysis of marmoset liver microsomes indicated that an anti-peptide 
antibody targeted against the C-terminus of human and cynomolgus monkey 
CYP2E1 failed to bind. Using sequenced C-terminus marmoset CYP2E1 prepared 
from human and cynomolgus monkey primers, selected according to conserved 
regions, this newly sequenced C-terminus marmoset CYP2E1 identified an extension 
of 2 amino acids in the marmoset CYP2E1 compared to that of either human or 
cynomolgus monkey. Immunising rabbits with this synthesised C-terminus of 
marmoset CYP2E1 produced anti-marmoset CYP2E1 antibodies, which in Western 
blot analysis with marmoset microsomal proteins displayed immunoreactivity to a 54 
KDa protein. Conversely, this newly-produced antibody targeted towards the C- 
terminus of marmoset CYP2E1 failed to bind to either human or cynomolgus 
CYP2E1, concluding that antibodies targeting the C-terminus of a protein are highly 
specific. In 2001 this collaboration went on to investigate the expression of hepatic 
cytochrome P450 enzymes in male marmosets using anti-peptide antibodies 
originally targeted against human cytochrome P450 enzymes (Schulz et al., 2001). 
The target region of the majority of antibody binding is towards the N-terminus, and 
this region was predicted to be similar between the marmoset and human CYPs. The
findings revealed that out of the antibodies investigated (CYP1A1, CYP1A2,
_
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CYP2B6, CYP2C, CYP2D6, CYP2E1, CYP3A4 and CYP4A11) only two failed to 
bind to marmoset cytochrome P450 enzymes. These were the antibodies originally 
targeted towards human CYP2E1 and CYP4A11; the former due to the 2 amino acid 
extension of the C-terminus, and it was hypothesised that CYP4A enzymes may vary 
in the region targeted by the antibody in a similar way. Using peptide sequence data 
a detailed table of the anti-peptide antibodies and their reactivity with human and 
marmoset P450 antigens was produced.
In contrast to the above investigation by Schulz et al., a study by Igarashi et al. 
(1997) at Hokkaido University, Japan, used anti-rat antibodies (CYP1A1, CYP2B1, 
CYP2C11, CYP2E1, CYP3A2 and CYP4A1) to investigate the expression of hepatic 
P450 proteins in female marmosets. Western blot analysis established the presence 
of CYP2B, CYP2C, CYP2D, CYP2E and CYP3A enzymes together with a small 
amount of CYP1A. However, Northern blot analysis showed no signal using 
cynomolgus CYP1A1 cDNA as a probe, although weak hybridisation was observed 
using human CYP1A2, suggesting constitutive expression of CYP1A2 as previously 
suggested by Schulz etal. (1996).
The more recent work published on the hepatic expression of marmoset P450 was 
conducted in Okayama University, Japan. Hichiya et al. (2002), and concerns the 
marmoset CYP2D enzyme. They first used primers based on the flanking regions of 
marmoset monkey CYP2D19 nucleotide sequence (GenBank Accession No. 
D29822) to produce a cDNA cloned from Japanese macaque monkey liver. 
Subsequently, in 2004 another CYP2D enzyme was cloned using the same primer 
set (Hichiya et al., 2004); this newly cloned enzyme was identified as marmoset 
CYP2D30. The resulting nucleotide and amino acid sequences were registered with
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GenBank. Using polyclonal anti-rat CYP2D1, Western blot analysis revealed a single 
imunoreactive band of about 50 KDa in marmoset liver microsomes and transformed 
yeast cells expressing either CYP2D19 or CYP2D30. The identities of CYP2D19 and 
CYP2D30 were confirmed following separation on Northern blots that were 
performed on digested and non-digested PCR products of RNA from different 
marmoset livers. PCR products of RNA digested with restriction enzyme Nde^ 
revealed bands at 1,127 base pairs (bp) and 367 bp in marmoset livers expressing 
CYP2D30, whilst a single band of 1,494 bp was present in untreated PCR products 
of RNA from livers expressing either CYP2D30 or CYP2D19. A/c/el digestion of PCR 
products of RNA from livers expressing either CYP2D19 however, revealed a single 
band of 1,494 bp, only.
Finally, Narimatsu et al. (2005) from Okayama University conducted further studies 
on the Japanese macaque monkey, in comparison with marmoset CYP1A2. Anti-rat 
antibodies were used for the Western blot comparative work and ethoxyresorufin O- 
deethylase activity was used to determine the enzymatic activity. Interestingly, both 
the Japanese macaque and the marmoset showed biphasic kinetic characteristics, 
and the authors postulated that CYP1A2 demonstrated both a high Km and a low Km 
ethoxyresorufin 0 -deethylase.
1.9: Summary
Members of the CYP enzyme superfamily generally contain highly conserved regions 
of amino acid sequences with relatively small differences in the primary amino acid 
sequences across species. However, even very small changes to these amino acid 
sequences may result in species differences in routes of metabolism, rates of
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metabolism and substrate-specific catalytic activity (Gibson and Skett, 2001; 
Martignoni et al., 2006). Hence, the small genetic changes in the amino acid residues 
of these enzymes are a major cause of the inter-species differences in drug 
metabolism described through numerous publications. It is therefore crucial to 
consider carefully which species is to be employed as an animal model for the testing 
of new chemical entities; such animal models may of course, be different for different 
compounds investigated. It is, therefore, essential for these animal models to be 
sufficiently well characterised for their intended use, and indeed the FDA (Food and 
Drug Administration) consider that these animals need to be ‘adequately evaluated 
for their responsiveness’ (FDA Guidance for Industry 2009). To this end, the principal 
objective of this study was to evaluate the utility of the common marmoset as a 
surrogate for human cytochrome P450 drug metabolism.
1.10: Aims and objectives
The expression and substrate specificity of hepatic cytochromes P450 are known to 
affect the utility of a species as a surrogate to human in drug development. The 
objective of this work is to evaluate whether the marmoset meets the needs of an 
alternative non-human primate animal model that is relatively inexpensive, easy to 
breed and non-aggressive. Marmosets are, thus, potentially a powerful preclinical 
model for human drug metabolism. The aim was therefore to quantitatively assess 
the function and expression of marmoset liver microsomal P450 enzymes in direct 
comparison to their human orthologues. The research programme aims to
• Initially conduct kinetic determinations of Km and Vmax on marmoset liver 
microsomes using known human chemical probes for cytochrome P450 
enzymes.
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• Identify and semi-quantify marmoset cytochromes P450 using commercially 
available antibodies targeted towards human CYPs, in immunoblot analysis in 
comparison to human and rat microsomes analysed in parallel.
• Finally, identify any similarity in the targeted amino acid sequence of the 
marmoset cytochromes P450 genes using qRT-PCR and oligonucleotide 
primer pairs and probes complementary to human CYP sequences.
26
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2.1: Chemicals
Androstenedione, coumarin, deuterium oxide, 7-ethoxyresorufin, glucose 6 - 
phosphate (disodium salt), glucose 6 -phosphate dehydrogenase (type VII, from 
baker’s yeast), 7-hydroxycoumarin, 2a-, 2p-, 6 a-, 6(3-, 7a-, 16a- and 16p- 
hydroxytestosterone, lauric acid, 7-methoxyresorufin, methylene blue, NADP"" 
(sodium salt), NADPH (tetrasodium salt, type I), paclitaxel, f"^C]paclitaxel (44.7 
pCi/pmol, 100 pCi/ml), 7-pentoxyresorufin, resorufin and testosterone were all 
obtained from Sigma Chemical Co Ltd (Poole, Dorset, UK). Debrisoquine sulphate 
was obtained from ICN Biomedicals Ltd (Thame, Oxfordshire, UK). 4- 
Hydroxydebrisoquine, 4-hydroxymephenytoin and S-mephenytoin were purchased 
from Ultrafine Chemicals Ltd (Salford, UK). [gi/an/d/ne-^'^CjDebrisoquine (53 
pCi/pmol, 50 pCi/ml), [phenylacetic acid ring-U-['^C]6\c\ofenac sodium (54 pCi/pmol, 
1000 pCi/ml), full range molecular weight markers (10,000-250,000 Da), [1-^"^C]lauhc 
acid (57 pCi/pmol, 50 pCi/ml), S-[4-‘"^C]mephenytoin (56 pCi/pmol, 50 pCi/ml), [4- 
^"^Cjtestosterone (57 pCi/pmol, 50 pCi/ml) and [nng-U-^'^C]tolbutamide (61 pCi/pmol, 
50 pCi/ml) were obtained from Amersham International pic, Amersham 
(Buckinghamshire, UK). Polyclonal anti-rat CYP1A1 (for immunoblot of rat/human 
CYP1A1/2) antibody raised in goat, monoclonal anti-human CYP2A6 antibody raised 
in mouse ascetic fluid, polyclonal anti-human CYP2B6 antibody raised in rabbit, 
polyclonal anti-human CYP2C9 antibody raised in rabbit, polyclonal anti-human 
CYP2C19 antibody raised in rabbit, monoclonal anti-human CYP2D6 antibody raised 
in mouse ascetic fluid, polyclonal anti-rat CYP2E1 antibody raised in goat, polyclonal 
anti-human CYP3A4 antibody raised in rabbit, polyclonal anti-human CYP3A5 
antibody raised in rabbit (Table 2.1), rat liver microsomes and recombinant human 
CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and 
CYP3A5 individually expressed in insect cells (Supersomes®) were purchased from
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BD Biosciences (Bedford, MA, USA). Polyclonal anti-marmoset CYP2E1 antibody 
raised in rabbit was generously supplied by Dr R.J,Edwards (Imperial College School 
of Medicine, Hammersmith Hospital, London, UK). Invitrogen (Carlsbad, CA, USA) 
supplied fluorogenic substrate 1,3-dichloro-9,9-dimethylacridin-2-one-7-yl phosphate, 
diammonium salt (DDAO phosphate), goat anti-rabbit IgG alkaline phosphatase 
conjugated antibody, LDS sample buffer, MOPS SDS running buffer, NuPAGE 4- 
12% Bis-Tris gels, rabbit anti-goat IgG alkaline phosphatase conjugated antibody, 
rabbit anti-mouse IgG alkaline phosphatase conjugated antibody, NuPAGE reducing 
agent (lOx), superscript II (containing DTT and 5x first strand buffer), RNase OUT, 
dNTPs and random hexamers . Nucleospin RNA II was obtained from Macherey- 
Nagel (Bethlehem, PA, USA). DNase I (plus buffer and stop solution) was purchased 
from Promega (Southampton, UK), and Abgene (Epson, UK) supplied Absolute 
QPRC ROX Mix, Absolute QPCR seal, TaqMan Universal PCR Master Mix and 
Thermo-Fast 96 well white PCR detection plates and Applied Biosystems 
(Warrington, UK) supplied RNA/afer ICE. Human CYP1A1, human CYP1A2, human 
CYP2A6, human CYP2B6, human CYP2C9, human CYP2C19, human CYP2D6, 
human CYP2E1, human CYP3A4 and human CYP4A11 PRC primers and PCR 
probes (Table 2.2) were obtained from Eurofins (Ebersberg, Germany). Canberra 
Packard (Groningen, The Netherlands) supplied Ultima gold scintillation cocktail. 
Other chemicals were purchased either from Fisher Laboratory Supplies 
(Loughborough, Leicestershire, UK), BDH Ltd (Poole, Dorset, UK) or from Waters 
Millipore (Elstree, Hertfordshire, UK) at the highest commercially available grade. 
Super pure water was distilled in situ by an Elgastat Option 4 plant (ELGA water 
systems Marlow, Buckinghamshire, UK).
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2.2: Analytical equipment
2.2.1: Fluorescence spectrophotometer - Hitachi F-4500 (Nissei Sangyo Co. Ltd., 
Wokingham, Berkshire, UK).
2.2.2: UVA/ls spectrophotometer - Philips PU-8700 (Philips Scientific, Cambridge, 
UK).
2.2.3: High performance liquid chromatography (HPLC) -  All HPLC analysis was 
conducted using either a Waters Alliance 2690 Separation module (Millipore Waters, 
Elstree, Hertfordshire, UK) with the eluate being monitored for UV absorbance using 
a Waters 486 tuneable absorbance detector, or a system comprising a Spectra 
System P4000 Quaternary HPLC pump (Thermo Fisher Scientific, Waltham, MA, 
USA) and a Spectra System AS3000 Variable-loop Autosampler. The eluate from 
this system was monitored for UV absorbance using a Spectra System UV2000 
UVA/is Detector.
[‘"^C]-Radioactivity was monitored using a (3-Ram Radioisotope System fitted with a 
solid CaF flow through detection cell. Data were collected using Laura system 
software (version 1.4a, LabLogic Systems Ltd., Broomhill, Sheffield, UK).
2.2.4: Liquid chromatography mass spectrometry, mass spectrometry (LC- 
MS/MS) -  TSQ7000 (Finnigan MAT, San Jose, CA, USA) and a Shimadzu HPLC 
system (Dysons Instruments Ltd., Tyne & Wear, UK) comprising LC-10AD pumps
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and SIL-10Avp autosampler. The eluate from this system was monitored for UV 
absorbance using a Shimadzu SPD-10Avp UV Detector.
Data were collected using Xcalibur, Version 1.2 (Finnigan).
2.2.5; Nuclear magnetic resonance (NMR) -  Bruker Avance NMR 500 MHz
spectrometer equipped with a 5 mm broadband BBC probe (Bruker BioSpin Limited, 
Coventry, UK).
2.2.6: Imaging system - Fujifilm FLA-5000 (Fuji Photo Film Co. Ltd., Minato-Kia, 
Tokyo, Japan.)
2.2.7: Reverse transcriptase polymerase chain reaction (RT-PCR) -  ABI Prism 
7000HT Sequence Detection System (Applied Biosystems, CA, USA).
2.3: Preparation of hepatic subcellular fractions 
2.3.1: Marmoset monkey and human Liver
Marmoset monkey liver was removed from naïve male common marmosets 
{Callithrix jacchus) from the marmoset-breeding colony. Eye Research Centre, 
Huntingdon Life Sciences, immediately post-mortem, the animals were sacrificed by 
exsanguination under barbiturate anaesthesia. The marmoset livers were either i) 
immediately frozen separately in liquid N2, or ii) rinsed and gently perfused with 
sodium chloride solution 0.9% (w/v) prior to being snap frozen in liquid N2 (Tables 
2.3-2.5). Resected human liver samples were obtained in a frozen state (on solid 
carbon dioxide) from the UK Human Tissue Bank (UKHTB) (De Montfort University,
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Leicester, UK) (Table 2.6). Livers were transferred in a frozen state for storage at - 
75°C at Huntingdon Research Centre, Huntingdon Life Sciences until required for 
processing and preparation of hepatic microsomal subcellular fractions.
Animal no. Age Body wt. (g) Liver wt. (g)
0414 8  years 8  months 376 15.0
0914 8  years 8  months 449 14.5
1554 8  years 3 months 424 14.9
0215 7 years 9 months 378 15.7
1595 6  years 11 months 571 24.6
Table 2.3: Batch 1 male marmoset details. Livers collected from marmosets at the Eye 
Research Centre breeding colony on 4th October 2002, and immediately frozen in liquid 
nitrogen prior to transport and storage.
Animal no. Age Body wt. (g) Liver wt. (g)
0473 1 year 1 0  months 388 16.4
0625 1 year 11 months 289 9.7
017B 4 years 3 months 392 14.3
023B 4 years 3 months 397 14.0
1274 11 years 351 18.5
Table 2.4: Batch 2 male marmoset details.Livers collected from marmosets at the Eye 
Research Centre breeding colony on 21st May 2005, and immediately frozen in liquid 
nitrogen prior to transport and storage.
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Animal no. Age Body wt. (g) Liver wt. (g)
0007 5 years 1 month 323 11.3
0017 5 years 291 1 1 . 6
0699 2 years 7 months 290 10.5
0977 8  years 7 months 368 17.1
0997 8  years 7 months 380 17.7
Table 2.5: Batch 3 male marmoset details. Livers collected from marmosets at the Eye 
Research Centre breeding colony on 15th June 2006, and immediately frozen in liquid 
nitrogen prior to transport and storage.
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2.3.2: Preparation of microsomal fractions
The following procedures were conducted at 4°C. Liver samples, or portions thereof, 
were removed from storage and thawed by immersion into ice-cold isotonic 50 mM 
Tris-HGI buffer, pH 7.4, containing 0.25 M sucrose for 20 minutes. Prior to 
homogenisation, liver samples were removed from the buffer and blot-dried. Each 
liver sample was scissor-minced, and a portion (ca. 4 g) homogenised in 4 volumes 
of 50 mM Tris-HGI buffer, pH 7.4, containing 0.25 M sucrose, using an electrically- 
driven glass Potter-Elvehjem-type homogeniser, fitted with a Teflon pestle. The 
homogenates were centrifuged at 13,000 x g for 20 minutes at 4°G (Beckman L8 - 
70M ultracentrifuge, fixed angle rotor 50.2 Ti: 12,000 rpm; Beckman Instruments Ltd, 
High Wycombe, Buckinghamshire, UK) and the resulting supernatant (S9 fraction) 
decanted off. The microsomal fraction was prepared by centrifugation of this 
supernatant at 105,000 x g for 1 hour at 4°G (Beckman L8-70M ultracentrifuge, fixed 
angle rotor 50.2 Ti: 34,000 rpm). The resulting cytosolic fraction was decanted off, 
whilst the microsomal pellet was either i) immediately resuspended in 50 mM Tris- 
HGI buffer, pH 7.4 such that 1 ml of the suspension was equivalent to approximately 
300 mg original wet weight of thawed liver (batch 1 marmoset liver only. Tables 2.3 
and 2.7), or ii) rinsed with 20 ml of 50 mM Tris-HGI buffer, pH 7.4, containing 0.25 M 
sucrose and re-centrifuged at 105,000 x g for 1 hour at 4°G (Beckman L8-70M 
ultracentrifuge, fixed angle rotor 50.2 Ti: 34,000 rpm) before being resuspended in 50 
mM Tris-HGI buffer, pH 7.4 such that 1 ml of the suspension was equivalent to 
approximately 300 mg original wet weight of thawed liver (batches 2 and 3 marmoset 
livers. Tables 2.4-2.5 and 2.7).
An aliquot from each sample was used to prepare a microsomal pool, for each batch 
of livers. These pooled fractions were used in preliminary linearity assays and
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Western blot analyses. The remaining microsomal fractions were divided into 1 ml 
aliquots. All subcellular fractions were immediately transferred to storage at -75°C for 
subsequent analysis.
Species Batch
designation
Date of 
receipt
Processing and 
preparation 
method
Use
Marmoset
1 04/10/02 No washing® Establish kinetic 
linearity; isolate and 
identify novel 
debrisoquine 
metabolites
2 21/05/05 Washed*^’ Kinetic analysis and 
Western blot 
) analysis
3 15/06/06 Washed*^  ^^ Kinetic analysis and 
PCR
Human Not
applicable
07/03/06 Washed^ Western blot and 
PCR
Table 2.7: Liver processing, microsomal preparation and use.
® Livers immediately snap frozen in liquid N2 prior to -70°C  storage. Preparation of 
subcellular fractions conducted using a single 1 hour 105,000 x g centrifugation of the S9 
fraction.
Livers rinsed and gently perfused with sodium chloride solution 0.9% (w/v) prior to being 
snap-frozen in liquid N2 and -70°C  storage.
 ^ Preparation of subcellular fractions conducted using two 1 hour 105,000 x g centrifugation 
steps of the S9 fraction, one of which was a rinse using 20 ml of 50 mM Tris-HGI sucrose 
buffer.
2.3.3: Protein determination
Protein concentration was determined by the method of Lowry at al. (1951). Aliquots 
(0.5 ml) of microsomal suspension (1 in 75 dilution, in duplicate) were mixed with 
alkaline copper tartrate reagent [1 part 2 % (w/v) potassium/sodium tartrate : 1 part 
1% (w/v) CUSO4 .5 H2O : 98 parts 2% (w/v) Na2C0 3  in 0.1 M NaOH] (3 ml) and the 
samples left to stand at room temperature for 20 minutes. An Aliquot (0.3 ml) of Folin 
and Ciocalteu's phenol reagent (diluted 1 : 1 with water) was then added, and
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samples allowed to stand at room temperature for a further 40 minutes for the colour 
to develop; absorbance was read at 750 nm against a distilled water reference. The 
amount of protein was calculated from a standard curve, prepared using bovine 
serum albumin (BSA) (0 - 200 pg) assayed under identical conditions. Results have 
been expressed as milligrams of protein (BSA equivalents) per millilitre of subcellular 
fraction and milligrams of protein (BSA equivalents) per gram of liver. See 
Appendices for concentration data.
2.3.4: Determination of totai microsomai cytochrome P450
Cytochrome P450 was assayed essentially as described by Rutten et al. (1987), a 
procedure derived from the ‘dithionite difference’ method described by Matsubara at 
al. (1976). Microsomal suspension (0.2 ml) was added to 100 mM potassium/sodium 
orthophosphate buffer, pH 7.4, containing 20% (v/v) glycerol (2.29 ml) in each of two 
cuvettes (test and reference). Samples were mixed by gentle inversion and carbon 
monoxide was then bubbled through both cuvettes for 35 seconds. After 4 minutes 
standing time, test samples were supplemented with 1.15 M sodium dithionite (10 pi), 
mixed by gentle inversion and left to stand for a further 6  minutes. The absorption 
difference spectrum (400 - 500 nm) was recorded using a double beam Philips 
spectrophotometer (bandwidth 2 nm, cell path 1 cm). Samples were assayed in 
triplicate and cytochrome P450 concentrations calculated using the mM extinction 
coefficient of 99 cm'^ mM'^ (Rutten at al., 1987) for the absorbance difference 
between the spectrum peak at ca 450 nm, and a baseline value at 490 nm. 
Cytochrome P450 concentrations have been expressed as nmoles per milligram of 
microsomal protein and nmoles per gram of liver. See Appendices for concentration 
data and example absorbance specta.
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2.4: Enzyme assays 
2.4.1: 7‘Ethoxyresorufin O-deethylase
7-Ethoxyresorufin O-deethylase activity was assayed by the discontinuous method 
adapted from that of Burke et al. (1977). Reaction mixtures consisted of 25 mM 
NADPH (in sodium/potassium phosphate buffer, 50 pi), 100 mM sodium/potassium 
phosphate buffer (pH 7.4) and marmoset liver microsomal protein (volume dependent 
upon protein concentration) in a total volume of 610 pi. Following an initial 3-minute 
pre-incubation period at 37°C in a shaking water bath, the reaction was initiated by the 
addition of ethoxyresorufin in DMSO : sodium/potassium phosphate buffer (500 pi) to 
give the final required concentration(s) (comprising of 0.45% (v/v) organic). Samples 
were then incubated for 3-15 minutes at 37°C in glass culture tubes, which were open 
to the atmosphere in a shaking water bath, after which, the reaction was terminated by 
the addition of 1.9 ml chilled acetone. The resulting protein precipitate was removed by 
centrifugation at 3,000 x g for 5 minutes (Mistral 30001 bench centrifuge; Sanyo 
Gallenkamp pic, Leicester, UK). The supernatant was removed and assayed for 
production of resorufin using a fluorescence spectrophotometer at an excitation 
wavelength of 530 nm and an emission wavelength of 586 nm.
The spectrophotometer was calibrated with resorufin standard curves (10-500 
pmoles/sample in duplicate) prepared in an identical manner to the incubation 
samples incorporating appropriate concentrations of marmoset microsomal protein 
equivalent to the reaction mixtures.
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2.4.2: 7-Methoxyresorufin O-demethyiase
7-Methoxyresorufin 0-demethylase activity was assayed in a similar way to that of 
7-ethoxyresorufin O-deethylase activity by a method adapted from that of Burke at al. 
(1-977), except for the change in substrate.
The spectrophotometer was calibrated with resorufin standard curves (10-500 
pmoles/sample, in duplicate) essentially as described for the EROD assay.
2.4.3: Coumarin 7-hydroxyiase
Coumarin 7-hydroxylase activity was assayed by a method adapted from that of 
Maurice et al. (1991). Reaction mixtures consisted of 50 mM sodium/potassium 
phosphate buffer (pH 7.4), cofactor solution (30 mM NADP'', 150 mM glucose
6 -phosphate and 2 0  units/ml glucose 6 -phosphate dehydrogenase in 2 % (w/v) sodium 
bicarbonate), 150 mM magnesium chloride, and marmoset liver microsomal protein in 
a total volume of 1495 pi. Following an initial 3-minute pre-incubation period at 37°C 
in a shaking water bath, the reaction was initiated by the addition of 5 pi coumarin in 
methanol, to give the required final concentration(s) (comprising 0.33% (v/v) organic). 
Samples were then incubated at 37°C in duplicate, in glass culture tubes that were 
open to the atmosphere. Reactions were terminated after 5 -30 minutes by the addition 
of chilled 20% (w/v) trichloroacetic acid (0.5 ml). The resulting protein precipitate was 
removed by centrifugation at 3,000 x g for 5 minutes. An aliquot (0.1 ml) of the resulting 
supernatant was transferred to a cuvette containing 1.9 ml 100 mM sodium bicarbonate 
buffer (pH 10). After the fluorescence spectrophotometer was calibrated with 7- 
hydroxycoumarin standard curves (10-500 pmoles/sample in duplicate), each
containing the appropriate concentration of microsomal protein equivalent to the
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incubation samples and prepared in an identical manner to the reaction mixtures, the 
incubation samples were assayed for production of 7-hydroxycoumarin at an excitation 
wavelength of 375 nm and an emission wavelength of 455 nm.
2.4.4: 7-Pentoxyresorufin 0-depentyiase
7-Pentoxyresorufin 0-depentylase activity was assayed by the method of Lubet at al. 
(1985). After a pre-incubation period of 10 minutes, marmoset liver microsomal 
protein and 5 pi of pentoxyresorufin, giving the required final concentration(s) 
(comprising 0.25% (v/v) organic) were added to quartz cuvettes containing 50 mM Tris 
HOI buffer, pH 7.65 and 250 mM MgCL, in a total volume of 1.99 ml. Samples were 
mixed and left for a further 3 minutes. The reaction was initiated by addition of 25 mM 
NADPH (10 pi). The production of resorufin was measured for up to 6  minutes at 
30°C using a fluorescence spectrophotometer at an excitation wavelength of 530 nm 
and an emission wavelength of 586 nm.
The spectrophotometer was calibrated with resorufin standard curves (10-100 
pmoles/ sample in duplicate) prepared in an identical manner to the incubation 
samples each containing the appropriate concentration of marmoset liver microsomal 
protein equivalent to the reaction mixture (i.e. 0.5, 0.75, 1.0, 2.0 or 3.0 mg/ml)
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2.4.5: Determination of paciitaxel 6a-hydroxyiase
Paclitaxel 6 a-hydroxylase activity was assayed essentially as described by Sonnichsen 
et al. (1995). Reaction mixtures consisted of 50 mM Tris-HGI buffer, pH 7.4 at 25°C, 
50 pi of cofactor solution ( 10 mM NADP"^ ,^ 50 mM glucose 6 -phosphate and T unit/ml 
glucose 6 -phosphate dehydrogenase in 2 % (w/v) sodium bicarbonate solution), and 
marmoset liver microsomal protein in a total volume of 495 pi. Following an initial 
3-minute pre-incubation period at 37°C for 10 -  120 minutes in a shaking water bath, 
the reaction was initiated by the addition of 5 pi [^"^Cjpaclitaxel in methanol to give the 
required final concentration(s) (comprising 1.0% (v/v) organic solvent). Control 
incubations were performed in the absence of cofactor, which was replaced with Tris- 
HCI buffer (50 mM, pH 7.4 at 25°C). The reaction was allowed to continue at 37°C in 
polypropylene microcentrifuge tubes, which were open to the atmosphere. Reaction 
was terminated by the addition of 250 pi chilled methanol with vortex mixing and 
transfer to ice. The resulting protein precipitate was removed by centrifugation at 17,000 
X g for 15 minutes (ALC 4214 microcentrifuge. Thermo Fisher Scientific, Waltham, MA, 
USA) and the supernatant was transferred to an HPLC autosampler vial and injected 
directly onto the HPLC system.
HPLC - The samples were analysed using a Supelcosil C i8 column (5 pm 
particles of silica, 150 x 4.6 mm; Hichrom, Reading, Berkshire, UK) fitted with a 
Ci8 pre-column (Hichrom) at ambient temperature. The eluate was monitored for 
UV absorbance at a wavelength of 235 nm.
HPLC solvents:
Solvent A = water : acetonitrile (60 : 40, v/v); solvent B = acetonitrile 
Solvent gradient: linear
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Run time Solvent A Solvent B
%) (%)(min)
0 100 0
14 100 0
14.5 0 100
17.5 0 100
17.7 100 0
30 100 0
Solvent flow rate through column = 1 ml/min; injection volume = 250 pi.
2.4.6: Diclofenac 4'-hydroxylase
Diclofenac 4 '-hydroxylase activity was assayed by a method based on that of 
Yamazaki etal. (1998). Reaction mixtures consisted of 50 mM Tris-HCI buffer, pH 7.4 
at 25°C, NADPH at a final concentration of 2 mM (in Tris-HCI buffer), and marmoset 
liver microsomal protein in a total volume of 990 pi. Following an initial 3-minute pre­
incubation period at 37°C in a shaking water bath, the reaction was initiated by the 
addition of 10 pi [^"^Cjdiclofenac in methanol to give the required final concentration(s) 
(comprising of 1.0% (v/v) methanol). Control incubations were performed in the 
absence of NADPH, which was replaced with Tris-HCI buffer (50 mM, pH 7.4 at 
25°C). The reaction proceeded at 37°C in polypropylene microcentrifuge tubes, which 
were open to the atmosphere. Reaction was terminated after 5 - 6 0  minutes by the 
addition of 500 pi chilled acetonitrile containing 6 % (v/v) glacial acetic acid with vortex 
mixing and transfer to ice. The resulting protein precipitate was removed by 
centrifugation at 17,000 x g for 15 minutes (ALC 4214 microcentrifuge) and the 
supernatant was transferred to an HPLC autosampler vial and injected directly onto the 
HPLC system.
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HPLC - The samples were analysed using a Waters Spherisorb Cie column (5 
pm particles of silica, 150 x 4.6 mm; Hichrom) fitted with a Cis pre-column 
(Hichrom) at ambient temperature. The eluate was monitored for UV 
absorbance at 280 nm.
HPLC solvents:
Solvent A = acetonitrile : 1 mM perchloric acid; solvent B = methanol 
Solvent gradient: linear
Run time Solvent A Solvent B
(min) (%) (%)
0 60 40
5 45 55
10 0 100
17 0 100
20 60 40
30 60 40
Solvent flow rate through column = 1 ml/min; injection volume = 500 pi.
2,4.7: Tolbutamide methyihydroxyiase
The assay of tolbutamide methyihydroxyiase activity was based on that of Miners et 
al. (1988). Reaction mixtures comprised 50 mM Tris HCI buffer, pH 7.4, 50 pi of 
cofactor solution (3.3 mM NADP" ,^ 80 mM glucose 6-phosphate and 10 units/ml 
glucose 6-phosphate dehydrogenase in 5 mM MgCl2), and marmoset liver microsomal 
protein in a total volume of 245 pi. Following an initial 3-minute pre-incubation period 
at 37°C in a shaking water bath, the reaction was initiated by the addition of 5 pi
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[^ "‘Cjtolbutamide in acetonitrile/Tris buffer to give the required final concentration(s) 
(comprising of 1.0% (v/v) organic solvent). Control incubations were performed in the 
absence of cofactor, which was replaced with Tris-HCI buffer (50 mM, pH 7.4 at 
25°C). Incubations were performed for 5 - 6 0  minutes in polypropylene 
microcentrifuge tubes, which were open to the atmosphere. Reaction was terminated by 
the addition of 0.15 M phosphoric acid (100 pi) with vortex mixing and transfer to ice. 
The resulting protein precipitate was removed by centrifugation at 17,000 x g for 
15 minutes (ALC 4214 microcentrifuge) and the supernatant was transferred to an 
HPLC autosampler vial and injected without delay onto the HPLC system.
HPLC - The samples were analysed using a Waters pBondapak Ci8 column 
(300 X 3.9 mm; Hichrom) fitted with a Ci8 pre-column (Hichrom) at ambient 
temperature. The eluate was monitored for UV absorbance at 229 nm.
HPLC solvents:
Solvent A = 0.1% ammonium acetate (w/v), pH 3.27; solvent B = acetonitrile 
Solvent gradient: linear
Run time Solvent A Solvent B
(min) (%) (%)
0 84 16
12 84 16
20 0 100
25 0 100
30 84 16
10 minute re-equilibration at initial conditions
Solvent flow rate through column = 1.5 ml/min; injection volume = 100 pi.
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2.4.8: S-Mephenytoin 4 '-hydroxylase and S-mephenytoin N-demethylase 
activities
S-Mephenytoin 4'-hydroxylase and S-mephenytoin A/-demethylase activities were 
assayed by a method based on that of Chauret at al. (1997). Reaction mixtures 
consisted of 100 mM sodium/potassium phosphate buffer, pH 7.4, 20 mM NADPH, 
and marmoset liver microsomal protein in a total volume of 230 pi. After an initial 3- 
minute pre-incubation period at 37°C in a shaking water bath, the reaction was started 
by the addition of 20 pi [^ '‘C]S-mephenytoin in methanol/buffer to give the required final 
concentration(s) (comprising of 1.0% (v/v) methanol). Control incubations were 
performed in the absence of NADPH, which was replaced with 100 mM Na/K 
phosphate buffer, pH 7.4. The incubation was conducted in polypropylene 
microcentrifuge tubes, which were open to the atmosphere. Reactions were terminated 
after 40 -  120 minutes by the addition of 40 pi chilled 70% perchloric acid (w/v) with 
vortex mixing and transfer to ice. The resulting protein precipitate was removed by 
centrifugation at 17,000 x g for 15 minutes (ALC 4214 microcentrifuge), and the 
supernatant transferred to an HPLC autosampler vial for analysis on the HPLC system.
HPLC - The samples were analysed using a Novapak Ci8 column (150 x 3.9
mm; Hichrom) fitted with a Ci8 pre-column (Hichrom) at ambient temperature.
The eluate was monitored for UV absorbance at 214 nm.
HPLC solvents:
Solvent A = 20 mM ammonium acetate, pH 5.0; solvent B = methanol
Solvent gradient: linear
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Run time Solvent A Solvent B
%) (%)(min)
0 75 25
10 75 25
20 60 _ _ 40
25 60 40
30 75 25
35 75 25
Solvent flow rate through column = 1 ml/min; injection volume = 45 pi.
2.4.9: Debrisoquine hydroxyiase
The debrisoquine hydroxylase activities were performed using a method based on that 
of Kronbach at al. (1987). 50 mM Tris HCI buffer, pH 7.69 at 25°C, 6 mM NADPH, and 
marmoset liver microsomal protein were prepared in polypropylene microcentrifuge 
tubes giving a total volume of 225 pi. Following an initial 3-minute pre-incubation 
period at 37°C in a shaking water bath, the incubation proceeded by the addition of 25 
pi [^"^Cjdebrisoquine in Tris buffer to give the required final concentration(s). Control 
incubations were performed in the absence of NADPH. The reaction continued at 
37°C for 10 -  120 minutes and was terminated by the addition of 35 pi chilled 70% (w/v) 
perchloric acid with vortex mixing and transfer to ice. The resulting protein precipitate 
was removed by centrifugation at 17,000 x g for 15 minutes (ALC 4214 microcentrifuge) 
and the supernatant was transferred to an HPLC autosampler vial and injected directly 
onto the HPLC system.
HPLC - The samples were analysed using a Nucleosil 120-5 Cis EXCEL column 
(100 X 4.6 mm; Hichrom) fitted with a Cis pre-column (Hichrom) at ambient 
temperature. The eluate was monitored for UV absorbance at 211 nm.
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HPLC solvents:
Solvent A = 10 mM trifluoroacetic acid 
Solvent B = acetonitrile; solvent gradient: Linear
Kun time Flow rate Solvent A Solvent B
(min) (ml) (%) (%)
0 0.5 90 10
10 0.5 90 10
15 0.5 85 15
20 1.0 85 15
25 1.0 0 100
30 1.0 85 15
35 0.5 90 10
40 0.5 90 10
Injection volume = 60 pi; solvent flow rate through column = 0.5-1.0 ml/min
2.4.10: Laurie acid 11- and 12-hydroxylase activities
The method utilised to assay lauric acid 11- and 12-hydroxylase activities was based 
on that of Orton and Parker (1980). The incubation mixture consisted of 50 mM Tris- 
HCI buffer (pH 7.69, at 25°C), 25 pi of cofactor solution (2 mM NADP'', 25 mM glucose
6-phosphate and 6 units/ml glucose 6-phosphate dehydrogenase in 2% [w/v] sodium 
bicarbonate solution), and marmoset liver microsomal protein and super-pure water in 
a total volume of 160 pi. Following an initial pre-incubation period of 3 minutes at 37°C 
in a shaking water bath, the reactions were initiated by the addition of 40 pi [^"^Cjlauric 
acid prepared in methanol : buffer to give the required final substrate concentration(s) 
(comprising 0.03% (v/v) methanol). Control incubations were performed in the 
absence of cofactor, which was replaced with Tris-HCI buffer (50 mM, pH 7.69 at
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25°C). The reaction was incubated at 37°C in polypropylene microcentrifuge tubes, 
which were open to the atmosphere for 5 - 6 0  minutes. Reactions were terminated by 
the addition of 100 pi chilled methanol and vortex mixing. The resulting protein 
precipitate was removed by centrifugation at 14,000 rpm for 15 minutes (ALC 4214 
microcentrifuge) and the supernatant was transferred to an HPLC vial for direct 
injection onto the HPLC system.
HPLC - The samples were analysed using a Supelcosil LC-8 column (3 pm 
particle size, 150 x 4.6 mm; Hichrom) fitted with a Cis precolumn (Hichrom) at 
42°C. The eluate was not monitored for UV absorbance due to the lack of 
chromaphore. Instead, the retention times were compared to validated historic 
data obtained from monitored [‘'"‘Cj-Radioactivity using a p-Ram Radioisotope 
System fitted with a solid CaF flow through detection cell (LabLogic Systems 
Ltd).
HPLC solvents:
Solvent A = super-pure water containing 0.1% acetic acid (v/v); solvent B 
methanol containing 0.1% acetic acid (v/v)
Solvent gradient: linear
Run time Solvent A Solvent B
(min) (%) (%)
Initial (0) 50 50
20 50 50
25 0 100
35 0 100
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10 minute re-equilibration at initial conditions
Solvent flow rate through column = 1.0 ml/min; Injection volume = 100 pi
2.4.11: Testosterone hydroxylase
Testosterone hydroxylase activities were assayed by a method based on those of 
Arlotto at al. (1991) and Waxman (1991). The incubation mixture consisted of Tris- 
HCI buffer (80 mM, pH 7.32 at 25°C containing 240 mM KCI, 1.6 mM EDTA and 
16 mM MgCb), super-pure water, NADPH at a final concentration of 1.25 mM 
(prepared in Tris-HCI buffer [80 mM, pH 7.32 at 25°C]), and marmoset liver 
microsomal protein in a total volume of 990 pi. Following an initial pre-incubation 
period of 3-minutes at 37°C in a shaking water bath, the reactions were initiated by the 
addition of 10 pi [^"^Cjtestosterone in methanol, to give the required final testosterone 
concentration(s) (comprising 1.0% (v/v) methanol) and vortex mixed. Control 
incubations were performed in the absence of NADPH, which was replaced with 
super-pure water. The reaction proceeded for 5 - 6 0  minutes in a polypropylene 
microcentrifuge tube which was open to the atmosphere and was terminated by the 
addition of 500 pi chilled acetonitrile and vortex mixing. The resulting protein 
precipitate was removed by centrifugation at 14,000 rpm for 15 minutes (ALC 4214 
microcentrifuge) and the supernatant was transferred to an HPLC vial for direct 
injection onto the HPLC system.
HPLC -  Method based on that of Sonderfan at al. (1987). The samples were 
analysed using a pBondapak column (10 pm particle size, 300 x 3.9 mm; 
Millipore Waters) fitted with a Cis pre-column (Hichrom) at ambient 
temperature. The eluate was monitored for UV absorbance at 254 nm.
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HPLC solvents:
Solvent A = methanol : super-pure watenacetonitrile (39:60:1, v/v); solvent B 
methanol super-pure water : acetonitrile (80:18:2, v/v)
Solvent gradient: concave 4
Run time Solvent A Solvent B
(min) (%) (%)
Initial (0) 90 10
25 0 100
30 0 100
35 90 10
45 90 10
Solvent flow rate through column = 1.5 ml/min; injection volume = 250 pi
2.5: isolation and identification of hydroxylated debrisoquine metabolites 
2.5.1: LC-MS/MS
The analysis of incubation samples from debrisoquine hydroxylase linearity assays (5 
mg/ml marmoset liver microsomal protein incubated for 120 minutes) was conducted 
to give initial partial identification of the hydroxylated debrisoquine metabolites. For 
on-line LC-MS analyses, the sample was injected on to an HPLC system, and the 
eluent from the column passed through a splitter, in the ratio of 9:1, with the majority 
of the eluent passing to waste (via UV and radio detectors) and the remainder to the 
mass spectrometer for electrospray ionisation. The spray voltage and the capillary 
temperature were set to 4.5 kV and 250°C, respectively. Nitrogen was used as
52
Chapter 2: Materials and methods
sheath gas at a head pressure of 60 psi and also as auxiliary gas at 10 units. Mass 
spectrometric data were acquired over an appropriate mass range at a scan rate of 1 
s/scan.
The mass spectrum of metabolites was obtained by averaging several scans across 
the appropriate region of the mass chromatogram, with appropriate background 
subtraction. This mass spectrum was examined to identify a candidate protonated 
molecular ion, MH"^ , for the compound, and any other structurally significant fragment 
ions resulting from in-source collisionally induced dissociation (CID).
The ESI mass spectrometric data were examined to identify candidate molecular ions 
for the metabolite(s) of interest, from which particular ions were selected for MS/MS 
analysis in the product ion scan mode. To achieve this, the Q1 mass analyser was 
set to pass only ions of mass corresponding to one of the candidate molecular ion 
species identified from the mass spectrum. This precursor ion was fragmented by 
CID in the Q2 region at a collision energy that was empirically optimised to provide 
maximum structural information (Argon, 2 mTorr). A mass spectrum of the fragments 
produced was recorded by scanning 03 across a mass range from m/z 10 to a point 
several mass units above the selected precursor ion mass, employing a scan rate of 
1 s/scan. Several scans were averaged to produce the product ion mass spectra of 
the putative metabolites.
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2.5.2: NMR
Analysis of hydroxylated debrisoquine metabolites was conducted on fractions isolated 
during the HPLC analysis of a larger scale preparation using a modified procedure of 
the debrisoquine hydroxylase assay used previously. Reaction mixture consisted of 
50 mM Tris HOI buffer, pH 7.69 at 25°C, 6 mM NADPH, and 4.75 mg/ml pooled 
marmoset liver microsomal protein in a total volume of 35 ml. Following an initial 
3-minute pre-incubation period at 37°C in a shaking water bath, the reaction was 
initiated by the addition of 3.5 ml of 5 mM f"^C]debrisoquine in Tris buffer to give a final 
concentration of 500 pM. The incubation was carried out for 180 minutes in a 100 ml 
glass conical flask open to the atmosphere, after which the reaction was terminated by 
the addition of an equal volume of chilled acetonitrile with vortex mixing and transfer to 
ice. The resulting protein precipitate was removed by centrifugation at 3,000 x g for 
20 minutes (Mistral 3000i bench centrifuge) and the supernatant transferred to a 250 ml 
round-bottomed flask. The organic component was then removed by evaporation in a 
Büchi R-114 rotavapor (Büchi, Postfach, FlawiI, Switzerland) prior to the sample being 
shell-frozen in a round bottomed flack by rotating it in an acetone/solid carbon dioxide 
cooling bath maintained at -80°C and subsequently lyophilised (Edwards Modulyo 
freeze drier, BOC Edwards, Crawley, West Sussex, UK). The dried sample was then re­
suspended in 5 ml 0.1% (v/v) trifluoroacetic acid and cleaned up by centrifugation at 
17,000 X g for 15 minutes (ALC 4214 microcentrifuge). The supernatant was then 
transferred to an HPLC autosampler vial and injected onto the HPLC system.
HPLC - The samples were analysed using an Inertsil 0DS3 Cis column (250 x 9 
mm; Hichrom) at ambient temperature. The eluate was monitored for UV 
absorbance at 211 nm.
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HPLC solvents:
Solvent A = 0.1% trifluoroacetic acid; solvent B = Acetonitrile
Solvent gradient: Linear
Run time Solvent A Solvent B
(min) (%) (%)
0 92 8
27 92 8
32 85 15
40 85 15
45 0 100
50 92 8
60 92 8
Injection volume = 1 ml; solvent flow rate through column = 4 ml/min
Each of the eluted metabolite fractions identified by [^"^Cj-radioactivity using a (3-Ram 
Radioisotope System was individually collected into round-bottomed flasks. The 
organic component of the HPLC eluate was then removed by evaporation prior to the 
samples being shell frozen using an acetone/solid carbon dioxide cooling bath, as 
previously indicated, and lyophilised. Dried samples were stored prior to NMR analysis.
Proton NMR spectra were obtained at 500 MHz by dissolving standards 
(debrisoquine and 4-hydroxydebrisoquine) and the dried HPLC fractions in D2O using 
water as an internal reference. Analysis was conducted in a Bruker Avance NMR 500 
MHz spectrometer equipped with a 5 mm broadband BBC probe. The position of
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hydroxyl substitution was deduced by proton coupling patterns and connectivity of 
protons 1 and 4 with the aromatic protons 8 and 5, respectively. The assignments of 
the NMR signals were made by long-range 2D correlated spectroscopy (COSY) 
experiments.
7
6
45
NH.
Figure 2.1: Structure of debrisoquine. Identification of proton location used for COSY 
experiments.
2.6: Immunoblot of cytochrome P450 apoprotein expression in liver 
microsomal subcellular fractions.
2.6.1: Sample preparation
Samples were prepared by adding 1 part NuPAGE LDS sample buffer (4x) to 3 parts 
protein suspension (marmoset liver microsomes, human liver microsomes, rat liver 
microsomes or Supersomes®), diluted in water and heated at 70°C for 10 minutes. 
10% (v/v) NuPAGE reducing agent (lOx) was then added to each sample prior to 
electrophoresis.
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2.6.2: Electrophoresis
Electrophoresis was essentially conducted according to the manufacturer’s 
instructions (Invitrogen). Namely, the prepared gel cassettes ( 8 x 8  cm, 9 wells, 
NuPAGE 4-12% gradient Bis-Tris) were secured in place in an Xcell SureLock™ mini 
gel box and the appropriate volume of NuPAGE SDS running buffer added.
2.6.2.1: Preliminarv range finding assav - Aliquots (20 pi) of pooled microsomal 
protein (10, 20 and 50 pg protein from human, marmoset and rat, respectively), 
negative control (no microsomal protein) and Supersomes® (as positive control 
and for standard curve construction (0.0-0.08 pmoles for CYPs 1A1/2, 286, 
2D6, 2E1, 3A4; and 3A5. 0.2-0.8 pmoles for CYPs 2A6, 2C9 and 2C19)), were 
each loaded into the appropriate wells. A 10 pi aliquot of a protein molecular 
weight marker (10,000-250,000 Da; Amersham Biosciences) was included on 
each gel. The gel was then subjected to electrophoreses at 150 V (200 mA) for 
70 minutes.
2.6.2.2: Inter-species comparison assav- Based on the results from the ‘range 
finder assay’, aliquots (20 pi) of pooled microsomal protein from human, 
marmoset and rat in duplicate, negative control (no microsomal protein) and 
Supersomes® (as positive control and for standard curve construction), were 
each loaded into the appropriate wells. A 10 pi aliquot of a protein molecular 
weight marker (10,000-250,000 Da) was also included. Electrophoresis was 
performed at 150 V (200 mA) for 70 minutes.
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2.6.3: Ul^estern immunoblotting
The proteins were transferred to a polyvinyldifluoride (PVDF) membrane by 
electroblot at room temperature for 1 hour at 25 V (200 mA) in 192 mM glycine, 25 
mM- Tris, 20% (v/v) methaniDl (transfer buffer) in a BioRad se^ nhi dry tr^nsblot 
apparatus (BioRad, Hercules, California, USA). The blot was then blocked with a 
solution (blocking buffer) comprising 50 mM Tris, 150 mM NaCI, 0.2% (v/v) Tween 
20, 0.25% (w/v) Mowiol 4-88, 0.5% (w/v) bovine serum albumin (BSA), 2 mM sodium 
azide, pH 7.5 for 1 hour at room temperature. Probing the blot with the primary 
antibody was conducted at room temperature for 30 minutes. Following three 10- 
minute washes in blocking buffer, the blot was then probed with the appropriate 
alkaline phosphatase conjugated secondary antibody at room temperature for 30 
minutes. After three 10-minute washes in blocking buffer and two 5 minute washes in 
50 mM Tris, 150 mM NaCI (washing buffer), the blot was allowed to air dry.
2.6.4: Detection of fiuorescent substrates
Digital images were captured on a Fujifilm FLA-5000 imaging system incorporating a 
red laser (635 nm). The blots probed with the alkaline phosphatase conjugated 
antibody were placed face down onto a 1 ml solution of 1,3-dichloro-9,9- 
dimethylacridin-2-one-7-yl phosphate (DDAO phosphate; Figure 2.2) (1.25 pg/ml) 
directly on the imaging bed; scanning of the DDAO reaction was performed 
immediately.
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H3C . ,CH3
2N H ,+
Figure 2.2: The phosphatase substrate DDAO phosphate (1,3-dichloro-9,9-
dimethylacridln-2-one-7-yl phosphate, diammonium sait). A substrate that yields a 
hydrolysis product that can be excited with the 635 nm laser (excitation/emission maxima 
~645/660).
Suitable conditions were determined for the interspecies comparative blots from 
initial Western blots using pooled marmoset liver microsomes, pooled human liver 
microsomes and pooled rat liver microsomes. Antibody dilutions remained 
unchanged from the ‘range finder’ experiments to the quantitative interspecies 
experiments. However, known amounts of protein from pooled marmoset liver 
microsomes, pooled human liver microsomes, pooled rat liver microsomes and 
Supersomes® (used for standard curve ranges) were altered as required to provide 
conditions conducive to producing fluorescent images of GYP apoprotein within the 
linear standard curve range.
2.6.5; Total protein stain
Coomassie Blue staining was used to confirm the total protein transfer from the gel to 
the PVDF membrane. Gels and membranes were soaked in excess 0.5% (w/v) 
Coomassie Brilliant Blue R-250 in 50% (v/v) methanol overnight. Destaining was 
performed initially with 50% (v/v) methanol for 4 hours with 3 changes of solution, 
then further destained by soaking overnight in 5% (v/v) methanol. Gels and PVDF
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membranes were then examined for visible protein bands. Representative images 
were captured by scanning the stained gel and the PVDF membrane on a Lexmark 
X1130, all in one printer system (Lexmark International Ltd., Marlow, 
Buckinghamshire, UK).
2.7: Determination of cytochrome P450 mRNA bands in human and marmoset 
liver 
2.7.1: RNA isolation
Portions of human and marmoset frozen liver (40-50 mg) were removed from -80 °C 
storage and soaked overnight in RNALater ice at -20°C to transition the physical 
state of the liver into a consistency that was compatible with homogenisation. The 
RNALater ice was removed and replaced with lysis buffer (350 pi RA1 together with
3.5 pi p-mercaptoethanol) from the Nucleospin RNA II kit, and the liver was 
homogenised by scissor mincing at room temperature before being spun (11,000 rpm 
for 1 minute) in a bench centrifuge in Nucleospin cartridges to shear and filter the 
lysate. Following the Nucleospin RNA II kit procedures, the lysed cells were 
combined with 1 volume of 70% ethanol, mixed and applied to a silica-gel based 
membrane, which binds RNA >200 nucleotides in the presence of ethanol. The RNA 
was washed three times to remove contaminants before being eluted in 50 pi water. 
The concentration of RNA was measured using a NanoDrop ND1000 
spectrophotometer (NanoDrop Technologies, Delaware USA) and stored at -20°C 
prior to analysis
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2.7.2; Removal of contaminating genomic DNA
One microgram of total RNA was added to 10% (v/v) DNase buffer and 10 units of 
DNase I. The mixture was incubated at 37°C for 30 minutes after which 2 mM EGTA 
was added and the mixture was heated to 65°C for 10 minufes.
2.7.3; Reverse transcriptase cDNA synthesis
An aliquot (0.346 pg) of DNase treated RNA was added to 1.25 mM dNTP’s and 
450 ng random hexamers. The mixture was heated at 65°C for 5 minutes then stored 
on ice. The reverse transcriptase reaction mixture (50% (v/v) 5x RT buffer, 25 mM 
DTT, 12.5% (v/v) RNase OUT, 3.125% (v/v) Superscript II) was added and incubated 
for the following cycle: 10 minutes at 25 °C, 50 minutes at 42°C then 15 minutes at 
70°C in an MJ Research PTC-225 DNA Engine System (Global Medical 
Instrumentation Inc. Minnesota USA). A control containing no Superscript II (RT 
minus) was included for all reactions. Generated cDNA was stored at -20°C until 
required for reverse transcriptase polymerase chain reaction.
2.7.4: Quantitative reverse transcriptase polymerase chain reaction
Five microlitres of cDNA was added to 20 pi of the real time Reverse transcriptase 
Polymerase Chain Reaction (qRT-PCR) reaction mixture (10 pmoles forward primer, 
10 pmoles reverse primer, 2-5 pmoles probe, 62.5 % (v/v) 2 x TaqMan Universal 
PCR Master Mix) in a white 96-well optical reaction plate sealed with an optical 
adhesive cover. The plate was centrifuged at 1000 x g for 1 minute to collect the 
reaction mixture at the bottom of the wells. The plate was cycled in an ABI Prism 
7000HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA)
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using the following program: 50°C for 20 minutes, 95°C for 15 minutes and 40 
repeats of 95 °C for 15 seconds and 60 °C for 1 minute. Results were compared to 
standards of human genomic DNA (10-100000 copies in a 5 point calibration curve). 
Data were analysed using Prism software to calculate the number of copies of RNA 
per well compared to the standard curve and normalised against 18S data.
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3.1: Introduction
Cytochromes P450, a super family of microsomal drug-metabolising enzymes, are 
the most important catalysts of phase I drug metabolism (Wilkinson, 2001). In the 
preliminary study, investigations of the linear assay conditions in relation to 
incubation time and microsomal protein were carried out for: 7-ethoxyresorufin 
0-deethylase, 7-methoxyresorufin 0-demethylase, coumarin 7-hydroxylase,
7-pentoxyresorufin 0-depentylase, S-mephenytoin A/-demethylase, paclitaxel 
6a-hydroxylase, diclofenac 4'-hydroxylase, tolbutamide methyl hyd roxy lase, 
S-mephenytoin 4'-hydroxylase, debrisoquine 4-hydroxylase, lauric acid 
11-hydroxylase, testosterone 6(3-hydroxylase and lauric acid 12-hydroxylase, these 
being established selective markers for various individual cytochrome P450 
enzymes. These linearity results were subsequently utilised to determine the 
marmoset liver microsomal kinetic parameters (Km and Vmax) for the following 
activities: 7-ethoxyresorufin 0-deethylase, S-mephenytoin A/-demethylase,
tolbutamide methylhydroxylase, debrisoquine hydroxylase, lauric acid 
11-hydroxylase, testosterone 6(3-hydroxylase and lauric acid 12-hydroxylase. These 
activities, which are indicative of the presence of specific cytochrome P450s 
expressed in the human liver, were evaluated in marmoset liver microsomes to 
investigate possible similarities between the two species.
3.2: Methods
The preparation of pooled marmoset microsomal samples was used to establish 
linear assay conditions; whereas microsomal preparations from five individual 
marmosets were used to determine kinetic parameters; detailed assay conditions 
and equipment are described in Chapter 2. Enzyme activities were measured by
Chapter 3: Cytochrome P450 kinetics in marmoset liver
monitoring either the rate of change with time or a single measurement after a timed 
incubation by either fluorescence spectrophotometry, HPLC with radiochemical 
detection or UV spectrophotometry. Initial linearity assay conditions are summarised 
in Table 3.1.
Seven hepatic cytochrome P450-depenant enzyme activities were then selected for 
full kinetic characterisation, determining their respective Km and Vmax values, The 
assay conditions for these analyses are summarised in Table 3.2.
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3.2.2: Data processing
The data in this chapter, excluding 7-alkoxyyresorufin 0-dealkylase activities 
measured by spectrophotometric/spectrofluorimetric methods, were derived from 
evaluation of-HPLC-ehromatograms-using the“ Laura“ system“ software1(LabL6gic). 
This enabled the amount of radioactivity attributed to each region of interest (ROI) to 
be expressed as a percentage of the total chromatogram radioactivity. The % ROI 
was subsequently used to determine the percentage formation of major metabolites 
of CYP substrates. Blank values (in the absence of NADPH) from each of the CYP 
substrates were subtracted from calculated metabolite formation quantities from each 
of the ROI values.
% Formation of metabolite = R - R °
R = % ROI of metabolites in incubation including NADPH
R° = % ROI of metabolites in incubation without NADPH
The % metabolism of substrates and formation of metabolites was then used to 
calculate the rate of formation, using the formula:
% formation  ^ , X concentration (pmoles)
Rate (pmol/min/mg protein) = —
time (min) x protein (mg)
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The rate data obtained from the kinetic incubations were plotted against the rate 
divided by the substrate concentration (V vs. V/[S] (Eadie-Hofstee plot)). These data 
were also analysed by non-linear regression using WinNonlin software (Phoenix). 
Using single-enzyme model kinetics:
(Michaelis-Menten equation) (Hill equation)
V .[S] V [S]"
Velocity (V) =_EC!3x  Velocity (V) =
K' + [S]"
Vmax = Maximum velocity
Km = The [S] that gives % Vmax (Michaelis constant)
[S] = Substrate concentration
K' = Affinity constant, composite of several constants
n = Hill coefficient
3.3: Results 
3.3.1: 7-Ethoxyresorufln O-deethylase activity (CYP1A1)
3.3.1.1 : Linearitv of 7-ethoxvresorufin 0-deethvlase activitv
7-Ethoxyresorufin O-deethylase activity, as measured by the formation of resorufin, 
was linear with respect to protein and time over the entire 15-minute incubation 
period at 0.05, 0.1 and 0.25 mg/ml of marmoset microsomal protein (Figure 3.1). 
However, conditions appropriate for best fit to the linear portion of the rate curve for 
the formation of resorufin with an origin intersect were considered to be the highest 
protein concentration investigated (0.25 mg/ml) and an incubation period of 5 
minutes. These offered a satisfactory amount of resorufin formation (104 pmoles, 
based on a standard curve constructed from the same protein concentration and
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accounting for 2.5% consumption of the parent compound), with a reaction rate of 83 
pmoles/min/mg protein.
250
0 .25  mg/ml
r 2= 0 .9925
200
Q .
150
0.1 mg/ml
100
0.05  mg/ml
82 4 6 10 12 14 160
T im e (minutes)
Figure 3.1: 7-Ethoxyresorufln O-deethylase time and protein linearity in marmoset liver 
microsomes. Data points are the average of duplicate incubations of 0.05, 0.1 and 0.25 
mg/ml marmoset microsomal protein over a 15-minute incubation period. Insert plot depicts 
optimal linear conditions at 0.25 mg/ml microsomal protein over a 5-minute incubation period 
and accounting for 2.5 % consumption of ethoxyresorufin.
3.3.1.2: Kinetic characterisation of 7-ethoxvresorufin 0-deethvlase activitv (CYP1A1 ) 
Initial incubations to determine the kinetic parameters of 7-ethoxyresorufin 
O-deethylase activity used two concentration ranges of 7-ethoxyresorufin, firstly 
ranging from 0.4 to 40 pM and then 0.04 to 4 jiM. However, the activities seen with 
both of these concentration ranges exceeded the calculated value for Vmax, resulting 
in Rate v Substrate concentration plots with little or no increase in the rate of 
formation of resorufin (data not shown). A third concentration range of 7- 
ethoxyresorufin from 0.002 to 0.2 |iM provided data that was suitable for calculating 
kinetic parameters. A single-enzyme model of Michaelis-Menten kinetics gave 
estimates of Km = 0.08 pM and Vmax = 123 pmoles/min/mg protein (Figure 3.2).
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Figure 3.2: Eadle-Hofstee plot for the formation of resorufin from 7-ethoxyresorufin.
Kinetic characterisation of 7-ethoxyresorufin O-deethylase activity from individual marmoset 
liver microsomal incubations using optimal conditions as determined in the linearity 
investigations and 2, 4, 8, 16, 32, 50, 100 and 200 nM 7-ethoxyresorufin.
Error bars represent average ± SD of analysis of 4 individual animals
3.3.1.3: Marmoset 0625 outlier
During the kinetic investigations it was determined that a single marmoset from batch 
2 marmoset liver microsomes (animal 0625) presented a low 7-ethoxyresorufin 
O-deethylase activity when compared to other marmosets used in this study (Figure 
3.3). As this marmoset demonstrated abnormal kinetics compared to the other 
marmosets investigated, it was considered an outlier and not included in further 
CYP1A kinetic evaluations. The properties of this marmoset were further 
investigated, however, to ascertain whether the low 7-ethoxyresorufin O-deethylase 
activity was related to reduced CYP1A enzyme expression (see Chapter 5).
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Figure 3.3: Rate v Substrate concentration plot of 7-ethoxyresorufin O-deethylase 
formation by batch 2 marmoset liver microsomes. Marmoset 0625 demonstrates a lower 
7-ethoxyresorufin O-deethylase function compared to the other marmoset liver microsomes
3.3.2: 7-Methoxyresorufin O-demethylase activity (CYP1A2)
As with the 7-ethoxyresorufin O-deethylase assay, 7-methoxyresorufin 
O-demethylase linearity for the formation of resorufin with respect to protein and time 
could be seen over a 15-minute incubation period at all protein concentrations 
investigated (0.05, 0.1 and 0.25 mg/ml. Figure 3.4). Conditions appropriate for best fit 
to the linear portion of the rate curve for the formation of resorufin were 0.1 mg/ml 
protein and an incubation period of 5 minutes. These conditions offered a satisfactory 
formation of resorufin, with a reaction rate of 88 pmoles/min/mg protein. However, as 
similar rates of 7-ethoxyresorufin O-deethylase and 7-methoxyresorufin 
O-demethylase activities were observed in the marmoset microsomal pool, the 
7-ethoxyresorufin O-deethylase assay was chosen as the marker activity of choice 
for putative CYP1A in the marmoset kinetic determination experiments.
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Figure 3.4: 7-Methoxyresorufin O-deethylase time and protein linearity in marmoset 
liver microsomes. Data points are the average of duplicate incubations of 0.05, 0.1 and 0.25 
mg/ml marmoset microsomal protein over a 15-minute incubation period.
3.3.3: Coumarin 7-hydroxylase activity (CYP2A6)
3.3.3.1: Linearitv of coumarin 7-hvdroxvlase activitv
Coumarin 7-hydroxylase activity was initially assessed by monitoring continuously 
the change in fluorescence with time, using marmoset liver microsomal protein at 
concentrations of 0.025, 0.05, 0.1, 0.25 and 0.5 mg/ml for 4 minutes in a 
fluorescence spectrophotometer. However, this showed negligible rates of 
hydroxycoumarin formation (data not shown). Therefore, it was decided that the use 
of an ‘end stop’ assay with increased protein concentrations of 0.25, 0.5 and 1.0 
mg/ml over incubation periods of 5, 10, 15, 20, and 30 minutes would provide 
conditions more conducive to product formation.
This method resulted in linear conditions over a 10-minute incubation period at 1.0 
mg/ml of microsomal protein (Figure 3.5). Under these conditions 61 pmoles of
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hydroxycoumarin were formed, which is equal to 6 pmoles/min/mg protein (based on 
a standard curve for the same protein concentration) with < 0.1% of the parent 
compound being consumed.
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Figure 3.5: Coumarin 7-hydroxylase time and protein linearity. Data points are the 
average of duplicate incubations of 0.25, 0.5 and 1.0 mg/ml marmoset microsomal protein 
over a 30-minute incubation period. Insert plot highlights optimal linear conditions at 1.0 
mg/ml microsomal protein over a 10-minute incubation period. However, this accounted for 
< 0.1% consumption of coumarin.
3.3.3.2: Kinetic characterisation of coumarin 7-hvdroxvlase activitv (CYP2A6)
Kinetic parameters proved difficult to determine as no increase in the formation of 
7-hydroxycoumarin was evident when a range of coumarin concentrations (0.1 -  
1000 pM) were incubated with various of marmoset liver microsomes concentrations 
(data not shown). Subsequent Western blot analysis (Chapter 5) indicated a possible 
lack of a CYP2A6-like enzyme in the marmoset liver incubations. This was in 
agreement with the low activities seen and consequently, the kinetic characterisation 
of coumarin 7-hydroxylase activity was not pursued any further.
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3.3.4: 7-Pentoxyresorufin 0-depentylase activity (CYP2B6)
Minimal activity of 7-pentoxyresorufin 0-depentylase activity was present over a 
6=minute rate assay utilising 0.5, 0.75, 1.0, 2.0 and 3.0 mg/ml of marmoset 
microsomal protein. The formation of resorufin was considered optimal at a protein 
concentration of 1.0 mg/ml, as this point appeared to relate to the linear portion of the 
Rate V Substrate concentration plot and achieved the highest rate of reaction (5 
pmoles/min/mg of protein). However, S-mephenytoin /V-demethylase activity 
appeared to be a far better marker for defining CYP2B activity, consequently kinetic 
characteristics of 7-pentoxyresorufin 0-depentylase activity were not determined.
3.3.5: Paclitaxel 6a-hydroxylase activity (CYP2C8)
Linearity for the formation of 6a-hydroxypaclitaxel was not evident under the 
conditions used. The formation of 6a-hyd roxy pad itaxel may have demonstrated 
initial linearity, but the Formation v Time plot implied depletion of one or more 
components within the incubation mixture, or possible product inhibition, with a drop 
in the reaction rate (Figure 3.6). Maximum metabolite formation was less than 5% of 
the incubated paclitaxel, even at high protein concentrations and extended incubation 
periods. When the rate of disappearance of paclitaxel was considered, rather than 
the formation of 6a-hydroxypaclitaxel, linear conditions were observed with 1.0 mg/ml 
of microsomal protein over 120 minutes (data not shown), although this trend was not 
evident at higher microsomal protein concentrations. Therefore, 6a-hydroxypaclitaxel 
formation was not considered a suitable probe activity for which to determine kinetic 
parameters in the marmoset.
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Figure 3.6: Paclitaxel 6a-hyd roxy lase time and protein linearity. Incubation of marmoset 
microsomal protein (1.0, 2.0 and 3.0 mg/ml) over a 120-minute incubation period.
3.3.6: Diclofenac 4'-hydroxy!ase
The formation of 4'-hydroxydiclofenac was evident from the HPLC radio­
chromatograms (Figure 3.7 A). However, the peak profile in control samples (no 
NADPH) was similar to that obtained in the presence of NADPH (Figure 3.7 B). This 
was reproducible over two separate incubation attempts, over protein concentration 
ranges of 0.25, 0.5, 1.0 and 1.0, 2.0, 3.0 mg/ml (data not shown) and, therefore 
suggested, formation of products, possibly due to non-enzymic degradation. 
Consequently, formation of 4'-hydroxydiclofenac could not be quantified. Previous 
investigations using control samples in the absence of microsomal protein, rather 
than the absence of NADPH, did not demonstrate the same phenomenon. Since 
tolbutamide methylhydroxylase activity is a suitable alternative for the marmoset 
orthologue of CYP2C9, and due to aforementioned complications it was decided that 
the diclofenac assay would not be pursued for the kinetic characterisation of CYP2C 
in the marmoset.
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Diclofenac 40-minute incubation 
in the presence of NADPH
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Figure 3.7: Diclofenac 4 -hydroxylase HPLC chromatograms. A: Metabolite formation 
profile of a 40-minute incubation of marmoset liver microsomes in the presence of NADPH. B: 
Profile depicting the elution of a peak, in the absence of NADPH, that co-chromatographed 
with 4'-hydroxydiclofenac, making this an unsuitable method for the determination of 
CYP2C9-like marmoset activity
3.3.7: Tolbutamide methylhydroxylase activity (CYP2C9)
3.3.7.1: Linearitv of tolbutamide methyl hydroxylase activitv
Tolbutamide methylhydroxylase activity was linear with respect to protein and time 
over the full incubation period investigated, up to 60 minutes, with 1.0, 2.0 and 3.0 
mg/ml of marmoset microsomal protein, although these conditions produced low 
rates of formation across the protein concentration range (Figure 3.8). The optimum
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conditions, as determined by the line of best fit intersecting the origin, were 
considered to be the highest protein concentration investigated over 20 minutes. This 
offered approximately 1% formation of methylhydroxytolbutamide (equivalent to a 
calculated rate of 25 pmoles/min/mg protein) with 1.3% consumption of tolbutamide.
1 mg/ml
R2= 0 .9878
2 mg/ml
o 0.8
3 mg/ml0.6
0.4
0.2
20 30 40 50 60100
Tim e (minutes)
Figure 3.8: Tolbutamide time and protein linearity. Data points are the average of 
duplicate incubations of 1, 2 and 3 mg/ml marmoset microsomal protein over a 60-minute 
incubation period. Insert plot highlights optimal linear conditions at 0.25 mg/ml microsomal 
protein over a 20-minute incubation period, accounting for approximately 1% product 
formation.
3.3.7.2: Kinetic characterisation of tolbutamide methvlhvdroxvlase activitv (CYP2C9) 
The optimal conditions established from the linearity investigations, and a 
tolbutamide concentration range of 20 to 2000 pM provided data for kinetic analysis. 
When a single-enzyme model was applied, the kinetic parameters were Km = 2216 
pM and Vmax = 789 pmoles/min/mg protein. The Eadie-Hofstee plot (Figure 3.9) 
suggests atypical enzyme kinetics; when a two-enzyme model was applied to the 
data it was observed that these data would not fit to the two-enzyme model.
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Figure 3.9: Eadie-Hofstee plot for the formation of methylhydroxytolbutamide. Error 
bars represent mean ± SD of 5 individual marmosets at tolbutamide concentrations of 20, 40, 
75, 120, 200, 500, 1000 and 2000 pM, and incubated under optimal conditions as determined 
in the linearity experiments.
3.3.8: S-mephenytoin 4'-hydroxy!ase (CYP2C19) and N-de/nefAiy/ase (CYP2B6) 
activities
3.3.8.1: Linearity of S-mephenvtoin /V-demethvlase activity
S-Mephenytoin 4 '-hydroxylase activity was negligible (< 0.5% formation of 
4'-hydroxymephenytoin) after a 120-minute incubation period in the presence of 1.0, 
2.0 or 3.0 mg/ml protein (data not shown). Therefore this activity was not pursued 
any further. However, linearity with respect to protein and time could be seen over a 
120-minute incubation period with both 1.0 and 2.0 mg/ml of marmoset microsomal 
protein for the formation of nirvanol (S-mephenytoin /V-demethylase, Figures 3.10 
and 3.11).
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Figure 3.10: S-Mephenytoin N-demethylase HPLC chromatograms. A: The formation of 
4'-hydroxymephenytoin compared to that of nirvanol from an incubation in the presence of 
marmoset microsomal protein. B: Control sample in the absence of NADPH.
At the highest protein concentration used (3.0 mg/ml) activity reacted a plateu after 
80 minutes, either due to the reduction of substrate concentration over time or a 
significant build up of product causing product inhibition. Optimal conditions for 
nirvanol formation were therefore considered to be a protein concentration of 2.0 
mg/ml and an incubation period of 80 minutes (Figure 3.11). These offered good 
linearity and good reaction rates (50 pmoles/min/mg protein), with 4% formation of 
nirvanol being detected with a similar amount of parent compound being consumed 
(4.1% consumption of S-mephenytoin). These results indicate that A/-demethylase 
activity is the major route of metabolism of S-mephenytoin by marmoset liver 
microsomes.
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Figure 3.11: S-Mephenytoin time and protein linearity. Nirvanol formation of duplicate 
incubations of 1, 2 and 3 mg/ml marmoset microsomal protein a 120-minute incubation 
periods to determine optimal linear conditions with regard to time and protein concentration. 
Insert plot presents the linear conditions at 2.0 mg/ml microsomal protein over an 80-minute 
incubation period, considered optimal for future kinetic analysis.
3.3.8.2: Kinetic characterisation of S-mephenvtoin N-demethvlase activitv 
The kinetic parameters of S-mephenytoin /V-demethylase activity were investigated 
using the optimal conditions determined from the linearity investigations and a range 
of S-mephenytoin concentrations (20 - 2000 pM); the Eadie-Hofstee plot is shown in 
Figure 3.12. The highest concentration of S-mephenytoin (2000 pM) resulted in 
spurious data, possibly due to reduced solubility of the substrate and, therefore, 
these data were not included in the analysis using the single-enzyme model of 
Michaelis-Menten kinetics, which resulted in a Km of 1325 pM and Vmax = 463 
pmoles/min/mg protein. The data were a good fit to this model with coefficient of 
variation values < 20%. A two-enzyme model of Michaelis-Menten kinetics was also 
fitted to these data and gave values of Km = 327 pM and Vmax = 103 pmoles/min/mg 
protein for the high affinity/low activity enzyme, and a Km = 17963 pM and Vmax = 
2062 pmoles/min/mg protein for the low affinity/high activity enzyme. However, the
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latter values were obtained through extrapolation of the existing data and 
confirmation of this low affinity/high activity enzyme proved impractical due to the S- 
mephenytoin solubility issues.
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Figure 3.12: Eadie-Hofstee plot for the formation of nirvanol from S-mephenytoin 
catalysed by marmoset liver microsomes. Each point represents mean ± SD for 5
marmosets, with each analysis conducted in duplicate, at S-mephenytoin concentrations of 
20, 40, 75, 120, 200, 500, 1000 and 2000 pM, incubated under optimal conditions as 
determined in the linearity studies.
3.3.9: Debrisoquine hydroxylase activity (CYP2D6)
3.3.9.1: Linearity of debrisoauine hvdroxvlase activitv
The formation of several hydroxylated products of debrisoquine were apparent in the 
radiochromatograms of incubates in the presence of NADPH. The major metabolite, 
eluting at 14 minutes, referred to here as metabolite formation-3 (MF-3) (Figure 
3.13), together with the other debrisoquine metabolic products were further 
characterised in Chapter 4. MF-3 demonstrated non-linear response for the major 
part of the reaction curve, for each of the protein concentrations investigated.
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Figure 3.13: Debrisoquine hydroxylase HPLC chromatograms. A: The formation of 
4-hydroxydebrisoquine, MF-1 and MF-3, following an incubation of marmoset microsomes for 
120 minutes in the presence of NADPH. B: Control sample in the absence of NADPH.
A similar non-linear response was associated with the formation of 
4-hydroxydebrisoquine. However, the amount of 4-hydroxydebrisoquine formed was 
low compared to that of MF-3. Linearity with respect to protein and time for the 
production of 4-hydroxydebrisoquine was considered to be < 10 minutes at 1.0, 3.0 
and 5.0 mg/ml of marmoset microsomal protein (Figure 3.14). The amount of MF-3 
formation was not substantially elevated by increasing microsomal protein from 3.0
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mg/ml to 5.0 mg/ml. Subsequently, the optimum conditions for the formation of MF-3 
were considered to be 3.0 mg/ml marmoset microsomal protein and an incubation 
period of 10 minutes, which offered a good compromise between linearity of reaction 
and readily detectable metabolites (Figure 3.15). The consumption of the parent 
substrate under these conditions was 6.8%, and the rate of MF-3 formation was 701 
pmoles/min/mg protein.
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Figure 3.14: 4-Hydroxydebrisoquine formation with respect to time and protein 
concentration. Data points are the average of duplicate incubations at 1, 3 and 5 mg/ml 
marmoset microsomal protein, over a 120-minute incubation period to determine optimal 
linear conditions for 4-hydroxydebrisoquine formation. The Insert plot represents the 
conditions that were considered to be closest to steady-state conditions for the formation of 
4-hydroxydebrisoquine (3.0 mg/ml microsomal protein over a 10-minute incubation period). 
As 4-hydroxydebrisoquine was only a minor metabolite, further kinetic analyses were not 
conducted.
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Figure 3.15: Formation of the debrisoquine metabolite MF-3 as a function of time and 
protein concentration. Data points are the average of duplicate incubations at 1, 3 and 5 
mg/ml marmoset microsomal protein over a 120-minute incubation period to determine 
optimal linear conditions for MF-3 formation. The Insert plot shows the conditions that were 
chosen for future kinetic analyses. An incubation period of 10-minutes using 3 mg/ml 
microsomal protein was considered to be closest to steady-state kinetics and therefore used 
for further kinetic characterisation.
3.3.9.2: Kinetic characterisation of debrisoauine hvdroxvlase activitv 
A single-enzyme model was applied to the data obtained from microsomal incubates 
using a debrisoquine concentration range from 50 to 5000 pM, and optimal 
conditions determined from the linearity investigations. Kinetic characteristics were 
Km = 285 pM and Vmax = 1090 pmoles/min/mg protein. The application of a two- 
enzyme model was also fitted to the data; however, standard deviations and 
coefficient of variation were large for the low affinity/high activity enzyme for some of 
the animals using this latter model. The kinetic values for the low affinity/high activity 
enzyme were Km = 16281 pM and Vmax = 2119 pmoles/min/mg protein. The Eadie- 
Hofstee plot (Figure 3.16) does indeed lend itself to the possibility of a second activity 
at the higher debrisoquine concentrations but, once again, solubility problems
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prevented further investigations at these higher substrate concentrations. On the 
other hand, this model is far more reliable for the high affinity/low activity enzyme Km 
= 89.4 pM and Vmax = 663 pmoles/min/mg protein. These kinetic parameters were 
confirmed by the use of a single-enzyme model at the lower range of substrate 
concentrations (50-500 pM; Km = 99.5 pM and Vmax = 729 pmoles/min/mg protein).
1400
1200
a ^  1000(DII(A a.
1 1
800
600
400
200
0 1 2 3 4 5 6
Reaction velocity (pmol/nnin/mg)/debrisoquine concentration (pM)
V/[S]
Figure 3.16: Debrisoquine Eadie-Hofstee piot for the formation of MF-3. Marmoset liver 
microsomes were incubated in the presence of NADPH and debrisoquine (50,100, 200, 300, 
500, 1000, 3000 & 5000 pM) using the optimal conditions determined in the linearity phase. 
Results are presented as mean ± SD for 5 marmosets, with each analysis conducted in 
duplicate.
3.3.10: Laurie acid 11-hydroxyiase (CYP2E1) and 12-hydroxyiase (CYP4A11) 
activities
3.3.10.1: Linearitv of lauric acid 11-and 12- hvdroxvlase activities 
During the determination of linear assay conditions with marmoset liver microsomes, 
both 11- and 12-hydroxy metabolites were formed (Figure 3.17). Linearity with 
respect to protein and time was seen over a 20-minute incubation period with 0.25,
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0.5 and 1.0 mg/ml microsomal protein for the formation of both 11-hydroxy and 
12-hydroxylauric acids (Figure 3.18). For the formation of 11-hydroxylauric acid, the 
highest protein concentration employed (1.0 mg/ml) and a 20-minute incubation 
period offered a 10% metabolite formation and a reaction rate of 503 pmoles/min/mg 
protein with a total consumption of 13.5% of the parent compound. However, the rate 
of reaction for the production of 12-hydroxylauric acid was much lower under these 
conditions, at 95 pmoles/min/mg protein and only < 2% metabolite formation. 
Therefore, whilst these were considered to be optimal, it was recognised that the 
quantification of the 12-hydroxylauric acid would be less readily achieved because of 
the lower formation rate compared to the 11-isomer.
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Figure 3.17: 11- and 12-hydroxylauric acid HPLC chromatograms. A: The formation of 
11- and 12-hydroxylauric acid metabolites from an incubation in the presence of marmoset 
microsomal protein and NADPH for a period of 20 minutes. B: Same incubation in the 
absence of NADPH.
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Figure 3.18: Formation of 11- and 12-hydroxylauric acids. Data points reflect the average 
of duplicate incubations at 0.25, 0.5 and 1 mg/ml marmoset microsomal protein over a 
60-minute incubation period to delineate optimal linear conditions for both metabolites. Insert 
plots highlight optimal linear conditions selected for each of the activities at 1.0 mg/ml 
microsomal protein over a 20-minute incubation period.
3.3.10.2: Kinetic characterisation of lauric acid hvdroxvlase activities
The kinetic parameters for lauric acid 11- and 12-hydroxylase activities were
investigated using the optimal conditions determined in the linearity investigations,
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and concentrations of lauric acid used in these incubations ranged from 10 to 
1000 pM (Figure 3.19).
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Figure 3.19: Eadie-Hofstee plots of 11- and 12 hydroxylauric acid from lauric acid.
Incubations were performed at a range of lauric acid concentrations (10-1000 pM). Each point 
represents the mean ± SD of 5 marmosets, with analysis for each animal conducted in 
duplicate.
Michaelis-Menten kinetic analysis for lauric acid 11- and 12-hydroxylase activities 
was used to calculate values of Km = 842 pM and 692 pM and Vmax = 6521 and 1633 
pmoles/min/mg protein, respectively, when a single-enzyme model was employed.
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The data were a good fit to this model with low coefficient of variation values of < 9% 
and 14%, respectively. A two-enzyme model of Michaelis-Menten kinetics was also 
fitted to these data, leading to Km values of 547 and 10.2 pM and Vmax values of 2.69 
and 39.6pmoles/min/mg protein, for lauric acid 11- and 12-hydroxylase high 
affinity/low activities respectively; the low affinity/high activity enzyme parameters 
were Km = 842 and 916 pM and Vmax = 6518 and 1790 pmoles/min/mg protein, for 
lauric acid 11- and 12-hydroxylase activities respectively. However, standard 
deviations and coefficients of variation were very large using this model, especially 
for lauric acid 11-hydroxylase activity, indicating a poor fit for this enzyme model.
3.3.11: Testosterone 6/3 hydroxylase activity (CYP3A4/5)
3.3.11.1: Linearitv of testosterone 66 hvdroxvlase activitv
The major metabolite formed by marmoset liver microsomes on incubation with 
^"^C-testosterone was 6p-hydroxytestosterone; formation of 16p- and 2a/2p- 
hydroxytestosterones and androstenedione were also evident to a lesser degree, as 
determined by UV identification using authentic reference standards (Figure 3.20). 
Linearity of 6p-hydroxytestosterone formation with respect to protein and time was 
seen over a 10-minute incubation period at 0.2, 0.5 and 1.0 mg/ml of marmoset 
microsomal protein (Figure 3.21). At 1.0 mg/ml protein more than 16% of the 
testosterone was consumed over the 10-minute reaction period, whilst with 0.5 mg/ml 
protein 7.7% of the parent compound was metabolised at a similar rate of reaction to 
the higher protein concentration (1873 pmoles/min/mg protein). Optimal conditions 
were therefore selected at this lower protein concentration providing final conditions 
for kinetic evaluations at a protein concentration of 0.5 mg/ml and an incubation 
period of 10-minutes, due to the lower consumption of testosterone.
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Figure 3.20: Testosterone 6p hydroxylase HPLC chromatograms. A; The formation of 
6p-hydroxytestosterone, along with 16p-, 1a-, 2a-hydroxytestosterone and androstenedione 
from an incubation in the presence of marmoset microsomal protein. B: Same incubation in 
the absence of NADPH. C: UV detection of authentic reference standards.
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Figure 3.21: Linear conditions for the formation of 6p-hydroxytestosterone. Marmoset 
liver microsomes at 0.25, 0.5 and 1 mg/ml microsomal protein, incubated in the presence of 
testosterone and NADPH over 60 minutes. Optimal linear conditions for steady-state kinetics 
chosen to be 0.5 mg/ml microsomal protein over a 10-minute incubation period, as shown in 
the insert plot.
3.3.11.2: Kinetic characterisation of testosterone 6B- hvdroxvlase activitv 
The use of optimal conditions determined from the linearity investigations and a 
concentration of testosterone ranging from 17.5 to 1750 pM generated data for 
kinetic analysis. A single-enzyme model of Michaelis-Menten kinetics led to 
calculated values of Km = 106 pM and Vmax = 2852 pmoles/min/mg protein. The 
Eadie-Hofstee plot (Figure 3.22) implies possible allosteric kinetic behaviour (multi­
site/multi-enzyme activity). Such allosteric effects have already been described in 
CYP3A enzyme systems (Kenworthy et al., 2001). Therefore, the data were also 
applied to the Hill equation to determine the allosteric nature of the marmoset CYP 
3A enzyme. However, both the K' and the Vmax calculated using the Hill equation 
produced similar values to the original results at 109 pM and 2883 pmoles/min/mg 
protein, respectively (Figure 3.23).
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Figure 3.22: Eadie-Hofstee plot for the formation of 6p-hydroxytestosterone. Kinetic 
characterisation of testosterone 6p-hydroxylase activity from marmoset liver microsomal 
incubations, conducted in duplicate using optimal conditions as determined in the linearity 
investigations and a range of testosterone concentrations (17.5 - 1750 pM). Error bars 
represent average ± SD of analysis of 5 individual animals
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Figure 3.23: Comparison of non-linear regression plots using a single enzyme model 
and the Hill equation for the formation of the 6p-hydroxytestosterone. Data points are 
mean values of 5 individual animals plotted against the predicted non-linear regression line 
determined by WinNonlin software. Plots generated by the one-enzyme model Michaelis- 
Menten equation and the Hill equation appear surprisingly similar, suggesting that allosteric 
kinetics do not play a part in marmoset liver microsomal GYPSA metabolism.
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3.4: Reproducibility/precision
Under the stated conditions, reproducibility was generally found to be good for all of 
the assays studied. Where sample volume and detectable rates of metabolism 
allowed, an acceptance criterion of < ± 5% difference from the mean of duplicate 
samples was employed. If this criterion was not fulfilled, then comparison to a third 
replicate was used to produce the lowest percentage difference from the mean, 
providing < ± 5%. If no replicate pair satisfied these criteria, the median value from 
all three replicates was selected.
3.5: Summary of results
A summary of the linearity experiments and the kinetic characterisation data using 
marmoset liver microsomes are given in Tables 3.3 and 3.4, respectively.
Linear incubation conditions
Activity
Protein
concentration
(mg/ml)
Incubation
time
(minutes)
Enzyme activity 
(pmoles/min/mg 
protein)
Substrate 
consumption (%)
7-Ethoxyresorufin
0-deethylase
0.25 5 83 2.5
S-Mephenytoin
A/-demethylase
2.0 80 50 4.1
Tolbutamide
methylhydroxylase
3.0 , 20 25 1.3
Debrisoquine hydroxylase 3.0 10 701 6.8
Lauric acid 11-hydroxylase 1.0 20 503 13.5
Testosterone
6p-hydroxylase
0.5 10 1,873 7.7
Lauric acid 12-hydroxylase 1.0 20 95 13.5
Table 3.3 Enzyme activities achieved under linear incubation conditions. Summary data of 
steady-state kinetic conditions together with mean enzyme activity and consumption of parent 
substrate. 7-Ethoxyresorufin consumption was calculated from the formation of resorufin only, 
not accounting for other undetected metabolites which may have been formed.
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3.6: Discussion
Enzyme investigations were carried out using pooled liver marmoset liver 
m i croso mes_fo r_th e_l i nea rity stud i es_to^esta b I is h_opti m a U n cu bat ion. co n d i tion s_wi th. 
regard to time and protein concentrations, and 5 individual marmosets were used for 
the subsequent kinetic characterisation. It has been proposed that enzyme 
concentrations selected for kinetic investigations should be low enough so that the 
amount of product formed is negligible compared to the substrate concentration i.e. 
ideally about 10% or less of the substrate should be consumed (Korzekwa, 2002). 
Under conditions where extensive amounts of substrate are consumed, the rate of 
reaction may be seen to decline either due to reduction in the substrate concentration 
or the build up of product that may inhibit its own formation (product inhibition). 
Therefore, in the present study linearity conditions with respect to protein 
concentration so as to produce an acceptable rate of metabolite formation that 
remained on the linear part of the reaction curve. Established linear conditions 
selected from these first order kinetics were considered suitable for the varying 
substrate concentrations required for the determination of Michaelis-Menten kinetics.
The incubation time selected for use in the enzyme assays allowed a long enough 
period to complete the practical aspects of the incubation, such as the addition and 
mixing of the substrate and co-factors (performed outside the temperature controlled 
water bath or spectrophotometer), whilst still ensuring about 10% or less of the 
substrate was depleted. The use of prolonged incubation times may of course raise 
questions over the stability of the enzymes and substrates used. However, no linearity 
experiments conducted herein were incubated for more than 120 minutes and the 
longest final incubation time for selected kinetic investigations was 80 minutes.
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7-Ethoxyresorufin 0-deethylase activity was detected in marmoset liver microsomes, 
which is in accordance with the literature that describes the constitutive expression of 
CYP1A2 in the marmoset liver (Sakuma et al., 1997; Igarashi et al., 1997; Schulz et 
al., 1996 and 2001). This marmoset microsomal 7-ethoxyresorufin 0-deethylase 
activity is more than two-fold that of human CYP1A2 mediated activity decribed by 
Sharer et al. (1995). The initial 7-ethoxyresorufin 0-deethylase kinetic incubations in 
this study were hampered by the observation that resorufin generation throughout the 
7-ethoxyresorufin concentration range (0 .4 ^0  pM) remained the same. These 
results demonstrate that the amount of resorufin produced was not influenced by the 
substrate concentration and was, therefore, not the limiting factor within the reaction. 
Consequently, the 7-ethoxyresorufin concentration range was reduced 200-fold 
before satisfactory kinetic studies could be performed. The Km values obtained for the 
marmoset liver microsomes were almost 4-times lower than the value reported for 
human liver microsomes (Campbell et al., 1987). These kinetic constants (Table 3.4) 
do however indicate the presence of an enzyme in the marmoset liver that 
deethylates 7-ethoxyresorufin. The presence of this enzyme is in agreement with the 
work of Sakuma et al. (1997) who described constitutive expression of marmoset 
CYP1A2, with an 88.2% identity (amino acid sequence) with the human form.
Quantifiable CYP2B marker activities identified in the present study were 
S-mephenytoin A/-demethylase and, to a much lesser degree, 7-pentoxyresorufin 
0-depentylase and testosterone 16(3-hydroxylase, the latter determined concurrently 
with testosterone 6p-hydroxylase. S-Mephenytoin A/-demethylase in human liver 
represents a much lower activity compared with S-mephenytoin 4 '-hydroxylase. This 
is not the case in marmoset, and highlights one of the interspecies differences 
between human and marmoset; furthermore, these substrate marker activities may 
be specific for quite different enzymes in the two species. However, substrate
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markers need to be selected on the basis of existing knowledge, and as the 
marmoset is being investigated as a potential animal model for future human 
toxicological work, all comparisons were made to established human substrate 
activities. S-Mephenytoin /V-demethylase activity was selected to determine CYP2B 
kinetic parameters due to the higher product formation compared with 
7-pentoxyresorufin 0-depentylase and testosterone 16p-hydroxylase activities. The 
Eadie-Hofstee plot generated from S-mephenytoin /V-demethylase depicted a typical 
plot commensurate with two or more enzymes contributing to the activity. The 
presence of CYP2B in marmoset liver has previously been established using 
antibodies raised against CYP2B6 by Schulz et al. (2001).
Measurable catalytic activities that were investigated as possible CYP2C markers in 
the marmoset were diclofenac 4 -hydroxylase and tolbutamide methylhydroxylase, 
both of which are human CYP2C9 substrates; S-mephenytoin 4 -hydroxylase 
(CYP2C19) and paclitaxel 6a-hydroxylase (CYP2C8) activities were both assayed 
but found to be very low, compromising product quantification. Similarly, diclofenac 
4 -hydroxylase activity could not be determined due to interfering peaks that eluted 
with the same retention time as the metabolites on the HPLC chromatography. As 
these fractions were present in repeated analyses, it is postulated that the presence 
of the marmoset microsomal protein in the absence of NADPH was producing an 
HPLC profile that precluded satisfactory analysis. Owing to the problems 
encountered with the diclofenac 4 -hydroxylase assay, tolbutamide 
methylhydroxylase was selected as the marker of choice for monitoring CYP2C 
activity, although the reaction rate (25 pmoles/min/mg protein) in the linear portion of 
the curve is only about one third of that seen in humans (Sharer et al., 1995 and 
Chauret et al., 1997). Although low, the presence of CYP2C in marmoset liver was 
implied by this activity and has been previously alluded to following immunoblotting
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experiments using antibodies raised against human CYP2C enzymes (Schulz et al., 
2001).
Metabolism of debrisoquine was interesting in that it generated three distinct 
metabolites following HPLC chromatography. 4-Hydroxydebrisoquine, the major 
human In vitro metabolite (Idle et al., 1979), was identified as one of the minor 
metabolites, whereas a later eluting metabolite (MF-3) was more extensively formed, 
and as such was used as the marker for possible CYP2D activity. Eiermann et al. 
(1998) has reported a metabolic pathway for the biotransformation of debrisoquine in 
human and the enzyme catalysis of the various steps. This pathway indicates that 
CYP2D6 catalyses the formation of several hydroxylated metabolites of debrisoquine 
(including 1-, 3- and 4-hydroxydebrisoquine). LC-MS/MS identification of the 
metabolites produced in the marmoset liver microsomal incubations for the 
determination of kinetic parameters indicate that MF-3 is a hydroxydebrisoquine, later 
determined to be a debrisoquine hydroxylation metabolite complex (Chapter 4). 
Therefore MF-3 was considered to be a suitable marker activity in marmoset liver as 
the well-established 4-hydroxydebrisoquine. The low 4-hydroxydebrisoquine activity 
in the marmoset has already been described by Hichiya et al. (2004) who failed to 
detect any 4-hydroxydebrisoquine in the marmoset liver.
Testosterone 6(3-hydroxylase activity was observed in marmoset liver microsomes, in 
accordance with previous studies describing the constitutive expression of CYP3A in 
marmoset liver (Igarashi et al., 1997; Schulz et al., 2001). Eadie-Hofstee analysis 
suggested possible allosteric kinetics of this enzyme as previously noted for human 
CYP3A4 (Kenworthy et al., 2001). However, when the Hill equation was applied to 
the data, the kinetic parameters were not substantially different from what was 
obtained using the single-enzyme Michaelis-Menten model. Furthermore, a slope
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factor of 1.01 from the Hill equation argues against allosteric kinetics of this enzyme 
in marmoset, at least with testosterone as the CYP3A substrate.
Eadie-Hofstee analysis of lauric acid 11-hydroxylase activity indicated the 
involvement of two enzymes. However, when these data were analysed using a 
Michaelis-Menten two-enzyme model equation, enormously high coefficient of 
variation values led to large standard deviations. Best fit was achieved with a one- 
enzyme model, with acceptable coefficient of variation values < 10%. Schulz et al. 
(1998) have identified a marmoset CYP2E1-like enzyme that contains an extra 2 
amino acids on the C-terminus end of the gene, compared to the human CYP2E1. 
This phenomenon is investigated in greater detail in Chapter 5.
The rate of formation of 12-hydroxylauric acid also demonstrated a good fit to a 
single-enzyme model. However, in contrast to the lauric acid 11-hydroxylase activity, 
only one of the animals demonstrated a poor fit to the two-enzyme model. The 
presence of CYP4A enzymes in marmoset liver has previously been measured by 
Hall etal. (1999), using 12-hydroxylauric acid as the probe substrate.
3.6.1: Marmoset liver enzyme mechanisms
The Eadie-Hofstee plots generated here did not generally indicate simple Michaelis- 
Menten kinetics of the activities. Most of the kinetic parameters determined using 
marmoset liver microsomes suggested a high affinity/low activity rate that is much 
closer to published human kinetic constants than the lower affinity/high activity. 
Additionally, the significance of these low affinity/high activities may be questionable, 
as the higher substrate concentrations used to calculate these are above 
concentrations that would be attained In vivo. Therefore, it may be considered that
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little relevant kinetic information is to be gained using substrate concentrations that 
have essentially no physiological relevance to the disposition or toxicology of the 
compound in question. However, the kinetic parameters were calculated from 
substrate concentrations using a range from one tenth to ten fold the estimated Km, 
without the benefit of previously published marmoset kinetic data available; this 
estimation was based on existing routine methods used in the department of in vitro 
metabolism at Huntingdon Life Sciences and as such, sometimes resulted in higher 
substrate concentrations than were required for the determination of marmoset 
kinetic parameters.
It is difficult to account for the enzymic mechanisms involved for each of the activities 
at this stage, as the involvement of two or more enzymes may function in similar 
ways to multiple active sites within a single enzyme. This has been recognised and 
documented for various P450 enzymes and may be explained by the binding of two 
substrate molecules, one which usually is a separate activator molecule, within the 
active site, producing a profile not dissimilar to that of a two-enzyme model 
(Korzekwa et al., 1998). Recently, it has been suggested that atypical enzyme 
kinetics involving cytochrome P450 enzymes are relatively common, with 
occurrences reported with virtually all of the enzymes studied in this chapter (Tracy, 
2003).
The use of proper kinetic models for estimating kinetic parameters from the data is of 
utmost importance if viable parameters are to be calculated (Houston and 
Kenworthy, 2000). However, as several solutions may satisfactory model the same 
set of data, and result in a good fit to a particular kinetic scheme, an accurate 
description of the enzyme-substrate interaction cannot be ensured. This, together 
with possible unknown interactions occurring within the active site of the enzyme(s)
ÏÔT
Chapter 3: Cytochrome P450 kinetics in marmoset liver
may have also resulted in mis-identification of abnormal kinetics. Examples of these 
active site interactions have been highlighted by Shou et al. (1994), who described 
apparent increases in enzymic activities produced by the uncoupling of the P450 
reaction cycl^, due tOL the ^ displacement oLwater .molecules .within_the_ active site 
when two substrate molecules bind simultaneously.
It is, therefore, recognised that caution should be exercised when describing kinetic 
behaviour, especially as the marmoset liver microsomes are essentially a 
multienzyme system, containing numerous Phase I catalytic activities, some of which 
are yet to be fully characterised. These can produce artificial sources of atypical 
kinetics that may have been incorrectly identified as behaviour from a single enzyme, 
rather than the interaction of one or more enzymes. Furthermore, there may be other 
confounding factors such as substrate or product inhibition, and deviations from the 
Michaelis-Menten equation that could influence the determination of parameters 
linked to possible marmoset CYPs. Therefore, the findings from the present kinetic 
investigations may not provide the full picture, bearing in mind that these results may 
be pure In vitro artefacts that may not be manifested in vivo. However, it is of course 
of great importance to appreciate kinetics In vitro, if In vltro-ln vivo correlations are to 
be performed.
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3.7: Conclusions
The kinetic investigations have established the possible expression of CYP1A, 2A, 
2B, 2C, 2D, 2E, 3A and 4A subfamilies in marmoset liver, in agreement with a 
previous study by Schulz et al. (2001) and Igarashi et ai. (1997) who have confirmed 
considerable levels of expressed CYPs 2B, 2C, 2D, 2E, 3A, and to a lesser extent 
1A, in marmoset liver by Northern blot and immunoblot analyses. However, 
identification of the presence of specific enzymes, based solely on enzyme activities, 
as in this chapter, cannot be used in isolation to determine expression with any 
confidence, as there may be considerable cross-family specificity of the probe 
substrates used within this investigation. For example, it has been demonstrated that 
human cells expressing CYP1A1 are efficient in the 4-hydroxylation of debrisoquine, 
which is normally associated with CYP2D6 (Granvil et al., 2002). This highlights one 
of the many problems associated with enzymic identification based purely on 
substrate specific metabolism, even within species with a long history of scientific 
investigation. Immunochemical analyses (Igarashi et al., 1997) have shown that the 
relative levels of expression of individual CYP also differ between marmoset and 
human To this end, further characterisation of the marmoset liver microsome CYPs 
was undertaken (Chapters 5 & 6).
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4.1: Introduction
CYP2D6 is an important enzyme in drug metabolism despite its relatively low hepatic 
abundance, and is one of the most important polymorphic drug metabolising 
enzymes responsible for adverse drug reactions. The CYP2D6 protein demonstrates 
a very high degree of inter-individual variation in the biotransformation of several 
drugs (Kroemer and Eichelbaum, 1995; Weinshilboum, 2003), including 
debrisoquine. Debrisoquine is a cardiac drug once used in the treatment of 
hypertension, and is mainly metabolised to 4-hydroxydebrisoquine in humans by 
CYP2D6 (Mahgoub et al., 1977).
In this chapter, the hydroxylation of debrisoquine by male marmoset liver has been 
investigated. The identities of the metabolites formed by the cytochrome P450- 
dependent mixed function oxidase systern and their generation have been 
investigated following incubation of debrisoquine with marmoset liver microsomes; a 
combination of analytical techniques was employed to bring about the isolation, 
identification and semi-quantification of these metabolites.
It was noted during the course of the marmoset kinetic linearity studies (Chapter 3) 
that throughout the determination of debrisoquine hydroxylase activity by radio- 
HPLC, the profile contained additional significant peaks other than those of the major 
human metabolite, namely 4-hydroxydebrisoquine. Under these initial analytical 
conditions, marmoset liver microsomes metabolised p"^C]-debrisoquine to 3 
metabolite fractions designated MF-1, MF-2 (a fraction eluting with the same 
retention time as an authentic 4-hydroxydebrisoquine reference standard) and MF-3 
(Figure 4.1). Notably, the peak eluting with the same retention time as the authentic
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4-hydroxydebrisoquine reference standard accounted for a smaller fraction of the 
total radioactivity than the peak designated as MF-3.
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Figure 4.1: Radio-HPLC chromatogram of debrisoquine metabolite formation and UV 
chromatogram of authentic reference standards. Radio-HPLC profile was obtained using 
the initial HPLC conditions following the incubation of marmoset hepatic microsomes with 
[ '^*C]-debrisoquine. UV detection was conducted at 211 nm.
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Consequently, additional studies were undertaken to define the nature of these f ' ‘C]- 
debrisoquine metabolites. In the first instance structural identification of the 
metabolites was attempted using Liquid Chromatography Mass Spectrometry, Mass 
-Spectrometry4LC=MS/-MS-),-in-electrospray-positive-ion mode-(ESIl). However^due to- 
inconclusive structural identification by the LC-MS/MS, further isolation and 
separation of the metabolite peaks was essential to allow the isolated metabolite 
fractions to be collected for Nuclear Magnetic Resonance (NMR) analysis. This 
further separation was achieved by a modification of the HPLC conditions.
4.2: Methods
[‘"*C]-Debrisoquine samples from marmoset liver microsomal reactions used for the 
initial LC-MS/MS analysis were produced as outlined in Debrisoquine hydroxylase 
section (Chapter 2). Modified HPLC conditions for the further separation of the 
debrisoquine metabolites and the procedures for LC-MS/MS and NMR are as 
described in NMR section (Chapter 2).
4.3: Results
As already described in the previous chapter, incubation of marmoset liver 
microsomes with debrisoquine in the presence of NADPH revealed a minor 
metabolite fraction eluting at 7 minutes, designated MF-1, and fractions eluting with 
similar retention times to authentic 4-hydroxydebrisoquine and debrisoquine at 11 
and 23 minutes, respectively. Moreover, a major metabolite peak, eluting at 14 
minutes was also present under these conditions, designated MF-3. Interestingly, the 
metabolite peak having the same retention time as authentic 4-hydroxydebrisoquine
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represented a less significant proportion of the complete metabolic profile than MF-3 
(Figure 4.1).
4.3.1: Debrisoquine metaboiite identification by LC-MS/MS
A representative sample from the debrisoquine kinetic incubation in the presence of 
marmoset liver microsomes (Chapter 2) was assayed by LC-MS. The LC-MS 
conditions accelerated the elution of the peaks of interest (Figure 4.2). The identity of 
these eluting peaks was confirmed by comparison with authentic debrisoquine and
4-hydroxydebrisoquine (Figure 4.3).
The metabolite peak area designated as MF-3 was further investigated by LC-MS/MS in 
positive electrospray ionisation mode (ESI+). The debrisoquine incubate sample 
contained a peak with a mass of m/z 176 eluting with the same retention time as 
authentic debrisoquine, and two peaks, one with a mass of m/z 192 that eluted with the 
same retention time as the authentic 4-hydroxydebrisoquine and one with a peak 
designated as MF-3 (Figure 4.4). It could therefore be postulated that the metabolite 
fractions of mass m/z 192 were likely to be different isomers of hydroxydebrisoquine, 
due to the increase of 16 mass units (mass of oxygen) compared to debrisoquine. Also 
postulated was the presence of a possible dihydroxylated debrisoquine with a mass of 
m/z 208, 32 mass units larger than debrisoquine (mass of two oxygen atoms). This 
metabolite fraction was identified as MF-1 on the original radiochromatogram. 
Flowever, detailed structural configuration of any of these metabolites proved difficult 
by mass spectrometry alone. Mass spectra of fragmented daughter ion products by 
LC-MS/MS analysis, provided only limited information, as the fragmentation of the 
structures occurred in such a manner that the location of the hydroxyl group(s) on the 
debrisoquine ring(s) could not be confirmed, as the prominent loss of m/z 42
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indicates the cleavage of CN2H2 (Table 4.1), while other fragmentations were 
resulting in loss of m/z 72 (C2N3H6), m/z 105 (CgHg), m/z 121(C8H8-OH) and m/z 133 
(C9H8-OH) (Figure 4.5). None of these fragmentations indicate the precise location of 
the hydroxyl group(s).
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Figure 4.2: Mass chromatograms of m/z 208, m/z 192 and m/z 176. Electrospray ionisation 
mass spectra chromatograms (ESF) of debrisoquine (500 i^M) incubation sample with 
marmoset liver microsomal protein (5 mg/ml) for 120 minutes, derived from kinetic analysis 
(Chapter 3). Trace A: ESF total ion current (TIC) chromatogram. Trace B: EST scan of mass 
m/z 207.5 -  208.5, Trace C: ESF scan of mass m/z 191-5 -  192.5, Trace D: ESF scan of 
mass m/z 175-5 -  176.5, Trace E; UV absorbance at 211 nm and Trace F: 
radiochromatogram of incubate.
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Figure 4.3: Mass chromatograms of m/z 192 and m/z 176 and UV trace for the
reference standards. Electrospray ionisation mass spectra chromatograms (EST) of 
authentic debrisoquine and 4-hydroxydebrisoquine. Trace A: EST total ion current (TIC) 
chromatogram, Trace B: ESr scan at mass m/z 191-5 -  192.5, Trace C: EST scan at mass 
m/z 175-5 -  176.5 and Trace D: UV absorbance of mixed reference standards at 211 nm.
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Figure 4.4: ESI+ Mass spectra of peaks eluting at 4, 6, 7 and 16 minutes. Liquid
chromatography mass spectrometry (LC-MS) of debrisoquine (500 pM) incubation sample in 
the presence of marmoset liver microsomal protein (5 mg/ml) for 120 minutes, derived from 
kinetic analysis (Chapter 3); Spectrum A; dihydroxyderbrisoquine with m/z 208 eluting at 4 
minutes, Spectra B and C: hydroxydebrisoquine with m/z 192 eluting at 6 and 7 minutes and 
Spectra D: debrisoquine with m/z 176 eluting at 16 minutes.
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Figure 4.5: Product ion mass spectra of peaks eiuting at 4, 6, 7 and 16 minutes. Liquid 
chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) of debrisoquine 
(500 |iM) incubation sample with marmoset liver microsomal protein (5 mg/ml) for 120 
minutes, derived from kinetic analysis (Chapter 3); Spectrum A: dihydroxydebrisoquine 
daughter ion of m/z 166 eluting at 4 minutes, Spectra B and C: hydroxydebrisoquine peaks 
eluting with prominent daughter ions of m/z 150 at 6 and 7 minutes, and Spectrum D: 
debrisoquine daughter ion of m/z 134 for eluting at 16 minutes.
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Identity Parent Product 
[MH]" ion
Parent structure Product structure
debrisoquine
208 166 HO-
NH
^ N ^ N H g
H^
HO-A
HO- HO-
4-Hydroxy- 192 150
debrisoquine
Debrisoquine 176 134
Hydroxy- 192 150 HO—
debrisoquine
NH
AN NH.
OH
NH
AN NK
NHAN NH.
HO—
+
NH.
OH
NH.
N H .
Table 4.1: Postulated structures of parent and significant daughter ions resulting from 
collisionally induced dissociation (CID) by LC-MS/MS. Identification of Parent and 
prominent daughter ion structures, postulated from the loss of m/z 42. This loss indicates the 
cleavage of CN2 H2 . Additional fragmentations (structures not shown) include: m/z 72
(C2 N3 H6 ): m/z 105 (CaHg): m/z 121(CQH8-OH) and m/z 133 (CgHa-OH) fail to provide the 
precise ring location of the hydroxyl group(s).
To ensure that the same metabolic profile was generated by the microsomes from 
each of the 5 individual animal livers, each was individually incubated with 
debrisoquine and the radio-chromatogram profiles compared. These profiles were 
generated from individual marmoset liver microsomal kinetic linearity incubations 
(Chapter 3) using ‘batch T animals (for full details of ‘batch T animals, see 
Chapter 2) and analysed by radio-HPLC using conditions optimised for time and 
protein (i.e. 3 mg/ml marmoset liver microsomal protein incubated for 10 minutes at
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37°C). These separate radio-HPLC profiles were overlaid for the purpose of inter­
animal comparison (Figure 4.6).
Note, all LC-MS analyses were conducted using a sample generated from the 
longest incubation time and highest protein concentration of the kinetic linearity 
investigation from Chapter 3 (5 mg/ml marmoset liver microsomal protein incubated 
for 120 minutes at 37°C).
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Figure 4.6: Incubations of hepatic marmoset microsomes with debrisoquine (500 pM) 
for Inter-anlmal comparison. Hepatic microsomes (3 mg/ml) from five marmosets were 
incubated with debrisoquine (500 pM) in the presence of NADPH. Overlaid radio­
chromatograms demonstrate the similarity in metabolic profiles from each animal.
MLM = marmoset liver microsomes
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The overlaid radio-chromatograms from the individual marmoset analysis 
demonstrate the consistency of profiles obtained from the five different animals, 
suggesting that the results from the mass spectrometry of the pooled marmoset liver 
microsomal sample from these animals is representative of each of the individual 
animals within that pool. The absence of the metabolite faction designated as MF-1 
in the above inter-animal comparison may be due to the fact that the radio­
chromatogram profiles were obtained from incubations conducted at a lower 
marmoset liver microsomal protein concentration and a shorter incubation time than 
the sample used as part of the kinetic linearity studies (3 mg/ml marmoset liver 
microsomal protein incubated for 10 minutes as opposed to 5 mg/ml marmoset liver 
microsomal protein incubated for 120 minutes, respectively). The comparison used in 
Figure 4.6 will therefore not include the metabolites formed by increased catalytic 
activity of the prolonged incubation time in the presence of higher enzyme 
concentrations, as in the case of the pooled sample used for the mass spectrometry 
analysis.
4.3.2: Structural identification of the debrisoquine metabolites by nuclear 
magnetic resonance (NMR)
For more detailed identification and ring location of the debrisoquine hydroxyl groups, 
further investigations by NMR analysis were required. To this end, a large volume 
incubation (35 ml) was conducted using the ‘Batch V pool of marmoset liver 
microsomes to provide sufficient material in each metabolite fraction for NMR 
analysis. This reaction was terminated by the addition of ice-cold acetonitrile rather 
than 70% perchloric acid due to the oxidative nature of the latter on the debrisoquine 
metabolites during sample concentration. After centrifugation at 17000 x g for 15 
minutes, the organic component was removed by rotary film evaporation (RFE). An
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aliquot (1 ml) of the aqueous residue was taken for HPLC analysis using revised 
conditions including; increased flow rate (4 ml/min) and run time (60 min) and the use 
of a semi-preparative Cig column as detailed in Chapter 2; a typical chromatogram is 
illustrated Ln_Figure A.Z._%his_chromatogram.-was used as-an elution-reference-to 
ensure that there were no structural changes brought about by the further 
evaporation and drying of the aqueous sample.
COo_u
•O
c
80Cfl
0
Q.
c3OÜ
20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
0
4 0 . 0 5 0 . 00 . 0 1 0 . 0 2 0 . 0 3 0 . 0 6 0 . 0
Time (min)
Figure 4.7: Radio-HPLC chromatogram of the aqueous aliquot analysed to verify the 
revised HPLC conditions. Hepatic marmoset microsomes (4 mg/ml) were incubated with 
debrisoquine (500 pM) in the presence of NADPH. HPLC analysis of aqueous sample residue 
prior to lyophilisation.
The Remaining aqueous volume (ca. 30 ml) was ‘shell-frozen’ in a round-bottomed 
flask by rotating the flask in a cooling bath maintained at -80°C, composed of dry ice 
(solid carbon dioxide) and acetone, prior to overnight freeze drying (Edwards, 
Modulyo). The lyophilised sample was resuspended in 5 ml trifluoroacetic acid (0.1%)
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and centrifuged at 17000 x g for 15 minutes to remove any particulates. The sample 
was then subjected to repeat HPLC analysis (Figure 4.8) from which individual 
metabolite fractions were collected and pooled. Total volume and radioactivity were 
determined in_each_fraction_and_used_to-estimate-the-mass-oHndividual-metabolite' 
fractions based upon the original total starting mass of [^'^Cj-debrisoquine.
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Figure 4.8: Final Radio-HPLC analysis for debrisoquine. Hepatic marmoset microsomes 
(4 mg/ml) were incubated with debrisoquine (500 pM) in the presence of NADPH. HPLC 
analysis following volume reduction, lyophilisation and reconstitution of sample in 
trifluoroacetic acid (0.1%).
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Fraction % Original activity Total estimated mass of 
fraction (pg)
1 3.4 133
2 5.9 230
3 5.7 222
4 14.2 554
5 1.0 39
6 1.0 39
7 0.9 35
8 1.0 39
Table 4.2: Estimated mass obtained from the fractions isolated by HPLC separation.
Total estimated mass was calculated from the final incubation volume of 35 ml of 500 pM 
debrisoquine (112.15 pg/ml, based on the molecular weight of 224.3) giving 3.9 mg total 
debrisoquine.
4.3.3: NMR analysis
Proton Nuclear Magnetic Resonance spectra were obtained at 500 MHz as 
described (Chapter 2). The assignment of the NMR signals was made by long-range 
Two-Dimensional Correlation Spectrophotography (2D COSY) experiments (Table 
4.3). The NMR spectra of HPLC fractions 1-4 and 6 (Figure 4.8) are presented in 
Figure 4.9 (aromatic region) and Figure 4.10 (aliphatic region). HPLC fractions 5, 7 
and 8 were identified as possible open ring degradation products of debrisoquine and 
as such were not further identified by NMR analysis due to the lack of associated 
groups within their structure.
The ring location of the hydroxyl group(s) on the debrisoquine metabolites and the 
resulting proposed structures are given in Table 4.3. A postulated metabolic pathway 
for debrisoquine hydroxylation by marmoset liver microsomes is illustrated in Figure 
4.11.
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Fraction Metabolite % Present in Fraction*
NH
6,7-dihydroxydebrisoquine
100
NH
N' nh2 6-hydroxydebrisoquine
88
NH
OH
NH,
NH
OH
'NH ,
NH
4-hydroxydebrisoquine
12
5-hydroxydebrisoquine
100
7-hydroxydebrisoquine
100
Not detected
OH
Not detected
NH
'N H , 8-hydroxydebrisoquine
100
Table 4.4: Metabolite(s) Identified from each of the HPLC Fractions by NMR analysis.
* Based upon the percent of the fraction containing metabolite.
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4.4: Discussion
Initial studies conducted in vivo in rat and human established that the 
antihypertensive drug debrisoquine was metabolised to trace amounts of the 
phenolic metabolites 5-, 6-, 7- and 8-hydroxydebrisoquine and, additionally, 
significant quantities of ring open acidic metabolites were generated (Allen et a!., 
1975). In humans, 4-hydroxydebrisoquine was the principal metabolite, the major 
catalyst being CYP2D6.
Marmoset monkey was recognised by Igarashi et ai. (1997) as expressing a liver 
enzyme sharing high amino acid sequence similarity with human CYP2D6. This 
marmoset enzyme was identified as CYP2D19. Interestingly, this CYP2D19 enzyme, 
unlike human CYP2D6, was found to have no debrisoquine 4-hydroxylase activity but 
high debrisoquine 5-, 6-, 7-, and 8-hydroxylase activities. Subsequently, in 2004 
Hichiya et ai. identified another marmoset liver enzyme of the CYP2D family in the 
liver of a single female marmoset bred at Kyoto University, Aichi, Japan. This 
enzyme was identified as CYP2D30 and, like human CYP2D6, exhibited high 
debrisoquine 4-hydroxylase activity and relatively low debrisoquine 5-, 6-, 7- and 8- 
hydroxylase activities. Both CYP2D19 and CYP2D30 enzymes are therefore 
expressed in the marmoset liver. However, Hichiya et ai. (2004) could not infer 
whether these CYP2D enzymes could coexist in the same marmoset liver.
Based upon the relative retention times of the initial HPLC analysis (Figure 4.1), it is 
apparent that MF-1 = Fraction 1, 4-hydroxydebrisoquine = Fraction 2 and MF-3 = 
Fractions 3 and 4 of the revised HPLC conditions (Figure 4.8). The abundance of 
debrisoquine metabolites formed were 7-hydroxydebrisoquine (Fraction 4) >
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5-hydroxydebrisoquine (Fraction 3) > 6-hydroxydebrisoquine (Fraction 2, 88% of the 
total fraction) > 6,7-dihydroxydebrisoquine (Fraction 1) > 8-hydroxydebrisoquine 
(Fraction 6) > 4-hydroxydebrisoquine (Fraction 2, 12% of the total fraction) after an 
extended incubation period of 3 hours (Table 4.4).
The data presented here demonstrates the formation of 4-hydroxydebrisoquine in 
addition to 5-, 6-, 7 and 8-hydroxydebrisoquine metabolites as well as a previously 
unidentified dihydroxylated debrisoquine product following incubation with a pool of 
liver microsomes from 5 male marmoset monkeys. These results imply that either: 
i) The individual marmosets used within the pool were expressing different forms of 
the CYP2D enzyme, namely either CYP2D19 or CYP2D30; ii) The enzymes coexist 
in the marmoset liver of one or more of the ‘Batch T animals. In order to clarify this, 
HPLC chromatograms of the metabolic profiles from the 5 individual ‘batch T 
marmoset livers were overlaid (Figure 4.6). It is evident from these similar HPLC 
profiles that the peak area of the metabolite fraction that co-eluted with authentic 
4-hydroxydebrisoquine was of a comparable magnitude in all marmosets. Therefore, 
it may be inferred that all marmoset livers within this batch were expressing very 
similar levels of a CYP2D enzyme (possibly CYP2D30) capable of hydroxylating 
debrisoquine at the 4-position. Equally, as the peaks representing 5- and 
7-hydroxydebrisoquine (designated MF-3 in Figures 4.1 and 4.6) are apparent in 
each HPLC profile, it is reasonable to conclude that each of these animals co­
expresses a CYP2D19 enzyme responsible for debrisoquine 5- and 7-hydroxylations, 
along with the CYP2D30 enzyme that is responsible for debrisoquine 
4-hydroxylation. The relative abundance of CYP2D30 expression in the ‘batch T 
marmoset livers is considered to be low compared to CYP2D19 expression, but 
co-expressed none the less. Unfortunately, as the separation of 
4-hydroxydebrisoquine and 6-hydroxydebrisoquine was not possible under the HPLC
Ü 5
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conditions employed in this study, the elution profiles from individual marmoset livers 
cannot be used to adequately quantify any interindividual differences in CYP2D30 
and CYP2D19 expression.
The proposed formation of a dihydroxydebrisoquine is not unique to the marmoset; in 
fact, Eiermann et al. (1998) identified a dihydroxydebrisoquine in a 0-8 hour urine 
sample from a human subject. This subject, however, was characterised as having 
an unusually high amount of active CYP2D6 genes (13 active CYP2D6 genes). 
However, the sites of hydroxylation of debrisoquine were proposed at position 4 and 
at a position on the aromatic ring. This is in contrast to the 6,7-dihydroxylated 
debrisoquine identified by NMR analysis in the current study. Eiermann et al. (1998) 
considered that the rapid metabolising capability of the subject with 13 active 
CYP2D6 genes was responsible for a further oxidation step occurring at the aromatic 
ring position. Similarly, it may be hypothesised that the dihydroxydebrisoquine 
present in the marmoset liver microsomal sample taken for LC-MS analysis and, to 
an even greater extent, the sample taken for NMR analysis (where the metabolite 
formation was maximised by the incubation conditions) may have only contained the 
dihydroxydebrisoquine metabolite as a result of the high marmoset liver microsomal 
protein content and the lengthy incubation times used, viz. 3 mg/ml marmoset liver 
microsomal protein for 10 minutes and 4 mg/ml marmoset liver microsomal protein 
for 3 hours, respectively.
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4.5: Conclusions
The monohydroxylation of debrisoquine by liver microsomes prepared from male 
marmosets from the Huntingdon Life Sciences breeding colony qualitatively resemble 
that of human. However, quantitatively the monohydroxylation of debrisoquine is very 
different from that of human, with the major human metabolite 
(4-hydroxydebrisoquine) representing only about 2% of the total metabolites 
generated by marmoset liver microsomes.
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5.1: Introduction
Immuno-blotting, often referred to as ‘Western blotting, after Burnette’s (1981) play 
on words from the Southern blot technique, enables detection of immunoreactive 
protein bands due to epitope targeting of antibodies that can be used to identify 
protein polypeptides with specific amino acid sequences. The use of antibodies that 
specifically target human P450 proteins have been used in this study to identify 
similarities between human and marmoset P450 proteins. As an additional 
interspecies comparison, highlighting the selective nature of the technique, rat liver 
microsomal proteins were also included in this part of the study.
The equipment used for the semi-quantification of the liver microsomal proteins 
resulted in a novel method, developed initially to utilise the analytical equipment 
available, namely, the detection of DDAO by laser (635 nm) incorporated in a Fujifilm 
FLA-5000 imaging system.
DDAO — -------  < >■ A ^  ^  ^ ------  DDAO phosphate
Alkaline phosphatase 
Secondary antibody
Primary antibody 
P450 protein
PVDF membrane
Figure 5.1: Schematic diagram of Western blot Immuno detection with DDAO 
phosphate. Quantification of the red fluorescent hydrolysis product was conducted using a 
Fujifilm FLA-5000 imaging system and Aida Bioimaging software. Figure adapted from 
Invitrogen literature.
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The limitations of the DDAO chemi-fluorescent method soon became apparent and 
related to the relatively narrow window of acceptable hydrolysis product, as 
overexposure limits could be readily exceeded by antibody and protein 
conc^ntration-^and_exp,as.ur.e_time_.for__the_de_velopment-of-the-resulting-fluorescent 
DDAO. In order to optimise these conditions, preliminary ‘range-finding’ experiments 
were required to provide appropriate antibody and protein concentrations that would 
produce detectable immunoreactive bands, without the problems associated with 
over conversion of the red fluorescent hydrolysis product.
5.2: Methods
The preparation of microsomal samples, electrophoresis, immunoblotting and 
detection of the resulting chemi-fluorescent images are described in Chapter 2.
5.2.1: Preliminary ‘range-finding’ experiments
Suitable conditions were determined for the interspecies comparative blots from 
initial Western blots using pooled marmoset liver, pooled human liver and pooled rat 
liver microsomes as detailed below (Table 5.1). Antibody dilutions remained 
unchanged from the range-finding experiments to the quantitative interspecies 
studies. However, protein concentrations and standard curve ranges (Supersomes®) 
were altered as required to provide conditions conducive to producing fluorescent 
images within a linear standard curve range.
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5.2.2: Quantitative interspecies Western biot anaiysis
Results from the preliminary ‘range-finder’ Western blot experiments were used to 
estimate suitable conditions for the investigation of the ‘definitive’ analysis as 
described in Table 5.2. Images of the linear standard curve ranges prepared from 
Supersomes® for quantification of each of the CYPs investigated are shown in Figure
5.2 and an example of a representative standard curve is presented in Figure 5.3.
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GYP
Marmoset
Protein loaded (pg) 
Human Rat
Standard curve range 
(pmoles)
1A1/2 20 1 20 0.01 -0.1
2A6 50 10 10 0.1 -1 .0
2B6 50 50 50 0.01 -0.1
2G9 50 10 50 0.06 - 0.6
2G19 10 50 50 0.06 - 0.6
2D6 50 20 50 0.01-0.1
2E1 1 0.5 0.5 0.01 -0.1
3A4 1 1 50 0.02-0 .16
3A5 5 20 50 0.02 - 0.2
Table 5.2: Definitive Western blotting conditions. Quantities of microsomal proteins that 
gave the most suitable detection limits for the quantification of enzymes within a linear 
standard curve range of the appropriate expressed GYP. Standard curves constructed from 1 
part NuPAGE LDS buffer (4 x ) to 3 parts human Supersomes® diluted in water as appropriate.
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Concentration of Supersomes® per well (pmoles of P450)
0.01 0.02 0.04 0.06 0.08 0.1
0.1 0.2 0.4 0.6 0.8 1.0
0.0 1 0.02 0.04 0.06 0.08 0.1
0.06 0.08 0.1 02 0.4 0.6
0.06 0.08 0.1 02 0.4 0.6
$
1
1
CYP1A2
CYP2A6
CYP2B6
%  w  CYP2C9
  <------- CYP2C19
0.01 0.02 0.04 0.06 0.08 0.1
A------- - CYP2D6
0.02 0.04 0.06 0.08 0.1
— A------- CYP2E1
0.04 0.06 0.1 1.2 1.6
—... A------- - CYP3A4
w 1
0.04 0.08 0.12 0.16 0.2
CYP3A5
Figure 5.2: Western blots of definitive standard curves. Linear standard curve ranges 
prepared from insect cells expressing single human cytochrome P450 enzymes 
(Supersomes®) for quantification of each of the CYPs investigated.
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Linear regression: y/LAU = 2.84310564 x/pmoles 
Correlation coefficient r^  =0.996337
SD ± 0.0038 pmoles
20000000-
O)
(D 10000000-
r r  p  1 1 1 I I I 1 V[  T i l I I
0 .0 70.01 0.02 0 .0 3 0 .0 4 0 .0 5 0 .0 6 0 .0 8 0 .0 9 0.1
Supersome" concentration (pmoles of P450)
Figure 5.3: Example of a standard curve. Standard curve was prepared from signal 
intensity (luminescence absorbance units, LAU) of appropriate calibration samples 
(Supersomes®) with background blot intensity subtracted (1x10 LAU). Signal intensity was 
used for quantification of microsomal protein, and calculations were performed using Aida 
Bio-imaging software.
5.2.3; CYP1A2 (animal 0625, batch 2 -  EROD outlier)
To investigate the spurious nature of 7-ethoxyresorufin 0-deethylase (EROD) activity 
from a single marmoset in earlier kinetic experiments (Chapter 3), the Western blot 
analysis was repeated using pooled marmoset microsomal protein as detailed in 
Table 5.2, and marmoset 0625 only; microsomal protein concentration for both 
samples was 20 pg, each sample being loaded in triplicate.
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5.2.4: CYP2E1 (anti-marmoset primary antibody)
Comparison of CYP2E1 under the same protein concentrations as outlined in Table
5.3 was also examined probing with an anti-marmoset CYP2E1 primary antibody 
(section 5.3.7).
5.2.5: Data processing
Data were derived from evaluations of chemi-fluorescent Western blot membranes 
using Aida Bio Package software v.4.15 (Raytest, Straubenhardt, Germany). This 
enabled the intensity of individual fluorescent bands to be quantified by comparison 
to a standard curve prepared from an appropriate expressed P450 protein standard 
(Supersomes®).
Quantity (pmole P450/mg protein) = pmole equivalents/protein loaded (pg) x 1000
Molecular weight determinations were calculated from Rf values of individual protein 
bands compared to Rf values of known molecular weight markers run concurrently 
on the same gel. These values were used to construct a weighted algorithmic 
standard curve within Multicalc v. 3.1 software.
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5.3: Results
5.3 1:CYP1A
Mwt
15 KDa
M marmoset human +ve 
1 2 3 4 5 6
rat -ve
25
35
50
75
105
160
250
t A
M marmoset pool +ve marmoset 0625 -ve 
1 2 3  4 5  6 7 8 9
^  IN»
B
Direction of migration
Figure 5.4: Immunoblots probed with anti-rat CYP1A1/1A2 primary antibody used for 
the detection of human CYP1A2. A: Interspecies blot; lane 1 (M) contained molecular 
weight markers, lanes 2 and 3 were loaded with 20 pg marmoset microsomal protein, lanes 4 
and 5 contained 1 pg human microsomal protein, lane 6 contained 0.06 pmoles human 
CYP1A2 Supersomes (+ve control), lanes 7 and 8 contained 20 pg rat microsomal protein, 
and lane 9 contained -ve  control (microsomal protein replaced by water).
B: CYP1A protein bands of marmoset 0625 in comparison with a pool of 5 animals; Lane 1 
(M) contained molecular weight markers, lanes 2, 3 and 4 were loaded with 20 pg marmoset 
pooled microsomal protein, lane 5 contained 0.06 pmoles human CYP1A2 Supersomes® (+ve 
control), lanes 6, 7 and 8 were loaded with 20 pg 0625 marmoset microsomal protein, and 
lane 9 contained -ve  control (in the absence of microsomal proteinVStandard curve used for 
quantification comprised of 0.01 -  0.1 pmoles CYP1A2 Supersomes" (Figure 5.2).
Visible bands were present in marmoset, human and rat liver microsomes probed 
with anti-rat CYP1A1/1A2 primary antibody (supplied by BD biosciences to probe for 
human CYP1A2). The human immunoreactive band intensity was clearly lower than 
that of the marmoset or rat (blot A). However, with 20-fold lower protein concentration 
loaded onto the gel for human, the calculated concentration for human was 20.0 
pmoles/mg microsomal protein, compared to 4.0 and 3.0 pmoles/mg for rat and 
marmoset microsomal protein, respectively. The linearity of the standard curve from
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the human CYP1A2 Supersomes® used for quantification had an r^  value of 0.995 
and all concentrations of microsomal protein were within the standard curve range. 
Average calculated molecular weights from duplicate fluorescent bands were 55.3 
KDa, _5i3.0LKDa_and_54.7_KDa_for-the marmoset,-human and-rat^ respectivelyy based 
upon calculated Rf values of the protein migration compared to that of the molecular 
weight makers.
The calculated concentration of the pooled marmoset microsomal protein on blot B 
was 3.0 pmoles/mg microsomal protein, which is in agreement with the original 
calculation of marmoset microsomal protein from the interspecies CYP1A2 blot (blot 
A). The calculated protein concentration for the immunoreactive bands from 
marmoset 0625, migrating in a similar way to those on blot A was only 1.5 
pmoles/mg microsomal protein, demonstrating that animal 0625 did contain a lower 
concentration of a protein that is reactive to the antibody used to probe for 
CYP1A1/2. Additionally, a strong immunoreactive band migrating further along the 
gel was present within the 0625 marmoset microsomal fraction. This band had a 
lower molecular weight of 43 KDa and although the band was also present in the 
marmoset microsomal pool, it had a very low intensity that may correspond to a 1 in 
5 dilution of this protein, present in animal (0625), during the preparation of the 
original pooled sample prepared from 5 individual marmoset livers.
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5.3.2: CYP2A6
M marmoset human +ve rat -ve 
1 2 3  4 5 6  7 8 9
Mwt
15 KDa
25 h 
35
50 f
75 «
105 
160 Ip
250
CYP2A6
Figure 5.5: Interspecies biot probed with anti-human CYP2A6 primary antibody. Lane 1 
(M) contained molecular weight markers, lanes 2 and 3 contained 50 pg marmoset 
microsomal protein, lanes 4 and 5 contained 10 ug human microsomal protein, lane 6 
contained 0.6 pmoles human CYP2A6 Supersomes (+ve control), lanes 7 and 8 contained 
10 pg rat microsomal protein and lane 9 was loaded with -ve control (microsomal protein 
replaced by water). Standard curve comprised 0.1 -  1.0 pmoles CYP2A6 Supersomes® 
(Figure 5.2).
No detectable immunoreactive bands were observed in the lanes loaded with 
marmoset hepatic microsomes (50 pg protein loaded in lanes 2 & 3 in the gel), 
whereas strong immunoreacting bands were observed in both human and rat, with 
these species having 10 pg of microsomal protein loaded onto the gel. The 
calculated protein concentrations of these immunoreactive bands were 20 and 22 
pmoles/mg for human and rat microsomal protein, respectively. The linearity of the 
standard curve from human CYP2A6 Supersomes® had an r^  value of 0.993 and all 
concentrations of microsomal protein were within the standard curve range. Average 
calculated molecular weights for the duplicate fluorescent bands were approximately
52.2 KDa for human and 51.5 KDa for rat.
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5.3.3: CYP2B6
Mwt
15 KDa
250
M marmoset human +ve rat -ve 
1 2 3  4 5 6 7 8 9
Mi 4-4
Jfcias CYP2B6
Figure 5.6: Interspecies blot probed with anti-human CYP2B6 primary antibody. Lane 1 
(M) contained molecular weight markers, lanes 2 and 3 were loaded with 50 pg marmoset 
microsomal protein, lanes 4 and 5 with 50 pg human microsomal protein, lane 6 contained 0.6 
pmoles CYP2B6 Supersomes® (+ve control), lanes 7 and 8 were loaded with 50 pg rat 
microsomal protein, and lane 9 was -ve control (microsomal protein replaced by water). 
Standard curve comprised of 0.01 -  0.1 pmoles CYP2B6 Supersomes® (Figure 5.2).
Fluorescent bands were present in all species along the CYP2B6 Supersome® (+ve 
control) migration region. However, very low responses were seen in the human and 
rat samples despite equal amounts of material being loaded onto the gel for all 
species. The calculated protein concentrations for the immunoreactive bands were 
1.0 pmole/mg for the marmoset and 0.2 pmoles/mg for human and rat. The CYP2B6 
standard curve (r  ^0.952) was used to calculate all concentrations which were within 
that standard curve range. Average molecular weights were estimated at 47.6 KDa, 
45.1 KDa and 43.9 KDa for the marmoset, human and rat, respectively.
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5.3.4:CYP2C9
Mwt
15 KDa
M marmoset human +ve rat -ve 
1 2 3 4 5 6 7 8 9
1 m.*
GYP2C9
Figure 5.7: Interspecies blot probed with antl-human CYP2C9 primary antibody. Lane 1 
(M) contained molecular weight markers, lanes 2 and 3 contained 50 pg marmoset 
microsomal protein, lanes 4 and 5 contained 10 pg human microsomal protein, lane 6 
contained 0.2 pmoles CYP2C9 Supersomes® (+ve control), lanes 7 and 8 contained 50 pg rat 
microsomal protein and lane 9 served as -ve control (microsomal protein replaced by water). 
Standard curve comprised 0.06 -  0.6 pmoles CYP2C9 Supersomes® (Figure 5.2).
The polyclonal primary antibody used to probe for CYP2C9 revealed several 
fluorescent bands across the 3 species, in addition to those immunoreactive bands 
migrating along the expected +ve control region of approximately 50 KDa; there were 
two bands between the 75 and 50 KDa markers and numerous bands for marmoset 
and rat below approximately 40 KDa. Average calculated molecular weights for the 
fluorescent bands migrating to a similar position to the positive control were 
approximated at 52 KDa for the marmoset and human, and 52.6 KDa for the rat. 
Weak immunoreacting bands were detected in the marmoset and rat samples which 
were loaded with the same amount of protein (50 pg), whilst human, with only a fifth 
of the protein loaded, exhibited a far greater intensity relating to 51 pmoles/mg 
microsomal protein, compared to 5.2 and 7.0 pmoles/mg microsomal protein for
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marmoset and rat, respectively. The CYP2C9 standard curve was linear 0.985) 
and all concentrations of microsomal protein were within the standard curve range.
5.3.5: CYP2C19
Mwt
M marmoset human +ve rat -ve 
1 2 3 4 5 6 7 8 9
15 KDa
CYP2C19
Figure 5.8: Interspecies biot probed with anti-human CYP2C19 primary antibody. Lane 
1 (M) contains molecular weight markers, lanes 2 and 3 contained 10 pg marmoset 
microsomal protein, lanes 4 and 5 contained 50 pg human microsomal protein, lane 6 
contained 0.2 pmoles CYP2C19 Supersomes® (+ve control), lanes 7 and 8 contained 50 pg 
rat microsomal protein and lane 9 was -ve control (microsomal protein replaced by water). 
Standard curve comprised 0.06 -  0.6 pmoles CYP2C19 Supersomes® (Figure 5.2).
As with the polyclonal primary antibody used to probe CYP2C9, the CYP2C19 
primary antibody binding revealed a similar pattern of high and low molecular weight 
fluorescent bands across the 3 species. The marmoset, which had a much lower 
concentration of protein loaded onto the gel compared to the other species (10 pg) 
resulted in a calculated CYP protein concentration of 22.0 pmoles/mg, whilst the 
human and rat microsomal immunoreactive protein bands equated to 4.2 and 2.4 
pmoles/mg respectively. The linearity of the standard curve from the human
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CYP2C19 Supersomes® was characterised by an r^  value of 0.985 and all 
concentrations of detected microsomal protein were calculated from within this 
standard curve range. Rf values of the molecular weight markers were used to 
construct a standard curve to determine estimated molecular weights of 51.8 KDa for 
the marmoset and human proteins, and 52.3 KDa for the rat.
5.3.6: CYP2D6
M marmoset human +ve rat -ve 
1 2 3 4 5 6 7 8 9
Mwt
15 KDa
25
35 É
M
50 1
75 g,
105 •
160 m
CYP2D6
250
Figure 5.9: Interspecies blot probed with antl-human CYP2D6 primary antibody. Lane 1 
(M) contained molecular weight markers, lanes 2 and 3 were loaded with 50 pg marmoset 
microsomal protein, lanes 4 and 5 with 20 pg human microsomal protein, lane 6 contained 0.2 
pmoles CYP2D6 Supersomes® (+ve control), lanes 7 and 8 were loaded with 50 pg rat 
microsomal protein and lane 9 acted as -ve control (microsomal protein replaced by water). 
Standard curve comprised of 0.01 -  0.1 pmoles CYP2D6 Supersomes® (Figure 5.2).
No immunoreacting bands were observed in the rat liver microsomes under the 
conditions used (50 pg of rat liver microsomal protein loaded onto the gel). The 
human response was strong, with 20 pg of microsomal protein loaded onto the gel, 
whilst 50 pg of marmoset microsomal protein was required to provide a similar 
fluorescent intensity. The calculated CYP protein concentrations for the
143
Chapter 5: Immunological characterisation of P45Q proteins in marmoset liver_______
immunoreactive bands were 0.6 and 1.5 pmoles/mg microsomal protein for 
marmoset and human, respectively. The standard curve consisting of CYP2D6 
Supersomes® (r  ^ 0.978) was used to calculate all concentrations, which in all cases 
were within the standard curve range. A single immunoreactive band was present at 
49.8 KDa for marmoset and 53.4 KDa for human.
5.3.7: CYP2E1
M marmoset human +ve rat -ve 
1 2 3  4 5 6 7 8 9
M marmoset human +ve rat -ve 
1 2 3 4 5 6 7 8 9
Mwt
15 KDa
Figure 5.10: Immunoblots probed with CYP2E1 primary antibody. A: anti-rat CYP2E1 
primary antibody; lane 1 (M) contained molecular weight markers, lanes 2 and 3 contained 1 
pg marmoset microsomal protein, lanes 4 and 5 contained 0.5 pg human microsomal protein, 
lane 6 contained 0.06 pmoles of human CYP2E1 Supersomes® (+ve control), lanes 7 and 8 
contained 0.5 pg rat microsomal protein and lane 9 provided -ve control (microsomal protein 
replaced by water). Standard curve comprised 0.01 -  0.1 pmoles CYP2E1 Supersomes® 
(Figure 5.2). B: anti-marmoset CYP2E1 primary antibody; gel loaded in an identical way to the 
immunoblot probed with the anti-rat CYP2E1 primary antibody (immunoblot A).
The immunoblot probed with anti-rat CYP2E1 presented strong responses from all 
three species, despite the fact that only 1 pg of marmoset microsomal protein was 
loaded onto the gel, with human and rat requiring even less (0.5 pg) to provide a 
similar intensity band. The calculated concentrations were 30 pmoles/mg microsomal
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protein for the marmoset and 60 pmoles/mg for both human and rat microsomal 
protein. A linear standard curve (r  ^0.980) was generated with human CYP2E1 
Supersomes® and all concentrations of microsomal protein fell within this standard 
curve range. Average calculated molecular weights were determined from Rf values, 
resulting in 61.2 KDa for the marmoset, 59.4 KDa for human and 56.7 KDa for rat. 
Whilst the immunoblot probed with anti-marmoset CYP2E1 (utilising the same 
conditions as those employed in the immunoblot probed with anti-rat CYP2E1) 
generated immunoreacting bands of 55.9 KDa in the marmoset, with no 
corresponding bands evident in the human or rat. However, higher molecular weight 
bands of low intensity in the human (64.7 KDa) and rat microsomes (61.9 KDa) were 
present. In the same way CYP2E1 Supersomes® gave similar low intensity 
fluorescent bands of >60 KDa. Quantification of the data from this blot was not 
possible as no suitable standard curve could be generated.
5.3.8: CYP3A4
M marmoset human +ve rat -ve 
1 2 3  4 5 6 7 8 9
15 KDa
GYP3A4
-  *
Figure 5.11: Interspecies blot probed with antl-human CYP3A4 primary antibody. Lane 
1 (M) contained molecular weight markers, whilst lanes 2 and 3 contained 1 pg marmoset 
microsomal protein, lanes 4 and 5 contained 1 pg human microsomal protein, lane 6 was 
loaded with 0.06 pmoles CYP3A4 Supersomes® (+ve control), lanes 7 and 8 contained 50 pg 
rat microsomal protein and lane 9 contained -ve  control (microsomal protein replaced by 
water). Standard curve comprised 0.02 -  0.16 pmoles CYP3A4 Supersomes® (Figure 5.2).
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The polyclonal primary antibody used to probe for CYP3A4 provided a high degree of 
non-specific binding that led to the appearance of many fluorescent bands across the 
three species. The expected P450 region, migrating in a similar manner to the 50 
KDa molecular weight marker.__w,as__present-at -lower- intensity—for- all—species.- 
moreover, the expected increase in the band intensity at approximately 50 KDa was 
proportional to the concentration increase of CYP3A4 Supersomes® used in the 
curve that was run in parallel (Figure 5.2). The major bands seen across the species 
and throughout the CYP3A4 Supersome® standard curve were not the bands of 
interest relating to CYP3A4 identification. These high intensity bands were also 
present in the -ve  control samples, demonstrating that the primary CYP3A4 antibody 
had a high affinity for a component of the LDS sample buffer. The CYP3A4 
immunoreactive protein concentrations were therefore calculated for the bands that 
migrated in a similar region to that of the 50 KDa molecular weight marker, providing 
a band in the +ve control and no corresponding fluorescence in the -ve control lane. 
These values were 40, 20 and 1.2 pmoles/mg microsomal protein for marmoset, 
human and rat, respectively. All concentrations were within the CYP3A4 
Supersomes® curve (r  ^ 0.990). Average calculated molecular weights were 
determined to be 56.5 KDa for the marmoset, 54.3 KDa for human, and 55.8 KDa for 
the rat, based upon calculated Rf values of the selected protein migration compared 
to that of the molecular weight markers.
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5.3.9: CYP3A5
M marmoset human +ve rat -ve 
1 2 3 4 5 6 7 8 9
Mwt 
15 KDa #
25
35 * Im  m
CYP3A5
Figure 5.12: Interspecies biot probed with anti-human CYP3A5 primary antibody. Lane 
1 (M) contained molecular weight markers, lanes 2 and 3 were loaded with 5 pg marmoset 
microsomal protein, lanes 4 and 5 contained 20 pg human microsomal protein, lane 6 
contained 0.06 pmoles CYP3A5 Supersomes® (+ve control), lanes 7 and 8 contained 50 pg 
rat microsomal protein and lane 9 was -ve control (microsomal protein replaced with water). 
Standard curve comprised 0.02 -  0.16 pmoles CYP3A5 Supersomes® (Figure 5.2).
The polyclonal primary antibody used to probe for CYP3A5 demonstrated some non­
specific binding, but not to the same degree as the CYP3A4. The calculated 
concentrations were 24.0 pmoles/mg microsomal protein for the marmoset, 6.0 
pmoles/mg for human microsomal protein and no immunoreacting protein was 
detected in the rat. The linearity of the standard curve from the CYP3A5 
Supersomes® was calculated as having an r^  value of 0.982 and all concentrations of 
microsomal protein were within the standard curve range. Average calculated 
molecular weights were 55.8 KDa for the marmoset and 53.2 KDa for human.
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5.3.10: Total protein stain
PVDF membrane Bis-Tris gel
D
*
,:'-r 111
Figure 5.13: Coomassie Blue total protein stain. The Coomassie Brilliant Blue R250 
staining procedure revealed total transfer of proteins from the NuPAGE 4-12% gradient Bis- 
Tris gel to the PVDF membrane by electroblot using the BioRad semi dry transblot apparatus.
The total protein staining of a representative gel and its associated PVDF membrane 
demonstrate the suitability of the transfer conditions applied to the semi-dry 
transblotting procedure. The PVDF membrane (above) clearly demonstrates the 
successful transfer of the Rainbo\A/ Molecular Weight Markers (lane 1), along with 
protein tracks produced from the microsomal suspensions (lanes 2-4 and 6-8), whist 
the gel undoubtedly demonstrates the absence of any remaining proteins. Therefore, 
the data obtained from the evaluated blots could be considered to be directly 
proportional to the quantity of sample originally loaded onto the gel.
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5.3.11: Summary o f results
CYP1A2
CYP2A6
CYP2B6
CYP2C9
CYP2C19
CYP2D6
CYP2E1
CYP3A4
CYP3A5
Figure 5.14: Western blot images of marmoset, human and rat microsomal P450s. A
composite figure, depicting selected sections of appropriate immunoblots. Varying quantities 
of protein were used during the accumulation of these results, depending upon the antibody 
response and the resulting fluorescence within a range determined during preliminary 
experiments. Therefore, the above intensities are not proportional to overall P450 expression, 
but rather relate to concentrations within specific associated standard curves.
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5.4: Discussion
The cassette style NuPAGE 14% gradient Bis-Tris gels (Invitrogen) produced 
consistent electrophoresis of the microsomal proteins, whilst the semi-dry electro 
blotting system (BioRad) ensured the complete transfer of the proteins from the gel to 
the PVDF membrane, as demonstrated by Coomassie Blue total protein staining of 
both the gel and the membrane (Figure 5.13). The Western blot analysis of total 
hepatic marmoset, human and rat microsomal protein using primary antibodies 
directed against a range of P450 proteins and alkaline phosphatase conjugated 
secondary antibodies together with the chemi-fluorescent substrate (DDAO 
phosphate) proved to be a suitable method for the detection and identification of 
hepatic microsomal P450 proteins. Aida software provided data in a format that 
allowed evaluation and quantification of the microsomal proteins relative to an 
appropriate Supersome® standard curve, which was run in parallel within the same 
electrophoresis apparatus. As a result data collection and analysis were both 
sensitive and reproducible.
The success of this method relies upon the human anti-peptide antibodies targeting 
marmoset P450 enzymes that belong to the same subfamily of P450 as that of the 
original human antigen targeted by the antibody. This type of analysis is often limited 
by the inability of antibodies to recognise antigenic epitopes in proteins from different 
species. The epitope, or antibody-binding site upon the microsomal proteins in this 
study generally consists of about 15 amino acids on the protein surface. However, 
only about 5 of these amino acids contribute to the binding energy, equally the 
paratope, or the part of the antibody molecule that binds to the epitope, also has 
about 15 significant amino acids, of which only about 5 of these contribute most of 
the binding energy for the epitope (Frank et al., 2002). These complementary regions
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of shape and charge, rather than just the amino acid compositions, form the well 
defined lock-and-key fit to the epitope (Wedemaye et al., 1997). Although the 
polyclonal antibodies consist of antibodies raised against numerous epitopes on the 
antigen in question and the antibody presumably has many overlapping paratopes 
that could potentially bind a variety of related epitopes (Frank et al., 2002), the 
opportunity for low specificity, non-specific binding and imprecision are compounded 
when antibodies from one species are used in an attempt to identify proteins from 
another. Therefore, these factors should be considered when interpreting the results 
of this section of the study.
CYP1A protein was detected in all three species investigated when probed with the 
polyclonal anti-rat CYP1A1/1A2 primary antibody. This result is to be expected as 
CYP1 is one of the most physiologically conferred GYP species, with mammals 
generally possessing two paralogous CYP1A genes, CYP1A1 and CYP1A2 (Kimura 
et al., 1984; Quattrochi et al., 1985). The presence of CYP1A2 in livers of untreated 
marmosets has previously been reported (Edwards et al., 1993, 1994; Kastner and 
Neubert, 1994) and the present study revealed that 2% of the total P450 expression 
could be accounted for by CYP1A2 in the marmoset liver (Table 5.3). Human 
CYP1A2 expression in the current investigation was 10% of the total hepatic P450 
expression examined, being similar to the expected level of expression in human 
liver (Gibson and Skett, 2001) and, thereby, 5-fold of that seen in the marmoset. 
Sakuma et al. (1997), published data suggesting that marmoset CYP1A2 expression 
levels are approximately one quarter of the expression levels present in human, 
consistent with the present study. An estimated molecular weight of 58 KDa was 
established for the immunoreactive band associated with human CYP1A2 and has a 
similar migration through the gel as the positive control and predicted data from BD 
Biosciences for this GYP deduced from mobility on SDS PAGE (Appendix of this
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chapter). The marmoset protein detected by the polyclonal CYP1A1 antibody had a 
molecular weight of 55.3 KDa, which is closer to the estimated molecular weight of 
the rat (54.7 KDa) rather than of the human protein. Previous kinetic investigations 
for this batch (Batch 2) of marmoset livers revealed that animal 0625 had a 
considerably lower EROD activity compared with the other animals within this batch 
(Chapter 3). When marmoset 0625 microsomal protein was probed by the CYP1A1 
antibody and compared to that of the 5-animal pool used throughout the Western blot 
analysis, it became apparent that not only did animal 0625 have a lower expression 
of the CYP1A2 protein that migrated with a similar Rf value as the positive control, 
but also a protein with a lower molecular weight of 43 KDa (Figure 5.4). This lower 
molecular weight protein may be a fragment of native marmoset CYP1A2 resulting 
from partial degradation, a short defective protein, or non-specific binding to a faster 
migrating component of animal 0625 microsomal suspension.
The monoclonal anti-human CYP2A6 antibody did not bind to any proteins in the 
marmoset microsomal suspension. This may have been because of the monoclonal 
nature of this antibody, resulting in the selectivity for a single epitope on the antigen 
that may not be present in the marmoset. Additionally, earlier kinetic investigations 
revealed negligible levels of the CYP2A6 mediated coumarin 7-hydroxylase 
(Chapter 3). This is in line with findings by Lake et al. (1989) who demonstrated that 
the marmoset, like the rat, and unlike man, is a poor 7-hydroxylator of coumarin. 
However, due to substrate selectivity, difficulty is always encountered when ascribing 
these activities to specific individual P450 enzymes from different species. 
Nonetheless, with the combined kinetic and Western blot data it is most plausible that 
marmosets have little or no hepatic CYP2A6 like protein.
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Although protein bands were identified by the polyclonal anti-human CYP2B6 in the 
marmoset, in human and rat hepatic microsomes, as expected, this enzyme only 
represents a very small proportion of the total hepatic P450 complement. Estimated 
molecular- weights are the lowest of all the P450s investigated in this study at 47.6 
KDa, 45.1 KDa and 43.9 KDa for marmoset, human and rat, respectively. These 
values are lower than the predicted human P450 molecular weights on the basis of 
amino acid sequence (Appendix of this chapter). Although low, these molecular 
weights were calculated from Rf values of the immunoreactive bands compared to 
the Rf values of known molecular weight markers run concurrently on the same gel 
Therefore, the molecular weight of 45.1 KDa for the human band detected by the 
polyclonal anti-human GYP2B6 primary antibody is considered to be a true estimate 
under the conditions and criteria employed within this study.
Binding of the polyclonal anti-human CYPC9 and CYP2C19 antibodies was observed 
in all three species. Interestingly, CYP2C9 represented one of the larger fractions in 
the human microsomes at 29% (Table 5.4) of the calculated total P450 expression, 
with only CYP2E1 accounting for a larger fraction. This is in contradiction to most of 
the published data for human hepatic P450 expression where human hepatic CYP2C 
expression is generally considered to comprise 10 to 20% of the total aggregate 
P450 content of the liver (deMorais et al., 1994; Shimada et al., 1994) However, 
Coller et al. (2002), using quantitative Western blot analysis calculated that resected 
human liver tissue exhibited CYP2C9 levels of 116 pmol/mg hepatic protein, this 
concentration being 2-fold higher than that of the CYP3A4 expression in the same 
liver samples. This current investigation shows human CYP2C9 levels of 51 
pmoles/mg protein, which, although lower than those published by Coller et al., are 
still much higher than those for CYP3A4. Marmoset protein detected by the 
polyclonal anti-human CYP2C9 primary antibody only represented 4% of the total
Chapter 5: Immunological characterisation of P450 proteins in marmoset liver_______
hepatic P450 complement investigated (Table 5.3). Estimated molecular weights for 
both the human and the marmoset proteins detected by the polyclonal anti-human 
CYP2C9 primary antibody were 52.0 KDa, whilst the rat protein was slightly higher at 
52.6 KDa (Figure 5.7).
The protein band detected by the anti-human CYP2C19 polyclonal antibody in 
marmoset microsomes represented 18% of the total P450 complement. Similar levels 
of expression were also seen for marmoset proteins detected by the polyclonal anti­
rat CYP2E1 (22%) and anti-human CYP3A5 (18%) antibodies. Estimated molecular 
weights for CYP2C19, CYP2E1 and CYP3A5 proteins were 51.8 KDa, 61.2 KDa and
55.8 KDa, respectively. Interestingly, the marmoset protein band detected by the 
polyclonal anti-rat CYP2E1 primary antibody revealed an unusually high molecular 
weight for this P450 protein. However, when the microsomal suspensions form all 
three species were probed with polyclonal anti-marmoset CYP2E1 primary antibody 
(Figure 5.10), the marmoset CYP2E1 protein band exhibited a molecular weight of
55.9 KDa, whilst the human and rat revealed high molecular weight bands of 64.7 
KDa and 61.9 KDa, respectively, although these faint immunoreacting bands present 
in the human and rat lanes could be non-specific binding to other components; this 
phenomenon has been seen with numerous other reactive bands being present on 
many of the immunoblots presented in this study. It is generally accepted that the 
function and regulation of CYP2E1 are well conserved among the mammalian 
species (Casarett and Doull, 2001). However, Schulz et al. (1998) have 
demonstrated by anti-peptide antibody targeting of the C-terminus of human and 
cynomolgus monkey CYP2E1 (Val-lle-Pro-Arg-Ser-Ser-Val) that the antibody failed 
to bind to the marmoset monkey hepatic microsomal fraction. The C-terminus of the 
marmoset CYP2E1 was consequently found to be extended by 2 amino acids. This 
anti marmoset antibody was subsequently used within this study, and these data
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confirm a structural difference in the CYP2E1 protein of the marmoset compared to 
that of human and rat.
A strong response was seen in both human and marmoset microsomes, with only a 
limited response in rat microsomes, when probed with a monoclonal anti-human 
CYP2D6 antibody. However, as relatively high protein loads were used for the 
electrophoresis, together with high amounts of expressed microsomal protein 
(Supersomes®) being required to achieve a suitably detectable linear standard curve, 
the strong response equates to approximately 1% of the total hepatic microsomal 
P450 for marmoset and human (Tables 5.3 and 5.4).
By far the largest fraction of marmoset CYP was accounted for by the protein 
detected by the polyclonal anti-human CY3A4 antibody (35% of the total fraction of 
the CYP enzymes investigated). When this is combined with the protein detected by 
the polyclonal anti-human CY3A5 antibody, the two CYP3A fractions account for over 
50% of the total marmoset hepatic P450s investigated within this study. The 
expression levels of the marmoset CYP3A were 40 and 24 pmoles/mg protein as 
detected by CYP3A4 and CYP3A5 antibodies, respectively. These data accord with 
the findings of Koehler et al. (2006) who identified the marmoset CYP3A enzyme as 
CYP3A21 with expression levels of 51-123 pmoles/mg protein. The primary CYP3A 
antibodies used in the current investigation appear to demonstrate high levels of non­
specific binding, resulting in increased levels of fluorescence along the molecular 
weight markers and binding of some components of the NuPAGE sample buffer, 
identified as such by the similar presence of bands in those lanes without microsomal 
protein (negative controls).
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The high level of CYP3A expression in marmoset liver is in marked contrast to the 
results from the human hepatic microsomes. The highest expressed human hepatic 
P450 in this study is CYP2E1, whereas it is generally considered that CYP3A is the 
most abundant CYP in adult human liver (Gibson and Skett, 2001), although up to 
40-fold interindividual variations in expression levels of CYP3A4 have been observed 
in the human liver, and genetic variability of the CYP3A4 coding region has been 
suggested (Sata et al., 2000; Eiselt et al., 2001). The low expression of CYP3A4 in 
the human liver samples may also be an influence of donor age. It has been 
demonstrated that several in vitro activities of CYP3A substrates declined in liver 
microsomal fractions from the elderly; this may be due to the function of the catalytic 
activity or reduced CYP3A gene expression (Ghoneim and Mewaldt, 1990; 
Schmucker, 2001; Cotreau et a i, 2005). Patki et al. (2004) used quantitative Western 
blotting techniques to determine the expression of CYP3A4/5 in various age groups 
including an elderly group at 61-72 years (n=5), that displayed the lowest expression 
level of CYP3A4 at 43.4 ± 16.6 pmoles/mg protein compared with 424.8 ± 149.7 
pmoles/mg protein for a 2 1 - 4 0  year age group (n=5). Therefore, although quite 
low, the human CYP3A4 expression data from the present study at 13 pmoles/mg 
protein may relate to a fall in CYP3A4 expression in the elderly subjects used within 
this study. Moreover, George et al. (1995) suggested that total P450 expression 
(including CYP3A) was reduced in human liver with chronic liver disease. Therefore, 
the combination of age and the less than healthy condition of the livers prior to 
resection may be responsible for the low CYP3A expression levels observed in this 
study. Increased expression levels of other human P450s such as CYP2C, CYP2E1 
and CYP1A may also add to the unexpected human P450 protein expression profile 
(Figure 5.15 and Table 5.4) as a consequence of induction brought about by drugs 
taken as part of the patients’ previous and ongoing treatment (Lin and Lu, 1998) 
together with substantial alcohol consumption (Perrot et a i, 1989; Tsutsumi et ai, 
1993) as in the case of subject 3799 (Chapter 2).
—
Chapter 5: Immunological characterisation of P450 proteins in marmoset liver_______
5.5: Conclusions
With the exception of CYP2A6, the anti-human and anti-rat antibodies used to detect 
human CYPs successfully targeted proteins in marmoset hepatic microsomes. This 
demonstrates that the marmoset liver contains an array of P450s that are closely 
related to those in human. For confirmation of the identities of the marmoset 
microsomal P450s and their relation to the human CYPs, further investigation into 
their nucleotide identities was conducted by PCR analysis (Chapter 6).
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5.6: Appendix
Enzyme Molecular Weight (KDa)
-Human-CYP1A-1 587165
Human CYP1A2 58.294
Human CYP2A6 56.541
Human CYP2B6 56.278
Human CYP2C9 55.574
Human CYP2C19 55.945
Human CYP2D6 55.801
Human CYP2E1 56.849
^Human CYP3A4 57.299
^Human CYP3A5 57.108
Table 5.6: Predicted molecular weight of CYP enzymes. These molecular weight 
designations have been predicted based on the amino acid sequence of each enzyme (BD 
biosciences, Bedford, MA, USA). These apparent molecular weights have been deduced from 
mobility on an SDS PAGE and may differ from predicted molecular weights. When an 
apparent mobility is known to differ from the predicted molecular weight, it is noted in the 
table.
 ^Human CYP3A4 (57.3 KDa) migrates more quickly (further) than human CYP3A5 (57.1 KDa) 
on an SDS PAGE even though their predicted molecular weights indicate otherwise.
Data obtained from BD biosciences (Bedford, MA, USA)
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6.1: Introduction
The work described in previous Chapters, indicated the possible presence of ‘human 
like’ cvtochrome P450__prdteins_jn marmoset- liver microsomes.-ln an attempt to 
investigate this further, the marmoset to human comparison of cytochrome P450 was 
examined at the genetic level. For continuity, the genetic investigations utilised 
human specific probes in the same way that human specific probe substrates were 
used for the kinetic evaluations, and human specific antibodies were used for the 
Western blot analyses. Primers and probes were selected to specifically match 
human CYP mRNA, and then used to determine sequence identity between the 
human hepatic CYPs and their marmoset counterparts. The human-marmoset 
genetic analysis of the cytochrome P450 genes was conducted by measuring the 
levels of expressed cDNA, synthesised from mRNA isolated from both human and 
marmoset livers using the TaqMan® method of qRT-PCR.
The TaqMan® method is founded on the real time polymerase chain reaction (RT- 
PCR) and resembles standard PCR methods (denature, anneal and extend) with the 
exception that a double-labelled fluorogenic probe (TaqMan® probe) is used (De la 
Vega et al., 2005). The probe is a >20-nucleotide single strand that is complementary 
to a segment of DNA that includes the target region, and anneals to the template 
between the two primers. It contains a fluorescent reporter molecule and a quencher 
molecule at its 5' and 3' ends respectively. As DNA is synthesised, the primer is 
extended. When the Taq polymerase reaches the bound probe, the exonuclease 
activity of the Taq polymerase digests the probe, thereby releasing the fluorophore 
from the quencher molecule. (Figure 6.1). The increase in fluorescence is directly 
proportional to the amount of product being generated and, therefore, the amount of
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starting template can be quantified. In this way real time amplification can be 
monitored to give a cycle by cycle quantification plot.
A
------------ - ---------
3’
Revere primer
B
TaqMarf probe
3 ’
Reverse primer S'
Adapted from Applied Biosystems
Figure 6.1 : Quantitative real-time polymerase chain reaction method utilising the 
TaqMan® qene expression assay.
A: TaqMan" probe, Taq polymerase and the template prior to extension.
B: The fluorophore is released during extension.
T= Taq polymerase, F = fluorophore, Q = quencher
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6.2: Methods
The isolation of RNA, integrity evaluation by electrophoresis, cDNA preparation and 
qualitative detection of CYP genes was conducted essentially as described in 
Chapter 2.
6.2.1: Liver samples
Snap frozen portions of human and marmoset (batch 3) liver were transported to the 
University of Surrey prior to portions being stored overnight in RNA/afer ICE (Applied 
Biosystems), to allow the physical transition of the tissue, from brittle livers samples 
into pliable tissue suitable for homogenisation and RNA isolation, without the RNA 
degradation associated with unstabilised thawing procedures. Liver portions 
remained frozen from the time of collection until the liver was used for RNA isolation.
6.2.2: Total RNA and 18S concentrations
RNA was purified from liver using a Nucleospin kit (Macherey-Nagel). The isolated 
RNA from human and marmoset liver homogenates was quantified by the 
absorbance at 260nm and the ratio at 260/280 nm, using a NanoDrop DN1000 
spectrophotometer. Average yields of isolated RNA from human and marmoset were 
674 and 966 pg RNA/ml purified eluate, respectively. Approximately 1 pg of RNA 
from each sample was then run, together with a DNA ladder, on a denaturing 
agarose gel, stained with ethidium bromide. The integrity of the RNA samples was 
then ascertained by visualisation under UV light (260 nm). 18S and 28S bands were 
prominent in the marmoset but weak in the human samples; however, no heavy 
smearing was present around the visible bands, suggesting minimal RNA
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degradation. From these isolated RNA samples, cDNA was synthesised for the 
determination of total 18S concentration and CYP quantification by qRT-PCR.
6.2.3: Preparation of working solutions
Each of the isolated RNA samples had any contaminating genomic DNA removed by 
incubation with DNase 1, as described in the methods section. cDNA synthesis was 
then performed by incubation of the DNase-treated RNA in the presence of dNTPs 
(1.25 mM) and random hexamers (450 ng), followed by incubation of the cooled 
cDNA with the reverse transcriptase mixture as detailed in Materials and Methods 
(Chapter 2). qRT-PCR was performed on the samples in a sealed 96-well plate in the 
presence of primers and probes for GAPDH and 18S RNA (house-keeping genes). 
After quantification of 18S in these samples (Table 6.1), the remaining human and 
marmoset reverse transcriptase-treated cDNA preparations were diluted in RNase- 
free water so that 5 pi aliquots contained the equivalent to approximately 10,000 
copies of 18S.
sample
Human 
188 (copies) per 5 jil sample
Marmoset
188 (copies) per 5 ul
3492 88,000 0007 100,000
3799 112,000 0017 103,000
3407 44,000 0699 1,110,000
2379 29,000 0977 1,330,000
3301 74,000 0997 111,000
Table 6.1: Copies of 18S RNA in undiluted cDNA preparations isolated from human and 
marmoset. Values obtained from qRT-PCR analysis, assayed in parallel with house-keeping 
genes (18S RNA and GAPDH) and quantified using a standard curve prepared from genomic 
DNA. Above concentrations then diluted with RNase free water to give working preparations 
that were equivalent to approximately 10,000 copies of IBS per 5 pi aliquot.
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6.2.4: TaqMan method
The reverse transcriptase, single stranded cDNA prepared from each human and 
marmoset liver samples was combined with forward and reverse primers, probe and 
TaqMan® Universal MasterMix as detailed in Chapter 2. The 96-well optical reaction 
plate containing the samples was then centrifuged (1000 x g for 1 minute) to 
accumulate sample in the bottom of the well prior to thermocycling in an ABI Prism 
7000HT Sequence Detection System (Applied Biosystems) as below:
Temperature (°C) Time (min) Cycles
50 2 hold
95 15 hold
95 0.25 40
60 1 40
Table 6.2: Cycle-sequencing program. qRT-PCR analysis was performed on human and 
marmoset cDNA using the above cycle program. Accumulation of amplicon measured during 
exponential phase of amplification.
6.2.5: Data processing
The number of copies of mRNA per well generated during qRT-PCR were analysed 
and quantified using ABI Prism software. Results were compared to a standard curve 
of human genomic DNA (r  ^ > 0.98), over 5 orders of magnitude to provide absolute 
quantification of expression of each gene-of-interest. All calculated values fell within 
the limits of the standard curve and individual 18S RNA values were used for the 
normalisation of all data.
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6.3: Results
The highest level of gene expression for all of the CYPs investigated was seen in 
human subject 3407 (full subject details in Chapter 2), although the 18S RNA values 
for this subject were unremarkable compared to the other human subjects; 44,000 
copies 18S per 5 pi of human 3407 cDNA compared to the mean average (n=5) of 
approximately 70,000 copies 18S per 5 pi cDNA (Table 6.1). All other human 
subjects demonstrated varied expression levels of the CYP genes. The marmoset 
liver samples revealed significant target binding of the human specific primer and 
probe set for only one of the CYP genes (CYP2B6). Details of the human primers 
and probe for CYP2B6 are outlined in Table 6.3.
CYP2B6 Sequence
Forward primer 5-GTGGTCATGCTGTGTGGAGTAGA-3'
Reverse primer 5-ATGGAGGTCGAATGTTCACTAGATC-3'
Probe 5'FAM-CCTGTCATCTCACATTTTCCCTTCCCTGA-3TAM
Table 6.3: TaqMan® probe and primers for human CYP2B6.Nucleotide sequences of the 
CYP2B6 probe (FAM, and TAM fluorescent labels), forward and reverse primers used for the 
identification of the human CYP2B6 gene.
A = adenine, C = cytosine, T = thymine and G = guanine
A summary of the mean quantity of mRNA, quantified from human and marmoset 
cDNA, as determined by target sequence conformity to human specific CYP primers 
and probes is given in Table 6.4. Full details of primer and probe sequences are 
given in Chapter 2.
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P450 gene Human
(copies mRNA/ng RNA)*
Marmoset
(copies mRNA/ng RNA)*
CYP1A1 41.8 ±83.7 ND
CYP1A2 462 ± 845 ND
CYP2A6 84 ±76 ND
CYP2B6 240± 151 154±114
CYP2C9 117± 113 ND
CYP2C19 80 ±93 ND
CYP2D6 90 ± 100 ND
CYP2E1 4424 ± 5459 0.6 ± 1.4
CYP3A4 275 ± 335 0.3 ±0.7
CYP4A11 202 ± 293 ND
Table 6.4: Quantity of CYP mRNA expression (mean ± SD) in human and marmoset 
iiver. Analysis conducted by qRT-PCR using primers and probes targeting human 
cytochrome P450 genes. All data is the mean of analyses from 5 human subjects and 5 
marmoset monkeys.
ND Not detected
* Normalised against 18S RNA values of each sample
6.3.1: CYP1A1 and CYP1A2
The highest levels of expression of CYP1A1 and CYP1A2 in human were 190 and 
1,957 copies of mRNA/ng of isolated RNA, respectively, with the lowest level of 
expression in subject 3799 (13 and 298 copies of mRNA/ng of isolated RNA, 
respectively). No expression of the CYP1A1 was evident in three of the human liver 
samples examined, while CYP1A2 was measurable in all but one of the human liver 
samples. The primer pair sets and probes for both human CYP1A1 and CYP1A2 did 
not appear to be complementary to any segment of cDNA within the marmoset liver 
preparation.
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6.3.2: CYP2A6
Expression of CYP2A6 was observed in all five human liver samples, with levels of 
expression ranging from 27 to 213 copies of mRNA per ng of isolated RNA. 
Whereas, the marmoset liver samples demonstrated no detectable amplification of 
mRNA by the primer pair set targeted towards human CYP2A6.
6.3.3: CYP2B6
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Figure 6.2: Expression of CYP2B6 in human and marmoset liver. The mRNA expression 
(normalised against 18S) of human and marmoset CYP2B6 was quantified by qRT-PCR 
using TaqMan" probe, and forward and reverse primers specific for CYP2B6.
Interestingly, CYP2B6 was amplified in all but one of the marmoset samples (Figure 
6.2), with quantities of expression comparable to that of human. Human CYP2B6 
expression ranged from 84 to 466 copies of mRNA per ng equivalents of isolated 
RNA, while the marmoset expression of CYP2B6 ranged from 75 to 281 copies of 
mRNA per ng equivalents of isolated RNA (excluding marmoset 0997). CYP2B6 was
171
Chapter 6: Cytochrome P45Û gene expression in marmoset liver_____________ '
the only marmoset CYP gene to be significantly amplified by qRT-PCR, using 
primers and probe targeted at a human P450 gene.
6.3.4: CYP2C9 and CYP2C19
CYP2C9 and CYP2C19 were present in all of the human liver samples to varying 
degrees, with the highest quantities of mRNA being 316 copies of CYP2C9 mRNA 
and 235 copies of CYP2C19 mRNA. Levels of expression in 3 of the 4 human liver 
samples were found to be similar for both CYP2C9 and CYP2C19, with levels 
ranging from 21 to 154 copies of mRNA per ng equivalents of isolated RNA, 
respectively. No CYP2C9 or CYP2C19 genes were detected in the marmoset by the 
qRT-PCR analysis using primer and probe sets specific for these human cytochrome 
P450 genes.
6.3.5: CYP2D6
The average mRNA expression levels of CYP2D6 in the human samples were found 
to be similar to that of CYP2C and CYP2A6 expression (Table 6.4) with values 
ranging from 17 to 266 copies of mRNA per ng equivalents of isolated RNA, with the 
exception of subject 2379, where no CYP2D6 expression was evident. No 
amplification of marmoset mRNA was achieved by using the primer pair and probe 
set for human CYP2D6 in the qRT-PCR analysis.
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6.3.6: CYP2E1
The highest level of human CYP gene expression was achieved in the qRT-PCR 
analysis of CYP2E1 (Table 6.4). Subject 3407 had a staggering level of CYP2E1 
mRNA in excess of 12,000 copies per ng equivalent of isolated RNA, with a similar 
trend being seen in subject 3301 with 8,000 copies mRNA, and to a lesser degree in 
the other three human samples (1119, 535 and 140 copies of mRNA per ng 
equivalents of isolated RNA). Marmoset 0017 was found to amplify CYP2E1 mRNA 
to a very limited degree with 3.2 copies of mRNA being formed per ng equivalent of 
isolated marmoset RNA. No other expression of marmoset mRNA was evident for 
CYP2E1 in these analyses.
6.3.7: CYP3A4
The largest quantity of amplified CYP3A4 mRNA in the human samples was 844 
copies of mRNA per ng equivalents of isolated RNA, whilst the lowest expressing 
human sample had a value less than 20 copies of mRNA per ng equivalent of 
isolated RNA. These values represent an unexpected average expression level of 
CYP3A4 in human liver that is lower than both CYP2E1 and CYP1A2 enzymes, and 
similar to that of CYP2B6. Marmoset 0699 displayed very low CYP3A4 mRNA 
amplification (1.6 copies per ng equivalent), a negligible amount was present in 0997 
(<1 copy per ng equivalent of RNA), and the remaining three marmosets showed no 
amplification.
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6.3.8: CYP4A11
The human primer pair and probe set of CYP4A11 used in these qRT-PCR analyses 
revealed that human CYP4A11 was present in all of the human liver samples. The 
highest expression of CYP4A11 mRNA was once again seen in subject 3407 with 
721 copies of mRNA per ng equivalents of isolated RNA. Remaining human liver 
samples had quantities ranging from 43 to 138 copies of mRNA per ng equivalents of 
isolated RNA. Only one of the marmoset liver samples (0007) had a measurable 
quantity of CYP4A11, although this was considered negligible as less than 2 copies 
of mRNA per ng equivalent of isolated marmoset RNA were amplified. All other 
marmoset cDNA samples resulted in non-detectable amounts of amplified material.
6.4: Discussion
Quantification of cytochrome P450 gene expression in human and marmoset liver 
were determined by qRT-PCR. Analysis was performed using isolated high quality 
RNA, as established by A260/280 values > 1.8 and intact 28S and 18S ribosomal RNA 
visualised following electrophoresis, from 5 separate male human and 5 separate 
male marmoset liver samples. All final quantified data were normalised to 18S 
concentrations for each individual human or marmoset sample, as appropriate.
The qRT-PCR method of mRNA quantification applied to the human and marmoset 
liver samples within this study determined the amount of PCR product at each cycle 
of the PCR, and were achieved by measuring cleavage of the fluorescent TaqMan® 
probe using the ABI Prism 7000HT Sequence Detection System (Applied 
Biosystems). This permitted the parallel assessment of mRNA expression of all of the
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major human liver CYPs. This method, during the exponential growth phase of 
amplification, provided detection of reporter fluorescence directly proportional to the 
number of amplifications. This quantification of expression is generally considered 
superior to the end-point PCR techniques that suffer from poor precision and 
sensitivity, and rely upon results obtained from time-consuming agarose gel 
detection, based upon size discrimination of the PCR end point products.
Sensitivity, specificity and reproducibility of PCR-based assays are also considerably 
dependent upon the use of appropriate primers and probes. Therefore, it is not 
surprising that there was an absence of amplification for most of the marmoset liver 
samples, as the primers and probes were designed specifically for human 
cytochrome P450 enzymes. Small variations in the amino acid sequences of these 
marmoset proteins compared to their human orthologues would, therefore, prevent 
the primers from annealing to these marmoset templates. It should be noted that 
these small genetic variations between the species, whilst resulting in non-detection 
in the PCR analysis, would not necessarily be sufficient to affect the epitope of these 
proteins and the consequential antibody binding evident described in Chapter 5. 
Although the human specific primers and probes failed to provide a response with 
most of the marmoset CYP genes, the underlying reasons could of course not be 
limited to the fact that the gene sequences are incompatible, (although this remains 
the most likely scenario). It may simply reflect the fact that marmoset does not have 
an enzyme of a similar nature to that encountered in human. CYP2A6, for example, 
could not be detected at the protein level in the Western blot analysis (Chapter 5) 
and the poor coumarin metabolism, a CYP2A6 probe substrate, during the kinetic 
studies (Chapter 3), collectively, suggest that the presence of a ‘CYP2A6-like’ 
enzyme in the marmoset is unlikely.
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Inter-species gene variation in gene sequences of the cytochromes P450 is to be 
expected (Cashman, 2005). Although the function and regions of CYP1A and 
CYP2E1 are highly conserved amongst mammalian species (Kimura et al., 1984, 
Okino et al., 1985, Quattrochi et al., 1985; Casarett and Doull, 2001), CYP1A and 
CYP2E1 therefore mày have been considered to be the most likely candidates to 
generate PCR products, but this was not the case. Only CYP2B6 demonstrated a 
direct species comparison on the genetic level, suggesting that not only does the 
marmoset have a CYP2B6 enzyme, but the primer and probe targeted binding region 
within this enzyme are identical (or very similar) to that of the human protein. 
CYP2B6 has previously been detected in the brain of the African Green monkey (Lee 
et al., 2005) and alluded to in marmoset liver by Schulz et al. (2001), who determined 
the presence of relatively high levels of CYP2B6 in marmoset liver; both groups, 
however, used an anti peptide antibody targeted against the amino acid sequence of 
rat CYP2B1 (IDTYLLRMEKEK, Research Diagnostics Inc.), which differs from human 
CYP2B6 sequence by a single amino acid (IDTYLL/-/MEKEK) (Lee et al., 2005). 
Ultimately, no specific references could be found to the identification of CYP2B6 in 
marmoset using human primers and probe as conducted in this study.
Surprisingly, the levels of CYP3A4 expression in the human samples were low 
compared to expected values (Gibson and Skett, 2001). Results from this study 
however suggest a low CYP3A4 gene expression which is consistent with low 
CYP3A4 protein quantities observed in the Western immunoblot analysis in 
Chapter 5.
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The expression of human P450, as determined by qRT-PCR in this study revealed a 
total hepatic complement that was dominated by CYP2E1. Although CYP2E1 is not 
generally regarded as the major phase I enzyme of human liver (Gibson and Skett, 
2Dj01)-_these -data--concord-with-the-high-GYP2E1—expression“ reveaTed~by"lhe 
immunoblotting (Chapter 5). Additionally, a quantitative RT-PCR method used by 
Rodriguez et al. (2000) demonstrated that CYP3A4 and 2E1 were the most abundant 
mRNAs in human liver and cultured human hepatocytes. Rodriguez’s data coupled 
with the established inducible nature of CYP2E1, the confirmatory Western blot and 
PCR data collectively suggest that the human liver samples used in this study did 
express high levels of CYP2E1. Other enzyme mRNAs that made up the human liver 
P450 complement within this study were CYP1A2 > CYP3A4 > CYP2B6 > CYP4A11 
> CYP2C9 > CYP1A1, CYP2A6, CYP2C19 and CYP2D6.
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7.1: Drug metabolism in non-human primates
The pharmaceutical industry is required to investigate the potential toxicity of new 
drug candidates in non-rodent species? usually dog or monkey, due to differences in 
metabolism and physiological functions between rodent and human (Newell et al., 
2004). For this reason rhesus or cynomolgus monkeys have been used for a number 
of years because of their genetic similarity to man. Whilst the rhesus and cynomolgus 
monkeys provide suitable non-human primate choices for these preclinical studies, 
the national supply of such animals has been unable to meet the current or projected 
demands of the research community.
In contrast to the rhesus and cynomolgus monkeys, the marmoset offers a logical 
alternative primate species on the basis of its small size, reliability in captive breeding 
programs with sexual maturity being reached by 18 months of age, and lower 
purchase price compared with macaques. The choice of the most appropriate animal 
species is however critical to ensure that the human metabolites are being tested for 
their potential toxicity (US FDA, 2008 and 2009). One inherent problem with any 
animal investigation is that the experimental data generated in animal systems must 
then be extrapolated to human. This is compounded by the use of species where the 
lack of detailed information on the function and expression of CYPs exists. 
Comprehensive characterisation of these liver cytochrome P450 systems promotes 
informed selection of suitable animal species for the study of phase I hepatic drug 
metabolism interactions.
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7.2: GYP expression from resected donor human liver
The fraction of human liver cytochrome P450 attributed to specific CYP isoforms 
within the human donor liver samples that were utilised during this study did not 
compare favourably to previously published CYP expression values that are 
considered normal in human liver (loannides and Lewis, 2004). These differences in 
human CYP expression were not considered to be a reflection on the methods used 
during the course of the study, as the trends observed in the immunological analyses 
were generally reproduced during the PCR investigations, but rather as a 
consequence of the nature of the available human liver. It is thought that a 
combination of age, lifestyle and patient medical conditions (details summarised in 
Chapter 2) were contributing factors that influenced the expression of certain CYPs. 
Bearing these factors in mind, the following points of discussion are primarily related 
to published material relating to human CYP activity and expression.
7.3: Function and expression of marmoset liver CYPs compared to human
This study examined the function of the marmoset liver CYPs by investigating the 
Michaelis-Menten kinetic parameters of known human biochemical probe substrates 
selectively metabolised by CYP enzymes. Moreover, the level of expression of 
marmoset liver CYPs was evaluated immunologically at the protein level by utilising 
antibodies raised against human CYP proteins and, finally, at the genetic level, for 
selected amino acid sequence recognition of human nucleotide regions. The 
experimental findings lead to the following inferences:
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The presence of a CYP1A enzyme in the marmoset was to be expected, as CYP1A 
is one of the more conserved CYP enzymes, with 7-ethoxyresorufin 0-deethylase 
activity being common across all species (Goldstone and Stegeman, 2006). The 
metabolic capability of marmoset liver microsomes towards 7-ethoxyresorufin O- 
deethylation was less than that seen in human, with a lower enzyme saturation point 
in marmoset liver microsomes as evidenced by a Km of 0.08 pM compared to 
approximately 0.3 pM in human. The rate of reaction for 7-ethoxyresorufin 
0-deethylation from the marmoset was found to be similar to that of human but the 
level of expression of CYP1A1/1A2, as defined by Western blot analysis, was 
markedly low. These findings could indicate the presence of another enzyme(s) with 
7-ethoxyresorufin 0-deethylase activity, such as CYP2B1, that would not have been 
detected with the antibodies used in this study. However, no evidence of primate 
hepatic CYP1B1 expression could be found. Interestingly, one of the marmoset livers 
investigated, in addition to the 55 KDa immunoreactive band, presented an equally 
strong band of 43 KDa. This molecular weight is considered too low for any known 
CYPs (human CYP1A2 is 58 KDa) and is more in line with the expected weight of a 
glycoprotein fraction, as discovered in rat liver membranes by Klee and Singh, 1991. 
However, the identification of this lower molecular weight protein was beyond the 
scope of this study.
The lack of coumarin 7-hydroxylase activity in marmoset liver microsomal fraction, 
together with absence of any detectable CYP2A6-like protein detected by Western 
blot analysis or mRNA detected by qRT-PCR techniques, draws attention to the 
possible limitations of this non-human primate species as a surrogate species, 
although different substrates are selective for CYP2A in different species (e.g. 
testosterone 7a-hydroxylase in rat). Cynomolgus money liver microsomes, on the
other hand, are effective in the catalysis of coumarin 7-hydroxylase. The absence of_ _
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the enzyme in the marmoset would make it a poor animal model for the oxidation of 
nicotine, cyclophosphamide, iphoshamide, fadrozole and aflatoxin B1 among other 
xenobiotics (Guengerich, 1997; Honkakoski and Negishi, 1997), since the 
metabolism of these compounds is catalysed primarily by CYP2A6. However, it 
should be noted that very few key drugs are metabolised by CYP2A6 and the FDA 
does not regard this enzyme as important CYP in drug development studies.
In contrast to marmoset CYP2A, the marmoset liver microsomes exhibit substantial 
CYP2B6, S-mephenytoin A/-demethylase activity, although biphasic kinetics are 
apparent. This similarity to human CYP2B6 is extended to the immunoreactive 
identification by polyclonal antibodies raised against the human protein. Furthermore, 
a direct comparison at the genetic level was achieved during qRT-PCR analysis 
using a primer pair and probe targeted towards human CYP2B6 nucleotide 
sequences. Collectively, these findings indicate that the marmoset would be very 
useful in the evaluation of the ever-increasing number of drugs that are being linked 
to the CYP2B6 enzyme (Ekins and Wrighton, 1999).
Antibodies targeted against both CYP2C9 and CYP2C19 recognised immunoreactive 
bands in marmoset liver microsomes, in agreement with the work of Schulz et al. 
(2001), however, unlike their human orthologues, CYP2C19 represented the largest 
member of the CYP2C family. Interestingly, this higher protein expression recognised 
by polyclonal antibodies raised against human CYP2C19, did not extend to the 
metabolism of S-mephenytoin 4 '-hydroxylase. This raises the possibility that the 
marmoset orthologue of CYP2C19 may display different substrate specificity to the 
human enzyme. Tolbutamide methylhydroxylase activity (CYP2C9) on the other hand 
displayed the highest metabolic capability of the biochemical probe substrates
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investigated for marmoset in this study, with a Km >2 mM. These findings are in 
contrast to the observations in rhesus monkey where CYP2 enzyme (CYP2C43) has 
been described as being similar structurally to CYP2C9, having no tolbutamide 
methylhydroxylase activity but high S-mephenytoin 4 -hydroxylase (human CYP2C19 
probe substrate). Nonetheless, the findings in the present study concord with the 
conclusions of Narimatsu et al. (2006) who recently cloned a cDNA encoding 
marmoset CYPM-2C, exhibiting a similar amino acid sequence to CYP2C8 but, 
similar to this study, methylhydroxylation of tolbutamide was the only CYP2C probe 
substrate to be catalysed by the marmoset CYP2C enzyme.
The utility of combined technologies allowed the function of marmoset liver CYP2D 
enzyme(s) to be fully explored within this study, enabling the construction of a 
proposed metabolic pathway for debrisoquine that includes the identification of a 
novel dihydroxy metabolite. This characterisation of the marmoset CYP2D enzyme 
also takes account the work of Hichiya et al. (2002 and 2004), who first described 
primate CYP2D enzymes by cloning CYP2D19 and CYP2D30 form marmoset liver, 
with the proposed human metabolic scheme for debrisoquine metabolites in urine 
from Eiermann et al. (1998), including the first detection of dihydroxydebrisoquine 
metabolite. Collectively, these observations indicate that marmoset CYP2D 
enzyme(s) is (are) capable of a full range of debrisoquine hydroxylations similar to 
that found excreted in human urine (Figure 7.1). As human CYP2D6 activity is of the 
utmost interest in drug discovery, generally due to the undesirable polymorphic traits 
of this enzyme, the presence of the CYP2D6-like metabolic activity in the marmoset 
may be considered as useful in human metabolic studies, even though 
4-hydroxydebrisoquine is not the major route of metabolism.
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Figure 7. 1: Debrisoquine metabolic pathway pertaining to rat, human and marmoset 
liver. Rat and human hepatic debrisoquine metabolic pathways are based upon the work by 
Hiroi et al. (2002). Debrisoquine metabolites from human urine indicated with dashed lines 
are based on the findings of Idle et al. (1979) and Eiermann et al. (1998). Marmoset 
microsomal debrisoquine metabolic pathway detailed from the present study.
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The Eadie-Hofstee plot for the formation of 11- and 12-hydroxylauric acid by 
marmoset liver implies that biphasic CYP2E1 and CYP4A enzyme kinetics were 
apparent, although, in the case of CYP2E1, the two-site model demonstrated a poor 
fit to the data in this type of analysis. The metabolic capacity of the marmoset 
CYP2E1 was 10-fold higher for lauric acid 11-hydroxylation compared with that of 
human, with a Km of >800 pM for marmoset CYP2E1, and represented almost a 
quarter of the immunologically defined CYP expression in marmoset liver. Different 
molecular weight proteins were identified in the marmoset liver microsomes 
dependent upon the source of the antibodies; anti-rat polyclonal antibodies raised 
against CYP2E1 were immunoreactive towards a marmoset liver microsomal protein 
of approximately 60 KDa, whereas anti-marmoset polyclonal antibodies reacted with 
a microsomal protein of 56 KDa, equal in mass to human CYP2E1. It is hypothesised 
on this basis that although this enzyme is strongly conserved among species, 
marmoset may express a second CYP2E liver enzyme as seen in rabbit (Peng et al., 
1991). In addition, differences in the amino acid sequence of CYP2E1 in marmoset 
liver compared to human CYP2E1 in human have already been established by 
Schulz etal. (1998).
CYP3A represented the largest CYP fraction in marmoset liver with a combined 
CYP3A4/5 proportion similar to that expected in human liver. The products of 
testosterone metabolism were similar to those generated by human liver with 
radiochromatogram peaks eluting with the same retention time as la-, 2a-, 6p-, 
16(3-hydroxytestosterones and androstenedione. In addition, although the marmoset 
CYP3A enzyme(s) exhibit very similar testosterone 6p-hydroxylase kinetic 
parameters to that of human, the marmoset CYP3A enzyme kinetics do not appear to 
demonstrate the same non-Michaelis Menten allosterism observed in human liver 
(Kenworthy at a i, 2001; Atkins, 2005). It is thus possible that the marmoset would
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provide suitable comparative metabolite formation for the prediction of human 
CYP3A activity, without the associated atypical kinetic characteristics.
7:4: Summary
The common marmoset may prove a suitable human surrogate animal species for 
metabolic studies involving CYP1A2, 2B6, 2D6, 2E1 and 3A4/5. The activity of 
marmoset CY2C is somewhat more complex, with the metabolic activity indicating 
possible predictive qualities for human CYP2C9, but questions remain surrounding 
the ability of this species to provide useful information for compounds metabolised by 
the other human CYP2C enzymes. The marmoset is also deficient in CYP2A6 and 
demonstrates biphasic enzyme kinetics for S-mephenytoin A/-demethylase 
(CYP2B6), debrisoquine hydroxylase (CYP2D6), testosterone 6p-hydroxylase 
(CYP3A4) and lauric acid 12-hydroxylase activities (CYP4A11). CYP1A2 and 
CYP2E1 are strongly conserved among species, so these activities are also present 
in other animal models.
This study has focussed on the hepatic P450 metabolism of marmoset; it should, 
however, be noted that, although the P450 system is generally considered highly 
relevant to xenobiotic metabolism and has been the subject of intense research in 
the past three decades and is investigated in relation to their interaction with drugs 
produced in the pharmaceutical industry as part of regulatory procedures, the P450 
system is one of many phase I enzyme systems. Consideration for the microsomal 
flavin monooxygenase system, the various oxidases, hydrolases and reductive 
enzymes should not be overlooked. The functionalisation of xenobiotics by the phase 
I enzymes increase the hydrophilicity of the compound in question (Parkinson, 1996).
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Phase II reactions which include conjugation and condensation that are catalysed by 
a number of transferase enzymes and are often considered the true detoxifying 
reactions will need to be considered at a later date, as it is the conjugation of bulky or 
polar groups that often terminates the activity of xenobiotic and facilitates elimination 
(Jia and Liu, 2007). In addition to reactions in the liver, to fully asses the utility of the 
marmoset as a suitable animal model, attention should also be given to other sites of 
action, such as the intestine, which influences the oral bioavailability and first-pass 
metabolism, the kidney which makes an important contribution to the metabolism of 
circulating compounds and the lungs, which are the site of metabolism of inhaled 
xenobiotics.
7.5: Further studies
♦ Develop an analytical assay with high sensitivity to enable the kinetic 
characterisation of debrisoquine 7-hydroxylase activity (the major debrisoquine 
metabolite produced by marmoset liver CYP2D19).
♦ Determine phase II drug-metabolising enzyme activities (e.g. UDP- 
glucuronosyltransferase and glutathione S-transferase) in microsomes and 
cytosol from marmoset livers.
♦ Compare the metabolism of model substrate(s), e.g. 7-ethoxycoumarin, by 
microsomes from 2 or more species, including marmoset.
♦ Investigate P450 induction in marmoset using phenotype inducers within in vivo 
and in vitro systems (analysis by enzyme assays. Western blotting and Taqman).
♦ Define the inhibitory characteristics of marmoset P450’s as a potential for 
identifying drug-drug interactions.
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♦ Compare marmoset P450/phase II activity and hepatic clearance data to that of 
an already recognised in vitro non-human primate model (Cynomolgus).
♦ Investigate the regulatory mechanisms of drug metabolism in marmoset 
(including drug transporters and nuclear receptors).
7.6: Conclusion
The evaluation of marmoset liver microsomes has demonstrated cytochrome P450 
expression and activity with relevance to human xenobiotic metabolism. This 
species, therefore, warrants further investigation into the mechanisms of toxicology to 
support the notion that the common marmoset should be considered a potential 
surrogate for human in drug development.
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Appendix 1: Absorbance difference spectra (400 -  500 nm) for the determination of 
marmoset liver cytochrome P450 concentrations. A: Livers prepared by immediately snap 
freezing in liquid N2 prior to -70°C storage, subcellular fractions conducted using a single 1 
hour 105,000 x g centrifugation of the S9 fraction. B: Livers rinsed and gently perfused with 
sodium chloride solution 0.9% (w/v) prior to being snap-frozen in liquid N2 and -70°C storage, 
subcellular fractions conducted using two 1 hour 105,000 x g centrifugation steps of the S9 
fraction, one of which was a rinse using 20 ml of 50 mM Tris-HCI sucrose buffer, 
demonstrating the removal a large amount of the contaminating peak at 420 nm, compared to 
that of the non-washed sample.
 ^ Peak at 420 nm 
 ^Peak at 450 nm
205
Appendices
Marmoset batch 1 
Animal no.
Microsomal protein 
mg/ml mg/g liver
Microsomal cytochrome P450 
nmoles/mg nmoles/g liver 
protein
Q4'| 4 ' ----  ~ 6.5 24.8 0.27 - ' 6:7
0914 5.1 19.7 0.30 5.4
1554 7.1 25.3 0.27 6.8
0215 6.9 22.5 0.24 5.4
1595 6.4 23.3 0.28 6.5
Marmoset batch 2 Microsomal protein Microsomal cytochrome P450
Animal no. mg/ml mg/g liver nmoles/mg
protein
nmoles/g liver
0473 4.0 12.1 0.41 5.0
0625 5.7 17.2 0.31 5.4
017B 4.4 15.7 0.46 7.2
023B 4.3 16.1 0.42 6.7
1274 4.8 14.6 0.32 4.6
Marmoset batch 3 
Animal no.
Microsomal protein 
mg/ml mg/g liver
Microsomal cytochrome P450 
nmoles/mg nmoles/g liver 
protein
0007 3.6 12.2 0.46 5.6
0017 3.8 10.6 0.33 3.5
0699 3.7 11.1 0.45 5.0
0977 3.4 10.7 0.23 2.4
0997 4.4 13.5 0.23 3.1
Human batch 1 
Subject no.
Microsomal protein 
mg/ml mg/g liver
Microsomal cytochrome P450 
nmoles/mg nmoles/g liver 
protein
3492 3.9 12.4 0.17 2.1
3799 4.0 14.5 0.19 2.8
3407 6.4 17.6 0.47 8.2
2379 4.8 16.0 0.48 7.7
3301 3.2 10.9 0.37 4.1
Appendix 2: Microsomal protein and cytochrome P450 concentrations in marmoset 
batch 1, 2 and 3 and human batch 1 livers. Microsomal protein results expressed as mg of 
protein (BSA equivalents) per ml of 30 % suspension or as mg of protein (BSA equivalents) 
per g of liver. Microsomal cytochrome P450 calculated using the mM extinction coefficient of 
99 cm'^  miyi'^  for the absorbance difference between the spectrum peak at ca 450 nm, and a 
baseline value at 490 nm.
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